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Diffuse, multivessel coronary artery disease (CAD) affects about one third of patients 
with CAD and is associated with worse outcomes. Abnormal vascular stiffness and 
function (e.g., reflected by increased endothelial microparticles and diminished 
microvascular endothelial-mediated responses), cell mediated pro-inflammatory status 
(e.g., reflected by levels of specific monocyte subsets), and platelet function (e.g., 
increased monocyte-platelet aggregates (MPAs) and platelet microparticles) have 
established roles in CAD pathogenesis but their contribution to the unfavourable diffuse 
CAD form is unclear. The aim of this study was to compare measures of vascular 
function, monocyte subsets, MPAs, and endothelial and platelet microparticles in patients 
with diffuse and focal CAD and subjects without CAD. Additionally, prospective changes 
in these characteristics were analysed over one year. I found increased counts of 
aggregates of Mon2 monocyte subset with platelets and apoptotic endothelial 
microparticles in patients with diffuse CAD and I identified a negative correlation 
between Mon2 MPAs and microvascular endothelial function and increased diastolic 
elastance. My findings suggest that excessive levels of Mon2 aggregates with platelets 
and apoptotic endothelial microparticles could be important contributors to the diffuse 
type of CAD by a mechanism involving microvascular endothelial dysfunction and 
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This opening section of the thesis contains a brief introduction to the topic of advanced 
diffuse coronary artery disease (CAD) followed by a generalised overview of the 
pathological processes underlying atherogenesis. Subsequently I review the literature 
pertaining to diffuse CAD and explore the pathogenesis in more depth, before discussing 
features relevant to the diagnosis of normal coronary arteries and concluding with a 
section summary. I provide an overview of the experimental work undertaken in section 
two with methodology validation in section three. Section four details the results of 
retrospective analyses that I performed as part of my research training and to illustrate the 
clinical landscape of CV disease in the region, compare our data with previously 
published literature (with emphasis on the ethnic differences pertinent to this region of 
the UK) and introduce the experimental data detailed in section five. Within section five 
are the results of all the experiments I performed, followed by conclusions and 


























Despite falling rates of age-adjusted mortality, coronary artery disease (CAD) remains 
the leading cause of death worldwide1, 2. Advanced obstructive CAD (often diffuse in 
nature) is becoming an important entity of modern cardiology as the population ages. 
More patients with historical coronary revascularisation procedures no longer have 
suitable coronary anatomy for additional procedures once grafts have occluded and 
restenosis has occurred at angioplasty sites3-5. Advances in the treatment of diffuse 
obstructive CAD are hampered by a poor understanding of the factors implicated in its 
development.  
Patients with diffuse CAD are at risk of developing refractory angina – resistant to 
conventional revascularisation techniques such as percutaneous coronary intervention 
(PCI) or coronary artery bypass grafting (CABG) – and not adequately controlled by 
optimal medical therapy (OMT). Studies have shown that up to 12% of symptomatic 
patients undergoing coronary angiography are ineligible for revascularisation6. Annual 
mortality rates in patients with refractory angina due to advanced CAD vary from 3-21% 
in randomised trials7, and from 2-17% in registries8. One-year rates of myocardial 
infarction up to 25.5% have been reported with 71% of one cohort being re-hospitalised 
at least once during the year6. Patients with this condition often have restricted physical 
capacity and severely impaired quality of life9. This has stimulated interest in alternative 
strategies, but satisfactory treatments are still to be developed10. 
Although the likelihood of developing clinically significant CAD is closely linked to the 
presence of traditional risk factors (e.g. diabetes4) the extent of coronary disease among 
individuals possessing one or more conventional risk factor at any one point in time is 
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highly variable. Some patients develop diffuse multivessel involvement while others have 
a single focal stenosis. Indeed, rates of normal coronary arteries amongst people referred 
for elective (invasive) coronary angiography range from 5-50%11.   
CAD is associated with generalised vascular dysfunction. The purpose of this thesis is to 
test the hypothesis that stable patients with advanced diffuse CAD have increased 
measures of vascular dysfunction compared to stable patients with focal CAD and 
patients without CAD, and that the variation in these measures over one year will differ 
between patients with diffuse and focal CAD. I also propose that there will be a 
relationship between the measures of vascular dysfunction and biochemical markers of 



















1.2 PRINCIPLES OF ATHEROGENESIS 
 
1.2.1 Normal arterial structure 
Healthy human arteries have a tri-laminar structure (Figure 1.1). The tunica intima is an 
inner layer of endothelial cells (ECs) lining the lumen called the endothelium. The 
endothelium is in direct contact with blood flow and arterial ECs possess highly regulated 
mechanisms of vital importance in maintaining vascular homeostasis. It is bound on the 
outside by internal elastic lamina, which separates the intima from the tunica media. The 
media contains numerous layers of SMCs. In large elastic arteries SMCs are arranged in 
a concentric manner within an elastin-rich extra cellular matrix which helps store kinetic 
energy required for the transmission of pulsatile flow. The media is bound on the outside 
by an external elastic lamina that separates the media from the adventitia. The adventitia 
consists mainly of fibroblasts, mast cells, and a matrix containing collagen and 



















Figure 1.1 Schematic cross section of a human artery showing endothelial, medial 


















1.2.2 Normal endothelial function  
The normal, healthy endothelium is the major regulator of vascular homeostasis – 
maintaining the balance between vasodilation and vasoconstriction, inhibition and 
stimulation of smooth muscle cell proliferation and migration, and thrombogenesis and 
fibrinolysis (Table 1.1)13. Initial insight as to the importance of the endothelium in 
vasomotor modulation came from animal experiments during the 1980s14-19. It 
subsequently became evident that the endothelium is an active paracrine, endocrine and 
autocrine organ capable of varying degrees of stimulation – a spectrum of endothelial 
disturbance exists that depends on the prevailing physiological, or pathophysiological, 
conditions20-22. Its main vasoregulatory functions include; 
• Generation of nitric oxide (NO), a potent vasodilator originally identified as 
endothelium-derived relaxing factor (EDRF)23. Other endothelium-derived 
vasodilators include prostacyclin and bradykinin both of which also inhibit 
platelet aggregation13.  
• Generation of vasoconstrictor substances such as endothelin and angiotensin II. 
Angiotensin II is pro-oxidant24 and both promote smooth muscle cell 
proliferation within the intimal layer13. 
In normal vascular physiology, NO is key to maintaining the vascular wall in a quiescent 
state by inhibiting inflammation, cellular proliferation, and thrombosis25. This is achieved 
through the expression of a set of protective genes (IκκB-a, A20, Bcl-2) that down-
regulate the expression of transcription factor nuclear factor (NF)-κB since activation of 
NF-κB triggers endothelial activation and renders the endothelium more susceptible to 
apoptosis21. NO also limits oxidative phosphorylation in the mitochondria. Laminar shear 
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stress (Figure 1.1) is probably the major factor that maintains this quiescent, NO-
dominated, endothelial phenotype with little or no expression of pro-inflammatory 
factors26. 
 





Antithrombotic Prothrombotic Vasodilator Vasoconstrictor 
Nitric oxide + - + - 
Bradykinin + - + - 
Prostacyclin  + - + - 
Endothelin  - - +† +‡ 
Thromboxane A2 - + - + 
Prostaglandin H2 - - - + 
Angiotensin II - - - + 




+ - - - 




- + - - 
Binding sites for 
factors IX and X 
- + - - 






1.2.3 Endothelial activation, injury and dysfunction 
Endothelial disturbance is characterised by distinct, often overlapping, phases21. 
Endothelial activation occurs in two stages and represents a change from the quiescent 
phenotype described above toward one that involves the host defence response 
(characterised by the expression of pro-inflammatory substances e.g. cytokines), which 
may be physiological, for example in response to infection27, or pathophysiological, in 
the presence of CAD risk factors. Essentially, a reduction of NO production leads to a 
lack of NO mediated cell signalling, thus creating an imbalance between endothelium-
dependent vasodilators and the opposing effects of endothelium-derived vasoconstrictors 
such as angiotensin II. Under these circumstances endogenous nitric oxide synthase 
(eNOS) favours the production of reactive oxygen species (ROS) which can consume NO 
and ‘activate’ endothelial cell (EC) processes (Figure 1.2)25. Endothelial activation 
implies reversibility – the activated ECs may return to a quiescent state upon withdrawal 
of inflammatory stimuli28. Unchecked endothelial activation may either result in EC 
apoptosis leading to irreversible endothelial injury, EC fragmentation and separation from 
the intima (for example, in atherosclerosis)21, 29, or EC dysfunction without evidence of 
injury (for example atherogenesis or increased permeability)28, 29. 
Endothelial dysfunction (ED) results from a persistent imbalance of vasoactive 
substances leading to an inability of the endothelium to regulate tissue perfusion. 
Irreversible EC injury may occur with chronic EC activation as critical levels of 
endothelial adhesion molecules, procoagulant molecules, cytokines and chemokines 
cause EC necrosis and other mural cell injury21. Circulating endothelial microparticles 













Figure 1.2 Endothelial activation in the presence of coronary risk factors (adapted 
from Deanfield et al25). 
The left-hand panel shows normal, quiescent endothelial physiology induced by nitric 
oxide (NO, green circles). The right-hand panel reflects endothelial activation 
characterised by increased membrane permeability and reactive oxygen species (ROS, 
red circles) which now predominate, altering the function of cellular constituents leading 
to phosphorylation of transcription factors and mitochondria as well as protease activation 
(eNOS endothelial nitric oxide synthase, p50/p65 nuclear factor-κB transcription factor, 
NADPH nicotinamide adenine dinucleotide phosphate). 
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1.2.4 The impact of conventional modifiable and non-modifiable cardiac risk 
factors on endothelial function in patients with and without coronary artery 
disease 
Numerous studies have examined the effect of conventional modifiable and non-
modifiable risk factors on endothelial function since endothelial activation and 
dysfunction occur early in the evolution of CAD. Tables 1.230-65 and 1.342, 66-80 represent 
a summary of key data. According to epidemiological data, nine modifiable risk factors 
account for more than 90% of the proportion of risk of a first myocardial infarction81. 
Conventional CAD risk factors favour a reduction in L-arginine induced NO synthesis 
leading to an increase in ROS and subsequent oxidative stress (Figure 1.2). This alteration 
in endothelial function results in a chronic inflammatory process accompanied by a loss 
of antithrombotic factors and an increase in measures of endothelial activation and 
dysfunction which independently predict the risk of subsequent cardiovascular (CV) 
events in patients with and without CAD82, 83. While treatment or cessation of these risk 
factors may improve endothelial function38 and, in some cases, reduce atherosclerotic 
progression84, the presence of multiple CAD risk factors are synergistically detrimental 
to endothelial function and increase CV risk exponentially81, 85, 86. Hypertension (HTN) 
has a complex relationship with endothelial dysfunction, with alterations in regulatory 
pathways dependent upon the mechanism of the HTN. Regards the microvasculature 
(which is relatively spared from direct pressure effects), most studies agree that HTN is 
associated with impaired endothelial-dependent function but there has been divergence 
of opinion in relation to endothelial-independent function. Other factors (e.g. diabetes) 
strongly influence the response of the microvascular beds to HTN43. Ethnicity may be an 
important non-modifiable risk factor with South Asians tending to develop more severe 
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CAD at a younger age then other ethnic groups. However, there is conflicting evidence 
as to the impact of ethnicity per se on endothelial function (Table 1.3). Reduced capability 
of repair has been implicated74. Much of the excess CV risk in South Asians is explained 






Table 1.2 Prospective studies of modifiable CAD risk factors on vascular endothelial and smooth muscle function in humans 
Author/year Design Total 
participants 
Indices of endothelial dysfunction and outcome 
Diabetes 
Yaqoob 199330 Cross-sectional 
Case control 





27 Endothelium-dependent: independent blood flow ↓≈40% poor glycaemic control 
to normal subjects.  
Johnstone 199332 Cross-sectional 
Case control 
31 Endothelium-dependent blood flow ↓ in diabetics (p<0.01).  
Clarkson 199633 Cross-sectional 
Case control 
160 FMD significantly impaired in diabetics (p<0.001). 
Caballero 199934 Cross-sectional 
Case control 
143 ↓ Forearm iontophoresis of ACh (p<0.001) and ↑ ET-1, vWF, soluble ICAM and 
VCAM in diabetics and non-diabetics with diabetic first-degree relatives (all 
p<0.05). 
Beer 200835 Cross-sectional 
Case control 
92 Iontophoretically applied ACh and SNP ↓ in diabetics compared with controls. 
Williams 199636 Cross-sectional 
Case control 








Panza 199037 Cross-sectional 
Case control 
36 Maximal forearm flow was higher in patient than controls (p<0.0002). 
Spencer 200238 Randomised 
substudy 
(ASCOT) 
442 Patients with TOD had ↑ vWF (P=0.002). vWF independently predicted TOD 
(p<0.05). 
Lip 199539 Cross-sectional 151 Hypertensive patients had ↑ soluble P-selectin (p=0.03), vWF p<0.01) and 
fibrinogen (p < 0.01). DBP and vWF levels were significant predictors for 
fibrinogen levels (p<0.05). 
Lip 200140 Longitudinal 
Observational 
102 Fibrinogen and vWF ↑in the malignant hypertension group>non-malignant 
hypertension group>normotensive group (p < 0.001). After mean BP reduction at 
6-months both soluble P-selectin (p<0.001) and vWF (p=0.0025) were 
significantly reduced. 
Felmeden 200341 Longitudinal 
Observational 
346 Plasma VEGF and vWF levels ↑ in hypertensive patients than controls (all 
p<0.001). VEGF and vWF levels correlated significantly with age, systolic and 
diastolic BP, 10-year CVD risk, and CVA risk scores (all p<0.01). 
Taddei 200142 Cross-sectional 
Case control 
96 Vasodilation to ACh and SNP ↓ in essential hypertension compared with 
normotensive controls (p<0.01).  
Shantsila 201143 Cross-sectional 
Case control 
95 Malignant hypertension patients ↓ endothelium dependent and independent micro- 









Cross-sectional 44 ACh mediated dilatation ↓ in smokers c/w controls (p<0.05) 
Harmer 201445 Randomised 
Substudy 
(FIELD) 
193 Dilator responses to glyceryl trinitrate were ↓ in past and present cigarette 
smokers (p=0.005). 
Newby 200146 Cross-sectional 25 Current cigarette smoking was associated with ↓ coronary release of active t-PA 
(p<0.05). 
Zeiher 199547 Cross-sectional 96 Coronary FMD ↓ in smokers compared with non-smokers (p<.0001). Ratio of 
coronary FMD to nitroglycerine-induced dilation ↓ in smokers (p<0.001). FMD 
absent in smokers with CAD. Angiographic CAD (p<0.0001) and smoking 
(p<0.001) independently associated with reduced coronary dilation. 
Johnson 201048 Randomised 1504 1-year FMD increased by 1% in quitters (p=0.005), but did not change in those 
who continued smoking (p=0.643). Improved FMD among quitters remained 





200 FMD was impaired or absent in smokers (p<0.0001). FMD in smokers inversely 
related to lifetime dose smoked (p<0.01).  
Dyslipidaemia 
Vlahos 201450 Cross-sectional 
Case control 
60 HFH children exhibited ↓ FMD c/w controls (p<0.004). 
Gilligan 199451 Cross-sectional 
Case control 






Creager 199052 Cross-sectional 
Case control 
24 Maximal methacholine induced flow ↓ in hypercholesterolaemic subjects c/w 
controls (p<0.05). 
Sorenson 199453 Cross-sectional 
Case control 
60 FMD impaired or absent in hypercholesterolaemic children c/w controls 
(p<0.0001). TC inversely correlated with FMD (r= -0.61, p<0.0001). In 
hypercholesterolaemic children, FMD inversely related to Lp(a) (r= -0.61, 







397 % increase in coronary blood flow to ACh ↓ in obese patients c/w controls 
(p=0.009). Overweight (OR 1.55; 95% CI 1.2–2.0) and obesity (OR 2.41; 95% CI 




Cross-sectional 75 Structural and functional alterations in skin microcirculation are proportional to 
the increase in global and central obesity. Obese subjects with metabolic 





53 Obesity independently predictive of ↑ media: lumen ratio and media cross-
sectional area, together with impaired endothelial-dependent vasodilatation. After 
bariatric surgery and consistent weight loss microvascular structure and oxidative 
stress/inflammatory markers improved significantly (p<0.05). 
Exercise  
Lee 200657 Randomised 81 Patients completing cardiac rehabilitation ↓ levels of vWF, fibrinogen and D‐
dimer. FMD ↑ (all p⩽0.001). Levels unchanged in controls. Mean 24-hour 






Lewis 199958 Longitudinal 
Observational 
9 Endothelium-derived NO increased after 4 weeks cycle training. 
Psychosocial factors 
Harris 200359 Longitudinal 193 In women not using HRT, psychosocial factors (type A/anger) related to impaired 
FMD (p=0.03). 
Do 201060 Population 
survey 
434 In age- and sex-adjusted models, hopelessness linearly correlated with soluble 
ICAM1 but not e-or p-selectin. 
Fruit and vegetable consumption 
McCall 200961 Randomised 112 A 1-portion increase F+V consumption, led to 6.2% improvement in forearm 
blood flow responses to intra-arterial ACh (p=0.03). 
Plotnick 200362 Randomised 38 4 weeks of powdered F+V and anti-oxidant supplement improved brachial artery 
FMD (p<0.05). 
Ali 201163 Randomised 
Cross-over 
64 No significant difference in endothelial function with daily F+V supplement 
versus placebo for 8 weeks. 
Regular alcohol intake  
Djousse 199964 Longitudinal  
Cross-over 
13 No benefit of red wine on endothelial function assessed by FMD. 
Agewall 200065 Randomised 12 FMD was significantly higher after drinking de-alcoholised red wine than after 






ACE angiotensin converting enzyme, ACh acetylcholine, BP blood pressure, CAD coronary artery disease, CI confidence interval, CVA 
cerebrovascular atherosclerosis, CVD cardiovascular disease, c/w compared with, DBP diastolic blood pressure, ED endothelial 
dysfunction, ET-1 endothelin-1, FMD flow mediated dilation, F+V fruit and vegetable, GTN glyceryl trinitrate, HFH Heterozygous 
Familial Hypercholesterolaemia, HRT hormone replacement therapy, ICAM, intercellular adhesion molecule, Lp(a) lipoprotein (a), NO 
nitric oxide, OR odds ratio, SNP sodium nitroprusside, TC total cholesterol, TOD target organ damage, t-PA tissue plasminogen activator, 








Table 1.3 Prospective studies of non-modifiable CAD risk factors on vascular endothelial and smooth muscle function in humans 
Author/year Design Total 
participants 
Indices of endothelial dysfunction and outcome 
Gender 
Skaug 201366 Cross-sectional 4739 Endothelial function assessed by FMD ↑ in females across all age groups. At age 40–49, 
prevalence of ED was significantly higher (p=0.03) in men. 
Juonala 
200867 
Cross-sectional 2265 FMD values ↑ in women (p<0.0001), present after risk factor correction but attenuated 
after adjustment for baseline brachial artery diameter. 
Hashimoto 
199568 
Longitudinal 34 FMD ↑ during the follicular and luteal phases of menstruation corresponding with 
higher levels of endogenous oestrogen (p<0.01 compared to age-matched males).  
Celermajer 
199469 
Cross-sectional 238 In men, FMD preserved until ≤40 years but declined thereafter at 0.21%/year. In 
women, FMD was stable until the early 50s, then declined at 0.49%/year (p=0.002 




Cross-sectional 150 Coronary endothelial-dependent dilation ↓ in patients with near normal coronary arteries 






100 FMD impaired in the family history group (p<0.005).  
Age 








Cross-sectional 238 ↓ FMD in older age on multivariable analysis (r= -0.34, p < 0.0001).  
Donato 
200772 
Cross-sectional 95 Brachial artery FMD ↓≈50% in older versus young men (p<0.01). Nitrotyrosine ↑ in 
ECs obtained from the brachial artery and antecubital veins of older men (p=0.01 and 
















49 Circulating endothelial progenitor cells ↓ in South Asian c/w Caucasian men. Ethnicity 
was the strongest predictor of EPC count (B=0.65, p=0.001) 
Loehr 200475 Cross-sectional 
Case control 
1627 Adjusted absolute and % change in brachial artery diameter ↓ in African American c/w 





40 On multivariate analysis, postmenopausal status was associated with impaired FMD in 





87 No difference in the indices of angiogenesis, platelet activation, and ED between South 






Makin 200378 Cross-sectional 284 No difference in vWF, P-selectin, TF, or fibrinogen in South Asians with PAD 
compared to White Europeans. 
Lip 199779 Cross-sectional 225 No difference in vWF between black, white or South Asian hypertensive patients. 
Gunarathne 
200980 
Cross-sectional 293 In a multivariable analysis of arterial stiffness and endothelial function measurements in 
South Asian stroke survivors, South Asian ethnicity was an independent predictor. 
ACh acetylcholine, ANOVA analysis of variance, CBF coronary blood flow, ECs endothelial cells, ED endothelial dysfunction, EPCs 
endothelial progenitor cells, FMD flow mediated dilation, GTN glyceryl trinitrate, NF-κB nuclear factor kappa B, PAD peripheral arterial 




1.2.5 Non-conventional cardiac risk factors 
A number of serological markers of arterial vulnerability are currently recognised88. Most 
reflect endothelial injury but do have a causal relationship with CAD. Possibly with the 
exception of hsCRP89 and homocysteine90, most current cardiovascular biomarkers add 
little primary predictive value to traditional risk factors91. 
1.2.6 Atherosclerotic plaque formation and morphology 
1.2.6.1 A brief history 
The first reports of ‘hardening of the arteries’ were recorded as early as the sixteenth 
century92. In the mid to late eighteenth century, William Heberden was among the first of 
a group of English physicians to describe ‘a disorder of the breast’ (anginal chest pain)93. 
He and colleagues Edward Jenner and Caleb Hillier Parry also described the process of 
calcification of the coronary arteries94. Sir Marc Ruffer was able to identify in 1911 
degenerative arterial changes suggestive of atherosclerosis in the left subclavian artery 
from an Egyptian mummy95. His findings were later confirmed with more modern 
twentieth century tissue fixation methods96. Perhaps the most influential pathological 
insights were from Rudolph Virchow who, in 1856, described three processes he believed 
encouraged thrombogenesis97 – abnormal blood constituents (haemostatic and 
fibrinolytic pathways), abnormal blood flow (viscosity and shear forces [rheology]) and 
abnormalities of the blood vessel wall (endothelial damage/dysfunction)98. This was later 
expanded by Druguid to include a role for platelets99. With the benefit of previous work, 
we now recognise the importance of the endothelium in regulating several physiological 
systems such that endothelial injury – leading to dysfunction – may disrupt sufficient 




1.2.6.2 Response to injury  
In the latter half of the twentieth century considerable advances in our understanding of 
atherogenesis have come from work by Russell Ross who published the ‘response to 
(endothelial) injury’ theory in a series of papers throughout the nineteen seventies100, 101. 
He outlined three main events preceding the development of atherosclerotic lesions; 
intimal proliferation of smooth muscle cells, formation by these cells of large amounts of 
connective tissue matrix including collagen, elastic fibre proteins and proteoglycans, and 
deposition of intra- and extracellular lipid which can contribute to a necrotic core in more 
advanced lesions101. The initial intimal event is caused by some form endothelial injury 
of which there are numerous possibilities ranging from traditional CAD risk factors 
(described previously) to less conventional mechanisms such as immunologic injury or 
infections. If the injuring stimulus persists, ECs undergo structural and functional changes 
which lead to exposure of the underlying collagen and platelet adherence and aggregation. 
Release of platelet factors and plasma constituents stimulates both medial and intimal 
smooth muscle cell proliferation101. Later versions of the theory emphasise endothelial 
dysfunction rather than denudation, implying potential reversibility and plaque regression 
under favourable circumstances. There is a balance of endothelial injury and repair – a 
cycle that may persist for many years – leading to progressive smooth muscle 
proliferation. In any case, the different forms injury increase the adhesiveness, 
coagulability and permeability of the endothelium102.  
Although a systemic disease, atherosclerosis is a characteristic response of particular 
arteries occurring most commonly in the aortic, coronary, cerebral, femoral and iliac 
arteries100. It affects different organ systems in different patients. Coronary 




driven by underlying systemic inflammation, is present in the walls of the coronary 
arteries103. Amongst patients with comparable vascular risk factors, there is considerable 
lesion diversity. 
1.2.6.3 Atherosclerotic plaque progression 
Atherosclerosis is essentially a continuous process (Figure 1.3) however Stary et al104, 
expanding on Ross’ theory, outlined six distinct morphological stages of atheroma 
formation supported by the American Heart Association’s committee on vascular lesions 
(Figure 1.4). They are classified according to their histological composition and structure. 
Within this process a pre-lesional sometimes reversible phase (types 1-3) occurring in the 
first 3 decades of life and a phase of progressive plaque growth (types 4-6) can be 
distinguished105.  
The principal morphologies and sequences can be considered to be a bi-directional 
continuum consisting of a multitude of pathogenetic developments, including 
macrophage foam cell formation and death, accumulation of extracellular lipid, 
displacement and reduction of structural intercellular matrix and smooth muscle cells, 
generation of mineral deposits, chronic inflammation, neovascularization, disruptions of 
the lesion surface, and formation and transformation of hematoma and thrombus to 
fibromuscular tissue106. These processes are facilitated by a complex network of 
cytokines, pro-inflammatory and anti-inflammatory mediators (Tables 1.4-1.6107, 108). 
Any one of these processes may dominate (or be lacking) during lesion development. 
Some may continue throughout whilst others appear at various stages. Towards the latter 





















Bloodstream – altered 



















2. Activated platelets adhere to monocytes 
stimulating monocyte migration and further 
release of pro-inflammatory factors 
6. Plaque rupture and 
platelet aggregation 
3. Lipid-laden macrophage Foam cells 
4. Vascular smooth cell 
proliferation due to PDGF and 
intimal thickening 










Figure 1.3 Atherogenesis and the unstable atherosclerotic plaque 
1. EC activation and dysfunction causes increased vascular permeability. Surface 
adhesion molecules (e.g. ICAM-1 and VCAM-1) adhere to ECs. 2. Attachment and 
infiltration of lipid and inflammatory cells into the subendothelial space. 3. Monocyte 
differentiation into macrophages, engulfing lipid to form foam cells and releasing pro-
inflammatory cytokines (e.g. MCP1, IL-6, IL-1β) creating an inflammatory environment. 
4. VSMCs proliferate in response to mitogens such as PDGF and synthesise collagen to 
form the fibrous cap that encloses the growing lipid core. 5. VSMC apoptosis, in part 
mediated by engagement of death receptors on VSMCs with death ligands on 
macrophages and T lymphocytes, and increased activity of matrix-degrading enzymes in 
the cap. 6. plaque rupture, with subsequent platelet attachment and thrombosis. (ICAM 
intercellular adhesion molecule, IL interleukin, MCP monocyte chemoattractant protein, 
PDGF platelet derived growth factor, VCAM- vascular cell adhesion molecule, VSMC 




























Figure 1.4 Progression of atherosclerosis. Adapted with permission, from Stary et 
al. Natural History and Histological Classification of Atherosclerotic Lesions. ATBV 
2000;20:1177-1178.  
Intima at highly susceptible arterial sites  Intima at moderately susceptible 
arterial sites 
1. Isolated macrophage foam cells 
2. Multiple foam cell layers formed 
3. Isolated extracellular lipid pools added 
4. Confluent extracellular lipid core 
formed 
5. Fibromuscular tissue layers produced 
6. Surface defect, haematoma, thrombosis 
7. Calcification predominates 
8. Fibrous tissue changes predominate 
Regression 




Lipids and cells 
accumulate faster and 
advanced lesions 
develop first at highly 
susceptible, rather than 
moderately susceptible 
sites 
Successive type 6 episodes may lead to fibrosis, loss of 
lumen and vessel occlusion 
Regression or 
change of lipid 
in lesion types 
4-6 may result 





The evolution of atherosclerotic lesions from type 1 to type 4 and of the possible 
subsequent pathways of progression to lesion types beyond type 4. The main histological 
characteristics of each step (lesion type) are listed.  
Thick or thin arrows denote the relative ease with which lesions develop at specific sites, 
























Table 1.4 Inflammatory regulating enzymes and pro-inflammatory mediators in 
atherosclerosis 
Enzyme Function 
5-lipoxygenase (5-LO) -Produces leukotrienes and inflammatory 
lipid mediators. 
12/15-lipoxygenase (12/15-LO) -Facilitates lipid peroxidation and affects 
the adaptive immune response. 
Heme Oxygenase -1 (HO-1) -Reduces monocyte chemotaxis in 
response to LDL oxidation. 
-Facilitates antioxidant-dependent 
protection from atherosclerosis. 
Paraoxonases Hydrolyses oxidised lipids in LDL. 
Pro-inflammatory mediators 
Oxidised low-density lipoprotein 
(OxLDL) 
-Induces of foam cell formation. 
-Alters nitric oxide signalling.  
-Initiates endothelial activation. 
-Expresses adhesion molecules that 
accelerate leukocyte homing to the site of 
atherosclerosis. 
C-Reactive Protein (CRP) -Stimulates the production of IL-1α, IL-
1β, IL-6, CXCL1, and CXCL8 by human 
monocytes in vitro.  
-Upregulation of liver X receptor-α.  
-Binds to minimally modified LDL 
preventing the formation of foam cells 
from macrophages. 
Advanced Glycation End Products 
(AGE) 
-Elicits oxidative stress. 
-Increases production of inflammatory 
cytokines and tissue factor. 
-Elevates expression of adhesion 
molecules. 





Amplifies platelet recruitment. 
Toll-Like Receptors (TLRs) -Induces production of pro-inflammatory 
cytokines and nitric oxide in 
macrophages. 
-Induces dendritic cell maturation. 
-Upregulates co-stimulatory molecules 
such as CD80 and CD86. 
LDL low density lipoprotein, IL interleukin, CXCL chemokine (C-X-C motif) ligand, 



















Table 1.5 Cytokines in atherosclerosis 




-Pro-inflammatory, stimulates endothelial and 
SMC activation. 
IL-2 Activated T cells -T-cell growth factor, stimulates NK activity and 
Treg cells. 
IL-4 Th2 cells, mast cells -Proliferation and differentiation of B cells (Ig 
switching to IgG1 and IgE) and Th2 cells (anti-
inflammatory by inhibiting Th1 immune 
responses). 
-Stimulates VCAM-1. 
IL-5 T cells, mast cells, EC -Stimulates growth and differentiation of B cell 
antibodies. 
IL-6 Macrophages, EC, 
SMC, T cells 
-Differentiates myeloid cells. 
-Induces acute phase proteins and SMC 
proliferation. 
IL-8 Monocytes, EC, T 
cells 
-Pro-inflammatory, promotes leukocyte arrest. 
IL-9 Th2 cells -Promotes proliferation and differentiation of 
mast cells. 
-Stimulates IgE production. 
-Inhibits monocyte activation. 
-Stimulates TGF-β in monocytes. 
IL-10 Macrophages, Th2, 
Treg and B cells, mast 
cells 
-Anti-inflammatory, inhibits Th1 responses and 
promotes proliferation and differentiation of 
regulatory T cells. 
IL-12 Th1 cells -Pro-inflammatory, promotes NK and cytotoxic 
lymphocyte activity and induces IFN-γ. 
IL-18 Macrophages -Pro-inflammatory, induces IFN-γ and other Th1 
cytokines. 
-Promotes Th1 development and NK activity. 




-Reduces IFN-γ production and other pro-
inflammatory cytokines. 
M-CSF Macrophages, EC, 
lymphocytes 
-Growth and differentiation of macrophages 
TNF-α Macrophages, T & B 
cells, NK cells, SMC 
-Pro-inflammatory, fever, neutrophil activation, 
bone resorption, anticoagulant, tumour necrosis 
TGF-β Platelets, 
macrophages, Th3, 
Treg & B cells, SMC 
-Anti-inflammatory and pro-fibrotic, promotes 
wound healing, angiogenesis and suppresses Th1 
& Th2 immune responses. 
IFN-γ Th1 cells, NK cells, 
SMC 
-Pro-inflammatory, promotes Th1 immune 
responses/secretion of Th1-associated cytokines. 
-Inhibits extracellular matrix synthesis by SMC. 
CD40L Platelets, T cells, NK 
cells, EC, SMC 
-Pro-inflammatory, promotes Th1 immune 
responses/secretion of Th1-associated cytokines. 
-Stimulates MMP secretion. 
EC endothelial cell, Ig immunoglobulin, IFN-ɣ interferon-gamma, IL interleukin, MMP 
matrix metalloproteinases, NK natural killer, OxLDL oxidised low-density lipoprotein, 
SMC smooth muscle cell, TGF transforming growth factors, Th T helper, VCAM 













Table 1.6 Chemokines in atherosclerosis 
Chemokine Function 
CCL2 -Recruits monocytes from bone marrow 
into the arterial wall. 
CCL5 and CXCL4 -Monocyte and T cell recruitment into the 
vessel wall. 
-Activates ECs by inducing the 
expression of E-selectin, NF-κB 
activation, and enhanced binding of 
oxLDL to ECs. 
CXCL8 -Proliferation and migration of SMCs and 
ECs and affects neovascularisation. 
Migration inhibitory factor (MIF) -Inhibits monocyte migration. 
-Regulates lipid deposition, protease 
expression, and intimal thickening.  
CCL2 chemokine (C-C motif) ligand 2, CXCL (C-X-C motif) ligand, EC endothelial 
cell, NF-κB nuclear factor kappa B, oxLDL oxidised low-density lipoprotein, SMC 

















In stage 4 lesions, the cap constitutes pre-existing intima, which at susceptible sites 
undergoes adaptive thickening; however, the composition is like that of the normal 
intima. Most people with stage 4 atheroma will not have obstructive CAD because of the 
vessel’s ability to remodel outwards109. Progression through these stages is not uniform 
and preferred sequences exist, for example, a lesion may become increasingly obstructive 
by repeatedly passing between stages five and six. Up to 61% of stable lesions without 
thrombi contain evidence of healed plaques (i.e. repeated plaque ruptures) at post-
mortem110. Haematoma and/or thrombus formed during these repeated ruptures that do 
not produce clinical events are transformed into fibromuscular tissue, thus increasing cap 
size.  
Monocyte-derived macrophages play a pivotal role in the progression of atherosclerosis. 
They are also implicated in the genesis of new vessels (angiogenesis) brought about by 
local hypoxia within the plaque as it grows111, 112. The microcirculation within the plaque 
increases transfer of leucocytes which may further facilitates plaque growth. This is 
supported by evidence from murine models where inhibition of angiogenesis has been 
shown to limit lesion expansion113. 
1.2.7 Platelets 
Increasingly platelets are being recognised as important contributors to inflammation and 
both innate and adaptive immune responses. Activated platelets interact with all types of 
leucocytes, particularly monocytes, leading to up-regulation of a wide range of pro-
inflammatory functions such as release of pro-inflammatory cytokines (Table 1.5), ROS 




compartments containing α-granules, lysosomes and dense core granules as well as a 
complex membranous system allowing storage and release of the various factors114. 
1.2.8 Genetic regulators 
Patients in whom risk factors are present do not always develop CAD. Similarly, patients 
with relatively little background risk may develop severe CAD. Despite a significant 
inheritable component to CAD (~50%), technological limitations have meant the 
isolation of specific genes has not been forthcoming115. Following the advent of genome 
wide association studies (GWAS), our understanding of different patterns of gene 
expression has increased exponentially, leading to the identification of more than 50 CAD 
loci with genome wide significance. Approximately 70% of these genetic variants have 
no obvious mechanism (e.g. 9p21) whilst the remainder increase CAD risk via their 
influence on conventional risk factors (e.g. PCSK9). Trials of PCSK9 inhibitors have 
shown them to be effective in lowering LDL cholesterol116 and reducing cardiovascular 
events117. 
Contemporary studies have revealed microRNAs (negative regulators of gene expression 
acting at the post-transcriptional level), that are involved in SMC regulation and further 
identified several target genes which are implicated in SMC pathophysiology. Paracrine 
microRNA regulated crosstalk between endothelial and SMCs has also been 
demonstrated, revealing a mechanism through which vascular cells communicate. 
Moreover, altering microRNA expression levels can prevent and even reverse the 
acquisition of SMC synthetic phenotype in vivo and reduce neointimal formation, thereby 






Under normal homeostatic conditions the endothelium maintains vascular tone and blood 
fluidity with minimal expression of pro-inflammatory factors. CAD is a chronic 
multistage inflammatory disease beginning in the second and third decade of life. 
Progression depends on the balance of endothelial activation, injury and repair. The 
principal acute complication (and main cause of mortality) is myocardial infarction (MI) 
usually occurring because of plaque rupture or erosion followed by superimposed 
thrombosis. The influence of known risk factors and/or recently discovered genetic 
variants on EC biology in can increase lifetime CAD risk. Nonetheless, neither the 
severity nor the spatial heterogeneity of CAD are fully explained by conventional or novel 
risk factors and the mechanisms linking many of the newer genetic variants with CAD 













1.3 ADVANCED DIFFUSE CORONARY ARTERY DISEASE 
 
Since the endothelium is equally exposed to injury stimulants such as lipoproteins, the 
distribution and morphology of CAD is challenging to explain in mechanistic terms. The 
complex patterns of disease and the fact that molecular genetic investigations have not 
yet revealed specific genetic variants for either CAD or AMI, suggest alternative 
mechanisms are involved. The following paragraphs review the epidemiology, 
pathogenesis and prognosis relating to diffuse, obstructive (advanced) CAD.  
To gather as much relevant information as possible, on a subject that lacks a standard 
definition, I performed multiple searches of electronic bibliographic databases (i.e. 
MEDLINE, EMBASE and the Cochrane Database) hand searching references from 
included articles and abstracts from congress meetings. For the sections relating to 
definition, prevalence, pathogenesis and prognosis I used interchangeable phrases such 
as ‘refractory angina’, ‘end stage coronary artery disease’ and ‘no option for 
revascularisation’ – with the caveats that refractory angina does not always equate to 
advanced CAD and that people may be unsuitable for revascularisation for other reasons, 
therefore I undertook careful review of the angiographic criteria used in such studies. 
Regards cardiac risk factors, pathogenesis, arterial stiffness, monocytes, monocyte-
platelet aggregates and circulating microparticles I performed separate searches using the 
relevant headings in relation to coronary artery disease applying adjectives such as 
‘severe’, ‘diffuse’, three-vessel’ or multivessel’. Bibliographies of all selected articles and 






1.3.1 Definition and prevalence 
There is no single definition of diffuse CAD per se. Moreover, a number of phrases are 
used interchangeably to represent an expanding group of patients unsuitable for 
conventional revascularisation, or patients in whom therapeutic options have been 
exhausted8. The European Society of Cardiology (ESC) has defined refractory angina as 
“a chronic condition (>3 months) characterized by the presence of angina caused by 
coronary insufficiency in the presence of CAD which cannot be controlled by a 
combination of medical therapy, angioplasty, and coronary bypass surgery”120. A flow 
limiting lesion can be considered diffuse in the presence of; a significant (usually ≥70%) 
stenosis longer than 20 mm or multiple significant stenoses in the same artery or 
significant narrowing involving the whole length of the coronary artery121, 122. In some 
studies diffuse CAD has been defined when ‘more than two-thirds of the left or right 
coronary artery is affected by irregularities or stenoses’123. The ACC/AHA classification 
system (Table 1.7) uses eleven variables to stratify lesions into one of four categories (A 
[simplest], B1, B2 and C [most complex]) predictive of PCI success121. Type A lesions 
are, by definition, discrete (<10mm). Type C lesions are diffuse (>20mm). Type B lesions 
display various complexities in between types A and C.  
A Swedish survey in 1994–1995 found that 9.6% of patients referred for coronary 
angiography with stable angina were not candidates for revascularization due to advanced 
CAD120. In the Minneapolis Heart Institute series of CAD patients, 6.7% were on optimal 
medical management and not candidates for revascularization (‘no option’ patients) and 
a further 9.3% were not candidates for revascularization but received additional medical 
therapy124. Among 5767 CAD patients covered by the Euro Heart Survey 21% were 




that 14% of a subset of 4409 patients was ineligible for traditional revascularization126. 
In one catheterisation laboratory population, the prevalence of advanced CAD (defined 
as unsuitable for revascularisation) is >15%. In the Mediators of Social Support (MOSS) 
study, the same authors found that 41% of patients with three vessel CAD were unsuitable 
for revascularisation4. A more recent analysis of 16,215 patients undergoing coronary 
angiography revealed that 5.9% of people with advanced (three vessel) CAD (1.3% 

















Table 1.7 ACC/AHA intracoronary lesion classification121 
Type Description 
A <10mm, discrete, concentric readily accessible, <45-degree angle 
smooth contour, little or no calcification, less than totally occluded, not 
ostial, no major side branch involvement, absence of thrombus. 
B1 One of the following characteristics: 10-20mm, eccentric, moderate 
tortuosity of proximal segment, irregular contour, presence of any 
thrombus grade, moderate or heavy calcification, total occlusion <3 
months old, ostial lesion or bifurcation lesion requiring two guide wires. 
B2 Two or more of the following characteristics: 10-20mm, eccentric, 
moderate tortuosity or proximal segment, irregular contour, presence of 
any thrombus grade, moderate or heavy calcification, total occlusion <3 
months old, ostial lesion or bifurcation lesion requiring two guide wires. 
C >20 mm diffuse, excessive tortuosity of proximal segment, total 
occlusion >3 months old and/or bridging collaterals inability to protect 














1.3.2 Coronary artery disease severity indexes 
A variety of scoring systems quantifying angiographic CAD burden exist (Table 1.8128-
134), many of which have been validated against IVUS and correlate well with each 
other135.  
In 1993 Bogaty et al published a report detailing topographically distinct patterns of CAD 
in patients suffering an index MI compared to patients diagnosed with stable angina 
without prior MI136. They devised a system to describe CAD severity, extent and pattern 
(The Bogaty score). The authors noted a discrete pattern in 54.5% of patients with 
unheralded infarction compared to 8.5% of those with uncomplicated angina (p<0.001). 
On the other hand, multivessel disease was found in 74.5% of subjects with 
uncomplicated angina, and 29.1% in patients with MI. These findings were subsequently 
reproduced by Cianflone et al137. It was proposed that different pathogenic processes led 
to some people developing diffuse (but stable) disease and others more focal disease 
prone to instability rather than the same pathophysiological process randomly producing 











Table 1.8 Coronary angiography severity scores validated against IVUS 
Author (Year) Score 
Gensini GG (1983)129 Gensini  
Ringqvist I (1983)130 CASS-50 
Ringqvist I (1983)130 CASS-70 
Dash H (1977)131 Duke Jeopardy 
Mark DB (1994)132 Duke CAD Severity Index 
Friesinger GC (1970)133 Friesinger 
Sullivan DR (1990)134 Sullivan vessel  
Sullivan DR (1990)134 Sullivan stenosis  
Sullivan DR (1990)134 Sullivan extent  
Jenkins PJ (1978)128 Jenkins  















1.3.3 The role of coronary risk factors in determining disease topography 
In general angiographic CAD burden increases with the number of documented CAD risk 
factors138. The nine modifiable risk factors listed in Table 1.2 explain more than 90% of 
the population attributable risk of acute MI in both men and women81. However, certain 
risk factors have been associated with particular CAD phenotypes (Table 1.9123, 139-151). 
The ‘smokers paradox’ for example refers to the observation in a number of pre-PPCI 
(primary percutaneous coronary intervention) studies142, that smokers have improved 
survival after reperfusion following MI. Insights from large trials of the era suggested this 
was, in part, due to the fact that smokers presenting with acute MI had less extensive 
CAD than non-smokers139, 141. This was explained by the prothrombotic effects of 
smoking leading to index events at a younger age when there are less associated 
comorbidities152. Indeed, when these cofactors are adjusted for the difference is 
attenuated – completely in some studies142 – partially in others153. 
South Asians (SAs) have the highest rate of CAD amongst all populations. 
Epidemiological studies suggest that the likelihood of developing CAD in SAs is twice 
that of Europeans and five times higher than Chinese people, irrespective of their country 
of residence154. Moreover, SA men and women are susceptible to premature (<40 years 
or pre-menopause), accelerated CAD with three vessel disease found in half of all SAs 
and one-third of premenopausal women155. Tillin et al148 reported longer, more severe 
CAD in the proximal LAD segments of South Asian men compared to white European 
men although no difference in overall coronary artery calcification (CAC) scores. In this 
small underpowered study, South Asians were also noted to have significantly smaller 
proximal LAD, carotid and femoral lumens than Europeans even after adjustment for age 




Interestingly, the difference in proximal LAD lumen diameter was eradicated in men with 
more advanced CAD, raising the possibility of either a tendency toward more outward 
remodelling in South Asians, or that inward remodelling occurs earlier in the atherogenic 
process and is then attenuated (hypothesised by the authors). Alternatively, comparable 
CAC scores between the two may indicate ongoing susceptibility to plaque rupture 
events. In contrast, Koulaouzidis et al149 found significantly more aggressive and diffuse 
calcification in South Asians compared to white Europeans (p = 0.003 for CAC 101-400, 
p = 0.004 for CAC 401-1000) but interestingly this was not the case in patients under 
fifty, despite established evidence that CAD affects South Asian people earlier than other 
ethnicities.  
Peripheral artery disease (PAD) evidenced by an ankle-brachial index <0.9 is associated 
with more complex lesions (B2 and C) at angiography but this could be a bi-directional 
association. However, the observation that South Asians have comparatively little PAD 
despite higher rates of diffuse or multivessel CAD would suggest that mechanisms behind 
PAD may relate to CAD but not vice versa156.  
Fischer et al123 retrospectively examined the inheritable patterns of CAD in families 
where multiple members had been diagnosed. They did not identify any particular genetic 
component to the overall diffuseness of CAD and certainly no consistent genetic 
contribution regards ‘focal versus diffuse’ but did note an increased likelihood of diffuse 
CAD in the left coronary artery as compared to the right. This is the largest study of this 
kind so the significance of that finding is uncertain although the authors also report 
increased likelihood of siblings developing other high risk angiographic patterns such as 
ostial, proximal and left main disease, ectasia or calcification at presentation, which tend 




In the Mediators of Social Support (MOSS) study age and diabetes were the only 
univariate predictors of patients with advanced CAD unsuitable for revascularisation. 
Other recorded risk factors such as hypertension, smoking and gender were similar when 
compared to patients with advanced disease but suitable for revascularisation4. In another 
study124, the presence of chronic kidney disease (CKD) was also more likely in patients 
not suitable for revascularisation however the presence of CKD may preclude 
revascularisation independently of CAD morphology and there was no multivariate 
analysis to delineate the true association. 
It is also interesting to note that in a dedicated refractory angina registry 33% had never 
smoked, 31% had no history of hypertension, 34% had no family history of CAD and 



















Table 1.9 Influence of selected CAD risk factors on angiographic CAD phenotype 







2573 Single-vessel and non-LAD 





3339 Never smokers more LAD 
infarcts (p<0.001). Current 





41021 Non-smokers ↑ TVD c/w 
smokers (p=0.001). 
Smoking associated with 
improved survival (OR 
1.25, 95% CI 1.11 to 1.39) 
Grines/1995142 Pooled RCT 
data 





116 Diabetics had similar 
number of diffusely 
diseased vessels as controls 
(p>0.05). CAD more 
extensive but not more 





546 Diabetics more severe and 




673 More severe, multifocal and 
diffuse forms of CAD in 
diabetics. 
Wilson/1983146 Case control 116 Diabetics had more severe 
CAD in the mid segments of 
epicardial arteries but no 







35 Coronary arteries and their 
branches significantly 




882 Diffuse CAD more heritable 
in LCA than RCA (p=0.03). 
No. of diseased vessels and 
lesion length did not show 
significant heritable 
components but proximal, 





83 South Asian men had more 
proximal LAD disease and 
longer lesions than 
European men. No 
difference in overall CAC. 
Koulaouzidis/2013149 Retrospective 
cohort 
202 South Asians over 50 years 





782 African Americans and 
Hispanic patients less CAD 
burden and CAC than White 
patients. 
Gender 
Kyriakidis/1995151 Prospective  735 More MVD and higher 
Gensini scores in men. 
CAC coronary artery calcification, CAD coronary artery disease, CI confidence 
interval, LAD left anterior descending, LCA left coronary artery, LMS left main stem, 
MLD minimal luminal diameter, MVD multivessel disease, OR odds ratio, RCA right 










1.3.4 Pathogenic mechanisms 
The absence of an objective definition of diffuse CAD and the evolutionary nature of 
atherogenesis make the precise pathophysiological mechanisms underlying its 
development more challenging to pinpoint. Genetic variations alter the expression of 
immuno-modulatory receptors and vascular endothelial cells which may adapt the 
mechanism outlined in Figure 1.4, causing some people to cycle more frequently between 
stages five and six of the atherogenic process or accelerate the calcification process. The 
following paragraphs detail current understanding of the pathophysiological situation in 
patients with different expressions of CAD.  
1.3.4.1 Endothelial shear stress 
Despite the global effect of injury stimulants on arteries, the topography of atherosclerotic 
CAD is highly variable between individuals. Part of the difference can be explained by 
differences in blood flow induced shear stress to which the endothelium is exposed – 
endothelial shear stress (ESS) – brought about by curvatures or branches in the arterial 
tree which cause disturbed flow patterns157. Shear stress is tangential stress derived from 
the friction of the flowing blood on the endothelial surface of the arterial wall and is the 
product of blood viscosity and shear rate at the artery wall. Blood tends to flow quicker 
at the wall then it does at the centre of the lumen. Shear rate is the gradient of flow speed 
from the middle towards the wall158.  
Different forms of shear stress exist according to the force per unit area on the blood 
vessel wall. Laminar shear stress (>12dyn/cm2 without oscillation) and pulsatile shear 
stress (>12dyn/cm2 with oscillation) are atheroprotective and both result in up-regulated 




stress (0-0.5dyn/cm2 with oscillation) cause up-regulation of monocyte chemoattractant 
protein (MCP)-1 and adhesion molecules through sustained release of atherogenic flow 
sensitive micro RNAs160. Turbulent blood flow, such as that caused by irregular wall 
geometry (e.g. bifurcations), leads to low (oscillatory) ESS which is detected by 
mechanoreceptors on the EC membrane. Signals are transmitted throughout the EC 
cytoskeleton initiating a cascade of inflammatory, proliferative and apoptotic pathways – 
thereby potentiating processes that favour the development and progression of 
























Figure 1.5 Pro-atherogenic pathways up-regulated by oscillatory shear stress.  
Disturbed laminar flow causes low endothelial shear stress (ESS) which leads to 
endothelial activation, ultimately promoting atherogenesis, atherosclerotic plaque 
formation and progression, and vascular remodelling. BMP bone morphogenic protein; 
DNA deoxyribonucleic acid; EC endothelial cell; EMP endothelial microparticles, ET 
endothelin; ICAM intercellular adhesion molecule; IFN interferon; IL interleukin; KLF4 
Krüppel-like factor 4, LDL low-density lipoprotein cholesterol; MCP monocyte 
chemoattractant protein; miR flow sensitive (mechano) micro RNA; MMP matrix 
metalloproteinase; NADPH nicotinamide adenine dinucleotide phosphate; NO nitric 
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factor; ROS reactive oxygen species (red circles); TGF transforming growth factor; TNF 
tumour necrosis factor; t-PA tissue plasminogen activator; VCAM vascular cell adhesion 




















The role of low ESS with a high oscillatory index in modifying EC function is 
fundamental to the development of atherosclerosis. On the other hand, very high ESS 
(≥70dyn/cm2) can produce endothelial damage, promote platelet deposition and may 
promote plaque rupture161. ESS undergoes continual modification in response to local 
surroundings and is influenced by the severity and duration of systemic risk factors, as 
well as arterial wall stiffness and remodelling162. Hence, plaque growth affects local ESS 
at the level of the plaque and immediately downstream which may cause a progressive 
cycle of atherosclerosis163. 
1.3.4.2 Vascular remodelling and ESS 
Intracoronary imaging studies (Table 1.10157, 163-169) have improved our understanding of 
the different forms of vascular remodelling, their effect on ESS and their relationship to 
CAD progression and plaque stability. Vascular remodelling influences not only the 
degree of luminal encroachment at that site but also plaque composition. Large plaque 
burdens with low ESS independently predict progressive enlargement and luminal 
stenosis163.  
A lesion is more likely to become flow limiting (obscuring ≥70% of the lumen) if it 
undergoes constrictive remodelling (Figure 1.6) however in vivo intravascular studies 
have demonstrated considerable heterogeneity in the local haemodynamic environment 
within which each plaque is situated158. The majority of severe plaques exist in a 
physiological ESS, usually brought about by a combination of compensatory expansive 
and subsequent constrictive remodelling164. Once normal ESS is re-established, the pro-
atherogenic molecular and cellular phenotype of ECs (shown in Figure 1.5) may be 




Advanced lesions that were exposed to low ESS during their initial phases (influenced by 
the degree of inflammation) continue to experience low ESS, maintenance of pro-
atherogenic EC phenotype and progression of CAD. Furthermore, Koskinas et al found 
that plaque-associated low ESS exacerbates atheromatous development in areas that 
already have a large plaque burden164. Thus, a severe (flow limiting) lesion associated 





























Figure 1.6 Types of vascular remodeling. 
1. Low ESS may initially cause compensatory expansive remodelling. If ESS returns to 
physiological levels, then the lesion may remain quiescent. 2. If ESS remains low then 
excessive expansive remodelling may occur associated with larger plaque burden and thin 
capped fibroatheroma. 3. High ESS may lead to constrictive remodelling associated with 
fibroproliferation and luminal stenosis. 4. The lesion itself modifies ESS causing 
oscillatory flow patterns at the distal shoulder facilitating further lesion progression. 
Alternatively, if the constrictive lesion exists within physiological ESS, it may not 
progress.
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Table 1.10 Natural history studies of endothelial shear stress and vascular remodelling in relation to coronary artery disease 
Author/year Design Objective Outcome/conclusions Comment 










progression and relate 
to clinical events. 
-Baseline large plaque burden and 
low ESS predicted increase plaque 
area and decreased lumen area at 
FU. 
-Significant change despite only 6-10 
months gap. 
-ACS patients only, more 






Assess the role of ESS 
and VR in CAD. 
-Most plaque caused compensatory 
expansive remodelling. 
-↓ ESS in areas of excessive 
expansile remodelling. 















development of CAD 
-Atherosclerosis more common at 
inner wall of curvatures and outer 
wall of bifurcations. 
-recirculated flow and ↓ ESS noted 
in these areas. 
-Detailed exploration of flow 







Assess the impact of 
ESS on CAD 
progression. 
- ↓ ESS develop ↑ plaque 
progression and constrictive 
remodelling (p<0.001) 









Stone 2003166 Pilot 
longitudinal 
6 patients. 
Assess ESS in 
prediction of 
progression of CAD 
and ISR. 
-↓ ESS showed ↑ in plaque 
thickness and outward remodelling 
at FU. 
-IVUS used. 
-Non-obstructive (≤50%) disease in 
native vessel and IMT in stented 
segment. 
-short (6 months) FU. 
Stone 2007167 Pilot 
longitudinal 13 
patients 
Investigate effects of 
different ESS 
environments on 
plaque and wall 
characteristics at 6 
months. 
-Remodelling responses to ↓ ESS 
are highly variable. 
-Plaque progresses in ↓ ESS areas. 
-IVUS used. 
-Stable CAD. 




cross section 21 
patients 
Assess relationship 
between local ESS 
and coronary plaque 
characteristics. 
-↓ ESS had ↑ lipid-rich plaques 
(p=0.019), ↑ thinner fibrous cap 
(p=0.004), and ↑TCFA (p=0.037)  
-↓ ESS had ↑ cross-sections with 
lipid plaque (p=0.021) and ↑ 
macrophage density within the 
fibrous cap (p=0.017). 



















Assess role of local 




-Eccentric plaque formation at FU 
in normal segments predicted by 
baseline ↓ ESS (p<0.001), ↑ ESS 
circumferential heterogeneity 
(p=0.001), and their interaction 
(p=0.026).  
-↓ ESS (p=0.003) and ↑ plaque 
burden (p=0.002) at baseline 
predicted ↑↑ plaque eccentricity 
index with ↑ stenosis at FU in 
diseased areas. 
-Significant change despite only 6-10 
months gap. 
-ACS patients only, more 
inflammatory than stable patients. 
ACS acute coronary syndrome, CAD coronary artery disease, ESS endothelial shear stress, FU follow up, ISR in-stent restenosis, IMT 
intima media thickness, IVUS intravascular ultrasound, OCT optical coherence tomography, TCFA thin capped fibroatheroma, VH-IVUS 




1.3.4.3 Arterial stiffness 
Arterial stiffness (ArS) refers to the ability of an artery to expand and contract in response 
to pressure changes170. Compliance (volume change [ΔV] in response to a change in blood 
pressure [ΔV/ΔP]) and distensibility (compliance relative to initial volume [ΔV/ΔP × V]) 
are measures (sometimes used interchangeably) that relate to wall stiffness. Distensibility 
can be measured directly using magnetic resonance or computed tomography171. 
Alternative non-invasive measures of ArS include pulse wave velocity (PWV), central 
and peripheral pulse wave analysis, aortic augmentation index (AIx) and arterial elastance 
(Ea)172-174. 
Increases in ArS favour a state of endothelial activation/injury – leading to subsequent 
damage/dysfunction – by altering the exposure of endothelial and vascular smooth muscle 
cells to ESS175. Animal models have shown that coronary perfusion falls with decreased 
aortic compliance176, 177. The alteration in shear forces could induce endothelial 
inflammation as well as causing subendocardial ischaemia with subsequent rise in ROS 
and pro-inflammatory cytokines. Furthermore, the outer wall of the ascending aorta 
receives blood supply from the vasa-vasorum which is linked to coronary circulation 
therefore reduced coronary perfusion could create a perpetuating cycle of abnormal aortic 
elasticity and worsening CAD178. Arterial stiffness is a strong predictor of future 
cardiovascular events and all-cause mortality and has been shown in numerous, mainly 
cross sectional, human studies to correlate with the presence, and in some cases, the 
severity of CAD (Table 1.11171, 178-192). Similar results were reported in a longitudinal 







Table 1.11 Studies of measures of arterial stiffness in humans with stable coronary artery disease 
Author/year Design No. of 
participants 






42 Determine differences in 
aortic distensibility between 
patients with and without 
CAD. 
-CAD patients had similar 
aortic pressures but markedly 
lower distensibility. 
-Normal coronary arteries 
defined as 0% stenosis – 
minor plaque excluded. 
-Small sample. 
-No differentiation of 
severity of CAD. 






164 Use CTCA to examine the 
relationship between 
changes in aortic stiffness 
and coronary atherosclerotic 
burden. 
-CAD burden (assessed by 
segmental involvement score) 
was inversely linearly 
correlated with ADI 
(p<0.001). 
-Aortic stiffness measured 
as distensibility. 
-Potential bias from 
interpretation of both 
outcome measures by the 
same investigator. 
-Severe disease (people 
with CABG or previous 
PCI) excluded. 
-Highly select group of 
people having two CTCAs 







intervention – hence only 






32 Evaluate the relationship 
between endothelial function 
and conduit vessel 
distensibility in normal 
subjects, patients with stable 
CAD, and patients with risk 
factors but no CAD. 
-Flow mediated dilatation 
significantly correlated with 
central pulse pressure (r= 
−0.457, p=0.019), central 
systolic pressure (r= −0.442, 
p=0.024), peripheral pulse 
pressure (r= −0.393, 
p=0.039), peripheral systolic 
pressure (r= −0.398, 
p=0.036), and proximal aortic 
compliance (r= 0.390, 
p=0.049). 
-No correlation between 
FMD and AIx or PWV. 
-Small sample size. 
-Flow mediated dilatation 




-PWV, aortic compliance 
and augmentation index 
used for arterial stiffness. 
-Groups not age matched. 
-Correction required for too 
many variables relative to 
sample size – could lead to 





46 Compared invasive measures 
of aortic distensibility with 
measures obtained non-
invasively, using 2D and M 
mode echocardiography. 
-Showed that estimates of 
aortic distensibility could be 
obtained non-invasively with 
a high degree of accuracy (r= 
0.949, p=0.0001) 
-Near perfect linear 
relationship between echo 
and catheter measurements. 
-Under estimation of pulse 
pressure using peripheral 













(26 for the 
substudy) 
Compare measures of aortic 
distensibility index with 
severity of CAD measured 
by CTCA. 
A substudy comparing CT 
with echo measurements was 
also performed. 
-Excellent correlation 
between CT and echo (r2= 
0.94, p<0.001). 
-Strong inverse correlation 
between ADI and coronary 
artery calcium (CAC) (r= -
0.69, p=0.0001).  
-Severity of CAC increased 
in each Framingham risk 
category as ADI decreased. 
-Patients with established 
CAD excluded. 
-The presence of CAC as 
an outcome measure 
suggests CAD is 
established anyway. 
-ADI independently 
predicted significant CAD. 
-Luminal stenosis difficult 





100 Compare regional aortic 
compliance in patients with 
and without CAD. 
-Patients with CAD or 
syndrome X ↓ or no 
measurable aortic 
compliance. 
-Very uneven groups (70 
normal controls, 10 CAD 






376 Assess the relationship 
between aortic distensibility 
and the extent and 
complexity of atherosclerotic 
lesions assessed with 
SYNTAX score (SS) in 
patients with stable CAD. 
-SS ↑ in patients with low AD 
c/w the high AD group 
(separated according to 
median value – 18.5 ± 10.2 
vs. 8.3 ± 5.9, p<0.001). 
-AD independently associated 
with age (β= –0.104, 
p=0.019), hypertension (β= –
-AD measured using 
echocardiography. 
-Large sample size relative 
to other studies of a similar 
nature. 







0.202, p<0.001) and SS (β= –
0.457, p<0.001). 
Shapiro-Wilk better for this 
sample size. 





96 Investigate the association 
between elasticity indexes of 
the aorta (aortic 
distensibility [AD] and 
aortic strain [AS]) and 
severity of CAD in patients 
with stable CAD. 
-AD (beta= -0.577, p=0.003) 
and AS (beta= -0.494, 
p=0.021) independently 
associated with Gensini score 
on multiple linear regression 
analysis. 
-Used echocardiography to 
measure aortic elasticity 
indexes. 
-Used Gensini score for 
CAD severity. 
-Patients in the control 











293 Determine the relationship 
of AD to the presence and 
morphological features in 
coronary and thoracic 
atherosclerosis.  
-The associations of AD with 
different morphologies of 
CAD were entirely explained 
by age and not independently 
related. 
-Defined non-calcified 
plaque as well as calcified 
plaque. 
-Used Hounsfield units 
>130 but no Agatston 
classification used. 
-Simultaneous acquisition 
of the AD measurements 













108 Evaluate the association of 
arterial elasticity indexes, 
serum uric acid and the 
presence and extent of CAD 
in patients with chronic 
stable angina. 
-Small artery elasticity index 
(SAEI) independently 
reflected the extent of CAD.  
-Serum uric acid associated 
with extent of CAD  
Serum uric acid 
independently associated with 
systemic vascular resistance 
and SAEI. 
-CAD severity assessed 
with the Gensini score.  
-Applanation tonometry 
used to assess arterial 
elasticity. 
-Stable angina diagnosed 
with symptoms, no 
document of ischaemia. 
-No control group. 
-SAEI only 22% of the 





151 Analyse to what degree 
SAEI and LAEI can reflect 
atherosclerotic burden as 
assessed by angiography. 
-SAEI independently predicts 
diffuse disease but LAEI does 
not. 
-Patients with valve disease 
included. 
-Classified angiographic 
disease as diffuse, focal or 
no CAD, no scoring system 
used – eyeball visual 






380 Examined the influence of 
CAD risk factors on the 
association between SAEI in 
-SAEI significantly ↓ in CAD 
patients than no CAD patients 







patients with and without 
CAD. 
elasticity index (LAEI) was 
similar in patients with and 
without CAD. 
-The association between 
SAEI and CAD in male 
hypertensive patients 
independent of conventional 
risk factors for CAD. 
-Severity of CAD not 
quantified. 







101 Examine arterial stiffening 
in angina patients with CAD. 
-Abdominal aortic and carotid 
distensibility lowest in the 3-
vessel disease group c/w 2 
and 1-vessel disease. 
-Suggests that large artery 
stiffening can be regarded as 
a marker of the coronary 
status. 
-CAD grouped according to 
one, two or three-vessel 
disease. 
-Arterial distensibility 
measured at the radial, 
subdiaphragmatic aorta and 
carotid sites. 
-Medications continued. 
-All patients had angina 
(not defined). 
-Not fasted morning of 
appointment. 







Dart 1991190 Cross 
sectional 
93 Examine the effect of CAD 
and hypercholesterolaemia 
without CAD on age-related 
aortic stiffness. 
-Presence of CAD associated 
with lower transverse arch 
aortic distensibility 
independent of age. 
-Paradoxical, unexplained 
finding that AD was higher in 
those with 
hypercholesterolaemia 
without CAD then in normal 
controls. 
-Four groups investigated 
including post-transplant 
patients. 
-Multivessel CAD only in 
CAD group. Diffuse or 
focal not quantified. 
-Echocardiography of the 
transverse aortic arch. 






96 Determine whether large 
artery stiffness 
independently predicts 
ischaemic threshold in 
patients with CAD. 
-Ischaemic threshold related 
to a critical stenosis, not the 
extent of CAD. 
-Systemic arterial 
compliance, distensibility 
index and carotid 
augmentation index were 
independent predictors of 
shorter time to ischaemia. 
-Measures of large artery 
stiffness included systemic 
arterial compliance, 
distensibility index, pulse 
wave velocity and carotid 
augmentation index. 
-CAD classified as 1, 2 or 






501 Investigate the relationship 
between CAVI and NT-
proBNP in hypertension and 
CHD subjects. 
-CAVI and NT-proBNP ↑ in 
hypertension subjects with 
CHD (p<0.001). 
-NT-proBNP predicted CAVI 
(β= 0.15, p=0.021). 
-Difference in medication 







AD(I) aortic distensibility (index), AS aortic strain, BP blood pressure, CAC coronary artery calcium, CAD coronary artery disease, CAVI 
Cardio-ankle vascular index, CT computed tomography, CTCA computed tomography coronary angiogram, c/w compared with, FMD flow 
mediated dilatation, LAEI large artery elasticity index, NT-proBNP N terminal-pro brain natriuretic peptide, PWV pulsed wave velocity, 




1.3.4.4 Monocyte subsets and their platelet aggregates in stable CAD 
1.3.4.4.1 Monocyte subsets 
Atherosclerosis is a result of complex interaction between leucocytes (primarily 
monocytes), ECs, ESS, vascular remodelling and platelets, influenced by cardiac risk 
factors and mediated by various growth factors and cytokines. Monocytes are 
mononuclear phagocytes of myeloid origin that represent approximately six percent of 
the total leukocyte population in adults193. They are currently considered to exist as three 
distinct subsets, partly explaining their diverse functionality (Table 1.12); Mon1 
CD14++CD16- (classical, about 85% of monocyte population), Mon2 CD14++CD16+ 
(intermediate, about 5%) and Mon3 CD14+CD16++ (Non-classical, about 10%)194. 
Monocytes play a key role in all stages of atherogenesis from vascular recruitment and 
diapedesis to and from injured ECs, to lipid-laden macrophage-like foam cell formation 
and repair following AMI. Moreover, specific subsets are differentially involved in a 
range of conditions including ACS, heart failure, stroke, kidney disease and inflammatory 
arthritis195-199.  
Knowledge from mouse models has informed our understanding of monocyte subset 
activity under homeostatic conditions in humans200. For example, comparisons of gene 
and protein expression in mice and humans have revealed several properties unique to the 
Mon3 (non-classical) population such as heightened metabolism and cytoskeletal 
features, consistent with their ‘patrolling’ phenotype201. Furthermore, the transcriptional 
range of Mon2 (intermediate) is in between that of Mon1 (classical) and Mon3197. Genes 
associated with maturity are more frequently found on Mon3. Indeed, studies have shown 




this is due to increased differentiation of CD16- monocytes or new production is not 
known.  
Several clinical studies, summarised in Table 1.13, have evaluated circulating total 
monocytes and monocyte subsets in stable CAD and its associated CV risk factors196, 203-
213. While many reports suggest increased ‘CD16+’ monocyte levels in more advanced 
CAD including in-stent restenosis, they are limited by the analysis of Mon2 and Mon3 as 
one CD16+ subset. Hristov et al210 showed that Mon1 counts were highest (p = 0.006) 
and Mon3 counts lowest (p = 0.001) in patients with ≥5 CAD risk factors elucidating a 
link between monocyte mediated endothelial inflammation and traditional risk factors in 
CAD. The number of risk factors also predicted the percentage of Mon2 monocytes 
(p=0.042) but interestingly, the extent of CAD (one, two or three vessel) showed no 
association with individual subset counts. This could have been due to small numbers in 
each of the disease categories. Expanding this, Czepluch et al observed a relative increase 
in the percentage of Mon1 counts in CAD patients214. In contrast, Krychtiuk et al211 found 
LDL particle size to be negatively correlated with Mon3 counts (r=0.25, p=0.017). Mon3 
counts were also significantly increased in multivessel CAD whereas Mon1 and Mon2 
were unchanged, although the lack of a control group in this study is a limitation. HDL 
cholesterol levels, on the other hand, have been negatively correlated with Mon2 counts 
in chronic kidney disease (CKD) patients215. Wrigley et al, in a study of acute ischaemic 
heart failure (HF), noted no difference in subset counts between their two control groups 
– one of CAD without HF, the other disease free216. Silent CAD in the latter is a 
possibility. Mon2 counts have been shown to predict CV events in different patient 





Table 1.12 Comparison of human monocyte subsets 
Monocyte 
subset 





CD14, CD86+, CD45, HLA-DR, 
CCR2, CXCR 1, 2 and 4, 
CD62L, CD93, CD64, CD32, 
CD36, FCN1 (ficolin-1), SIRPA 
(signal-regulatory protein alpha), 
CCR1, CD11a/CD18, 
CD11b/CD18, CD36, class A and 
B scavenger receptor, AP-1 
transcription factor genes, 
CLEC4D, IL-13Rα1, VEGFR1.  
-Production of IL-10 and IL-
6, IL-8, TNF-α, IL-1β and 
CCL2.  
-High myeloperoxidase and 
phagocytic activity - ingest 
native LDL. 
-Preferential differentiation 
into M1 macrophages. 
-CCR5 and CX3CR1 
mediated recruitment to 
atherosclerotic plaques. 
-Angiogenesis 
-Recruitment during the early 





CD14, CD16, CD86, CD45, 
MHC II, HLA-DR, CCR2, 
CX3CR1 CCR1, CCR2, CXCR2, 
CCR5, CD43 (ACE), Tie2 
(angiopoietin receptor), CD64, 
CD36 scavenger receptor, 
CD11a/CD18, CD11b/CD18, 
CD11c/CD18 integrins, GFRα2, 
CLEC10A. 
-Production of TNF-α or IL-
1β upon LPS stimulation.  
-Stimulate CD4+ T-
lymphocyte proliferation.  
-High affinity for VCAM-1 
(particularly after MI).  
-May support endothelial 
regeneration through 






CD14, CD16, CD86, CX3CR1, 
CD45 HLA-DR, Nur77, LFA1 
(lymphocyte function–associated 
antigen-1 [CD11a integrin]), 
CD11c/CD18, CD294, Siglec10, 
ILT4. 
-Secretion of IL1-β and TNF-
α (when triggered by viruses 
and nucleic acids). 
-Patrols the vascular 
endothelium 





-Mediates removal of 
damaged ECs. 
-CCR5 mediated recruitment 
to atherosclerotic plaques. 
-Preferential differentiation 
into M2 macrophages and 
dendritic cells. 
-May emigrate from 
atherosclerotic plaque back to 
circulation. 
-Remove oxLDL from 
circulation. 
-Recruitment during 
reparative phase of MI.  
-Possibly arteriogenesis and 
vascular repair. 
ACE angiotensin converting enzyme, CCL2 chemokine (C-C motif) ligand 2, CCR 
chemokine (C-C motif) receptor, CD cluster differentiation, CLEC C-type lectin 
domain family, CXCL (C-X-C motif) ligand, EC endothelial cell, GFRɑ2 GDNF family 
receptor alpha-2, HLA human leucocyte antigen, IL interleukin, ILT immunoglobulin-
like transcript, LPS lipopolysaccharides, NF-κB nuclear factor kappa B, oxLDL 
oxidised low density lipoprotein, MHC major histocompatibility complex, MI 
myocardial infarction, ROS reactive oxygen species, SMC smooth muscle cell, TNF 
tumour necrosis factor, VCAM vascular cell adhesion molecule, VEGFR vascular 






Table 1.13 Studies quantifying monocyte subsets in patients with stable coronary artery disease 
Author/year Design No. of 
participants 
Objective Outcome Comment 
Ozaki 2012203 Cross 
sectional 
125 Determine association 
of monocyte subsets 
with severity of CAD 
-Significant association 
between CD14+CD16+ 
monocytes and severity of 
CAD. 
-Monocytes analysed as two 
subsets. 
-Significant positive 
correlation between CD16+ 
monocytes and Gensini score. 
-Forty-four percent of ‘no 
CAD’ group had a history of 
coronary intervention. 
Schlitt 2004213 Cross 
sectional 
247 Examine levels of 
CD14+CD16+ 
monocytes in CAD 
versus control patients 
plus association with 
TNFα. 
-Higher levels of 
CD14+CD16+ monocytes 
found in CAD patients. 
Significant association with 
TNFα found. 
-Monocytes analysed as two 
subsets.  
-Control group might have had 
occult CAD.  
-Groups not matched for age 
and sex. 
-Study group included ACS 
and found no difference 





73 Evaluate the 
relationship between 
monocyte subsets and 
-Association between 
CD14+CD16+ and presence 
of vulnerable plaques 







the presence, extent 
and vulnerability of 
non-calcified CAD 
assessed by CT. 
(defined by positive 
remodelling and low 
attenuation plaque). 
-Small patient numbers. 
-CT over estimates disease. 
 
Liu 2010206 Cross 
sectional and 
longitudinal 
71 Assessment of 
monocyte subsets as a 
marker of ISR after 




numbers ↑ in people with 
ISR and correlated with 
significantly with late lumen 
loss. 
-Monocytes analysed as two 
subsets. 
-No control group. 
-Only BMS used. 
-Not clear proportion of pre-
dilation versus direct stenting. 
-Unclear methodology (timing 
of blood samples, repeat 
angiogram driven by 







3779 Study different 
leucocytes as a risk 
factor for premature 
CAD in men 
-Monocytes significantly 
higher in early CAD. 
-Men only. 
-Mainly White Europeans. 

















cardiovascular risk in 
patients referred for 
elective coronary 
angiography.  
-Association found between 
CD14++CD16+ 
(intermediate) monocytes 
and cardiovascular events. 
-Monocytes analysed as three 
subsets. 
-Median follow up 2.6 years. 
-Small (for epidemiological 
study) but largest 
epidemiological monocyte 
study so far. 
Huang 2013209 Cross 
sectional 
140 To compare levels of 
CD14+CD16+ 
monocytes in patients 
with coronary artery 
disease and blood 
stasis syndrome versus 
those with CAD and 
no blood stasis 
syndrome. 
-Protein level of 
CD14+CD16+ monocyte 
levels increased in CAD 
patients with blood stasis 
syndrome c/w controls.  
-Monocytes analysed as two 
subsets. 
-Inflammatory cytokines 
tumour necrosis factor-α and 






103 Characterisation of 
monocyte subsets and 
their expression of 
receptors in patients 
with CAD. 
-Total count of classical and 
intermediate monocytes and 
their MPAs were similar. 
However, non-classical 
MPAs were higher in CAD 
patients. Significant up-
regulation of CXCR4 on 
non-classical monocytes and 
CD34 on all subsets. 
-Monocytes analysed as three 
subsets. 








Hristov 2010210 Cross 
sectional 




cardiovascular risk and 
extent of CAD. 
-Non-classical monocytes 
reduced in high risk (≥5 risk 
factors) patients with CAD. 
Classical monocytes highest 
in this group. Significant 
negative association 
between family history and 
non –classical. 
-Monocytes analysed as three 
subsets. 
-No control group. 






90 Examine whether 
monocyte subsets are 
associated with sdLDL 
serum levels. 
-Patients in the highest 
sdLDL tertile had highest 
levels of Mon3 which 
correlated (R = 0.25, p = 
0.017) and lowest levels of 
Mon1.  
- MVD significantly 
increased Mon3 (p = 0.015).  
-Mon1 and Mon2 not 
associated with CAD 
severity.  
-Used mean (SD) when 
absolute counts of individual 
subsets clearly skewed. 





70 Investigate expression 
of atheroprotective 
KLF4 on monocyte 
subsets in patients with 
CAD 
- Down regulation of KLF4 
in all CAD monocyte 
subsets compared to control 
(p < 0.01 for all). 
-KLF4 lowest in Mon1 
compared to Mon2 and 
-Use of control group, albeit 
small. 







Mon3 for both CAD and 
controls. 
-Monocytes analysed as 3 
subsets. 
-CAD severity/morphology not 
assessed. 
ACS acute coronary syndrome, AMI acute myocardial infarction, BMS bare metal stent, CAD coronary artery disease, CD cluster 
differentiation, CT computed tomography, c/w compared with, ISR in-stent restenosis, KLF4 Krüppel-like factor 4, MPA monocyte-





1.3.4.4.2 Monocyte-platelet aggregates  
Activated platelets adhere to monocytes (as well as each other) and form monocyte-
platelet aggregates (MPAs). This union alters the function of the monocyte. Experiments 
in healthy volunteers has revealed increased expression of CD16 on the surface of 
CD14++CD16- monocytes incubated with autologous platelets compared with 
CD14+CD16- monocytes in the medium alone (p<0.001) – an effect which correlated 
directly with degree of MPA formation (r=0.88, p<0.0001) and was associated with 
increased monocyte adhesion to ECs, and thus, a mechanism for atherosclerosis 
progression219. MPAs are a robust signal of platelet activation – increased levels are 
present in ACS and in patients undergoing PCI. 
MPAs are early markers of diabetes, endothelial activation/dysfunction and subclinical 
atherosclerosis220-222. Studies generally show increased MPAs with the presence of CAD 
(Table 14214, 222-225) although they have tended to be small with homogenous 
populations224, 225. In patients undergoing elective single vessel PCI, Mickelson et al 
found increased MPA levels to be associated with target vessel restenosis and CAD 
progression requiring surgical revascularisation225. However, the study was limited by 
many confounders including recent AMI in two (out of eleven) subjects and heart failure 
in others plus four patients had MVD at baseline and would be more likely to progress 
independent of MPA levels. In contrast De Serafino et al recently found no relation 
between MPA levels and CAD extent (r=0.005, p=0.45)222. A major drawback is that 





Contemporary studies have the advantage that monocytes are correctly categorised as 
three subsets. Unfortunately, this makes them difficult to compare with studies performed 
previously. Whilst there is probably overall agreement that CD16 positivity seems to be 
more readily associated with more severe CAD phenotypes, considerable divergence of 
the available evidence exists such that the precise pathophysiological situation requires 
further clarification. Certainly there are significant changes in receptor expression across 






Table 1.14 Studies of monocyte-platelet aggregates in human coronary artery disease 
Author Design No. of 
participants 
Objective Outcome Comments 
Furman 1998223 Cross 
sectional 
38 To examine whether patients 
with stable CAD have 
increased platelet reactivity 
and an enhanced propensity 
to form MPAs. 
-Stable CAD patients 
had ↑ circulating MPAs 
c/w controls. 
-Small numbers. 
-Difference could be due to 
difference in risk factors 
between the groups. 






145 To see if MPA are associated 
with the presence of 
functionally significant 
coronary stenoses or with 
coronary arterial endothelial 
dysfunction. 
-Neither MPA nor 
coronary endothelial 







-Fractional flow reserve 
(FFR) used to quantify 
functional significance. 
-Uses the Bogaty score to 
quantify CAD pattern. 
-Even distribution of risk 
factors. 
-Four percent of people with 
a negative FFR are 






40 Assess the relationship 
between platelet activation 
and endothelium-dependent 
-Platelet-monocyte 
binding was higher in 







vasomotion in patients with 
CAD. 
CAD patients than 
healthy men.  
-Significant inverse 
correlations were seen 










124 To examine MPAs and 
expression of CCR5 in 
individuals with coronary 
atherosclerosis. 
-MPA formation ↑ in 
patients with CAD in 
all three monocyte 
subsets. 
-CCR5+ monocyte 
number ↓ in patients 
with CAD. 
-Monocytes analysed as 
three subsets. 
-Multiple baseline 
differences not corrected for 
including age. 
-Attempted age-matched 
cohort in nine people. 








11 To determine if leukocyte 
activation occurs, whether 
leukocyte-platelet 
complexes develop and 
whether there is any 
association between 
-After angioplasty, 
LPAs ↑ (p=0.02). LPAs 
were also higher in the 
six patients that had 
clinical events during 
follow up. 
-Small sample size. 
-All male population. 
-Heterogeneous population 
(some having had a recent 






these findings and clinical 
outcome after elective single 
vessel coronary angioplasty. 
-Pre-DES era. 
CAD coronary artery disease, CCR5 chemokine receptor 5, c/w compared with, DES drug eluting stent, FFR fractional flow reserve, LPA 






1.3.4.5 Circulating microparticles 
Microparticles (MPs) are small, anucleoid phospholipid vesicles released from the plasma 
membranes of various source cells in response to stimuli such as apoptosis, platelet or 
endothelial activation, ESS, inflammatory cytokines or oxidative stress226, 227. MPs are 
primarily identified by their diameter (0.1-1µm), as opposed to exosomes (0.04-0.1µm), 
or apoptotic bodies (>1.5µm)228. Following appropriate stimuli, a cascade of events – 
beginning with calcium-dependent phosphatidylserine shift from the inner to the outer 
monolayer of the eukaryotic cell membrane – occurs, leading to MP formation229. 
Calcium-dependent proteolysis of the cytoskeleton causes intracellular changes that 
promote ‘blebbing’228. Therefore, MPs contain the same cytoplasmic material and express 
the same surface proteins as the parent cell allowing them to be classified. 
Factors precipitating an atherogenic EC phenotype, such as low ESS, favour MP 
formation in many cell types. Indeed, haemodynamic forces are a major influence driving 
EMP (endothelial microparticle) release from damaged ECs. EMPs in turn promote the 
expression of adhesion molecules on the EC surface which corroborates evidence from 
clinical studies that increased EMP levels predict the presence of CAD risk factors, 
increased arterial stiffness, coronary endothelial dysfunction and CAD in certain 
groups230-233. In some cases, MPs may be even more potent than their parent cells234. 
Clinical studies evaluating microparticles in CAD are summarised in Table 1.15227, 231, 
235-242. Biasucci et al compared levels of EMPs, PMPs (platelet microparticles) and AMPs 
(apoptotic microparticles) in patients with stable angina, stable angina and PVD 
(peripheral vascular disease), non-ST-segment elevation myocardial infarction and ST-




subjects with ACS compared with stable patients, but no difference between the two 
stable groups236. However, prolonged endothelial activation may result in more severe 
CAD then PVD. Although Tan et al also found no correlation between PMPs and the 
degree of CAD238. Furthermore, Cui et al235 reported no difference in EMPs or PMPs 
between stable CAD patients and controls (p=0.763 and p=0.853, respectively) but the 
numbers in both groups were small compared to the unstable groups. Also, asymptomatic 
CAD could have been present in the controls. In contrast, EMPs were predictive of CAD 
presence in a well powered Japanese diabetic cohort (OR 3.5, 95% CI 1.8 to 6.9, 
p<0.001). Post PCI MP measurement provides additional evidence that endothelial injury 
results in higher MP levels227, 239. Some of these studies are limited by small samples, 
male only populations and the lack of a control group227, 236, 237, 239. In any case the role of 
MPs in CAD severity remains inconclusive. 
Whilst MPs are important mediators throughout many stages of atherogenesis some – 
neutrophil MPs for example – possess anti-inflammatory effects capable of down 
regulating macrophages, for example, murine models of MI have shown an excess of 
extracellular vesicles (size 118±4nm and 252±18nm, therefore in the MP range) from 
cardiomyocytes and endothelium within 24 hours of coronary artery ligation which 
facilitated monocyte transition from Ly6Chigh (proinflammatory) to Ly6Clow (favouring 
repair)243, 244. Intra plaque MPs – derived mainly from leucocytes – have been shown to 
engulf immunoglobulins and have a proliferative effect on CD4 T lymphocytes, thus 
modulating tissue inflammation245. Moreover, low levels of PMPs and EMPs are present 






Table 1.15 Studies of microparticles in human populations with stable coronary artery disease 
Author Design No. of 
participants 





200 Evaluate whether MPs are 
an independent predictor of 
cardiovascular outcomes in 
stable CAD patients. 
Over median 6.1 (6-6.4) 
year follow up, 
CD31+/Annexin V+ EMPs 
were associated with 
increased cardiovascular 
mortality and need for 
revascularisation. 
EMPs not associated with 
CAD extent ‘number of 
diseased vessels’. 
No control group. 
No relation to all-cause 
mortality. 
Cui 2013235 Cross 
sectional 
110 Investigate endothelial, 
platelet, lymphocyte, 
monocyte and tissue factor 
positive microparticles in 
CAD patients and evaluate 
their correlation with 
Interleukin-6 and C-
reactive protein. 
-No difference in any 
microparticle population 
between stable angina 
patients and controls. 
-Study examined ACS 
patients which did show 
significantly higher 
microparticle levels across all 
cell types. 
Koga 2005231 Cross 
sectional 
334 Examine whether CD144-
EMP (endothelium-derived 
microparticles) is useful as 
a specific marker of 
endothelial cell dysfunction 
and to determine whether 
plasma levels of circulating 
-CD144-EMP levels ↑ in 
DM patients with CAD 
c/w those without CAD. 
-CD144- EMP levels 
independently predicted 
CAD in patients with DM 











CD144-EMP predict CAD 
in patients with type 2 DM. 
without symptomatic 
episodes of angina. 









76 To assess the release of 





did not affect MP levels in 
stable patients (although 
levels of MP in ACS 
patients were higher than 
stable patients with or 
without PVD. 
-Small sample size. 
-No control group. 
-Severity of CAD judged by 







50 To determine if endothelial 
function is influenced by 
the degree of endothelial 
cell apoptosis. 






-No control group. 
-Patients with no CAD or 
severe diffuse CAD were 
excluded. 
-Intracoronary acetylcholine 
used for endothelial function. 
Horn 2015227 Cross 
sectional 
28 To quantify the release of 
MPs during stent 
implantation into stable 
atherosclerotic lesions and 
compared the release 
between RCAs and SVG-
RCAs. 
-In patients with 
comparable plaque volume 
and composition in RCAs 
and SVG-RCAs, 
intracoronary PMPs and 
EMPs were increased after 
stent implantation into 
their RCAs and SVG-
RCAs. No difference 
-Male patients only. 
-Small sample size. 
-Symptomatic. 
-IVUS used to quantify 
plaque burden. 
-Limited to right coronary or 






between RCA and SVG-
RCA. 
-MPs measured directly after 
and in the vicinity of, stent 
implantation. 
Tan 2005238 Cross 
sectional 
89 To determine if PMPs are 
related to severity of CAD. 
-No evidence to suggest 
that PMPs are related to 
degree of CAD. 
-Peripheral blood. 
-Age and sex matched 
controls. 




20 To compare circulating 
PMPs with that of P-
selectin in patients with 
stable angina undergoing 
PCI. 
-Circulating PMPs and P-
selectin expression 
enhanced following stent 
implantation. 
-PMPs increased 24-48 h 
after coronary stenting in 
the coronary sinus whereas 
P-selectin increased 15 
min after stenting and 
remained elevated for 48 
h; the changes were less 
striking in peripheral 
blood. 
-MPs measured in peripheral 
blood and coronary sinus. 
-Small sample. 
-Stent related changes. 
-First generation stents. 





113 To quantify PMPs in 
patients undergoing PTCA 
stratified according to 
treatment with abciximab. 
-PMPs ↑ following 
angioplasty in the group 
without abciximab 
(p=0.019).  
-No change in PMP levels 
following angioplasty in 









patients who received 
abciximab, despite 
requiring more complex 
angioplasty procedures. 





19 To monitor PMP levels in 
the coronary circulation. 
-Significant ↓ in arterial 
PMPs from heparinisation 
to contrast administration 
(p=0.001), followed by a 
significant ↑ to the end of 
angioplasty (p=0.004). 
-Small sample. 




ACS acute coronary syndrome, CAD coronary artery disease, CD cluster differentiation, c/w compared with, DES drug eluting stent, DM 
diabetes mellitus, EMPs endothelial microparticles, IVUS intravascular ultrasound, MPs microparticles, PCI percutaneous coronary 
intervention, PMP platelet microparticles, PVD peripheral vascular disease, PTCA percutaneous transluminal coronary angioplasty, RCA 




1.3.5 Prognosis of patients with CAD unsuitable for revascularisation 
Despite improvements in age-adjusted mortality1, diffuse obstructive CAD remains 
highly prevalent and confers a higher probability of adverse outcomes, particularly when 
conventional revascularisation is precluded247. Anatomic reasons prohibiting traditional 
revascularisation include severe diffuse CAD, collateral-dependent myocardium, 
multiple coronary restenoses, chronic total coronary occlusions, degenerated saphenous 
vein grafts, poor distal targets, or lack of conduits due to prior CABG – all of which 
equate to advanced CAD124. Despite much interest in alternative strategies including 
myocardial angiogenesis (protein, gene, or stem cell therapy),248-252 novel 
pharmacological agents (for example ranolazine, which has recently shown no benefit in 
patients with incomplete revascularisation after PCI)253, enhanced external counter 
pulsation254, spinal cord stimulation,255 and transmyocardial revascularisation, 
satisfactory treatments are still to be developed7, 256-259. 
 
Data on CAD patients not eligible for revascularisation – a highly subjective condition – 
is mainly limited to case series, extrapolation from patients undergoing coronary 
angiography and small randomised controlled trials (RCTs) of alternative therapies for 
refractory angina in which annual mortality is up to 21% (some of which are summarised 
in Table 1.164, 7, 8, 124, 127, 256, 259-266). The wide range of RCT mortality outcomes is due, in 
part, to the low power of these studies for this outcome but a recent pooled analysis of 
randomised trials of transmyocardial laser revascularisation confirmed an overall 
mortality of around 12% in both the treatment and the control arms5. The Mediators of 




Duke University also suggested high mortality (38% at 2.2 year mean follow-up)4. In 
contrast, 1-year mortality from the Euro Heart Survey for patients with stable angina 
treated medically was 5%125. In patients ineligible for revascularization, 7% died at 1 year 
compared with 3.7% in the cohort eligible for revascularization126. Furthermore, event-



























Table 1.16 Clinical endpoints in studies of patients with advanced CAD unsuitable 
for revascularisation 






Event rate (%) 
Allen/1999256 RCT/275* 12 69 CV re-hospitalisation† 
11 death† 




Frazier/19997 RCT/192* 12 89 combined†‡ 
21 death†§ 
69 UA† 
Aaberge/2000259 RCT/100* 12 8 death† 
Aaberge/2002261 RCT/100* 43 24 death† 
Allen/2004262 RCT/212* 60 48 death† 
Burkhoff/1999263 RCT/182* 12 10 death† 
77 UA† 
Oesterle/2000264 RCT/221* 12 3 death† 
56 combined‡ 
Schofield/1999265 RCT/188 12 4 death† 
Kandzari/20014 Prospective 
cohort/487 
26†† 38 death 
Lozano/2014127 Retrospective/220 45†† 62 death 
Williams/2010124 Retrospective/493 36†† 32 death§§ 
Henry/20138 Prospective/1200 61†† 17.5 death 
Povsic/2015266 Retrospective/1908** 36†† 13 death 
17.1 death and NFMI 





CHF congestive heart failure, CV cardiovascular, MACCE major adverse 
cardiovascular or cerebral event (defined as death, MI, stroke, cardiac rehospitalisation, 
and revascularisation), NFMI non-fatal myocardial infarction, RCT randomised 
controlled trial, UA unstable angina, * 1:1 transmyocardial revascularisation:medical 
therapy, † medical therapy arm only, ‡ acute myocardial infarction, death, unstable 
angina, and class IV angina § non cross-over, †† median, §§ in groups not receiving 






Substantial improvements in therapies for acute CAD coupled with higher general life 
expectancy and better prognoses from other comorbidities such as HIV and certain 
malignancies is likely to increase the number of patients experiencing complex CAD in 
future years. Despite some signs of efficacy in reducing symptoms and recurrent cardiac 
hospitalisations, novel therapies have shown no impact on mortality with some resulting 
in early mortality excess. The shortfall in evidenced based therapy drives an urgent 
requirement for a deeper understanding of the pathogenesis underlying this type of 











1.4 NORMAL CORONARY ARTERIES – EXISTING AND CHANGING 
PATTERNS 
 
1.4.1 Normal coronary arteries amongst patients referred to hospital 
The prevalence of normal coronary arteries amongst the individuals referred for elective 
coronary angiography ranges from about 5% to 50% depending upon a number of 
factors11. There is significant inter-hospital variation, reflecting both the varying 
prevalence within the local population and the varying thresholds for undertaking 
invasive angiography. The definition used to represent ‘normal’ is an important 
consideration. In a Danish registry of 11223 patients receiving elective coronary 
angiography between 1998 and 2009, the rates of normal coronary angiography were 19% 
for men and 48% women (34% overall)267. This was using a definition of 0% luminal 
stenosis to represent normal. Interestingly, in a similar American registry study, 21% of 
elective coronary angiograms undertaken between 2007 and 2010 were considered 
normal – normal being defined as < 20% luminal stenosis. In a paper by Ashbury et al268 
examining the psychosocial impact of cardiac syndrome X in females, the definition of 
syndrome X was “patients aged <80 years with chest pain, positive exercise test for 
myocardial ischaemia and angiographically smooth coronary arteries.” Alternatively 
Zachariae et al defined normal as <50% luminal stenosis269. Such a definition is likely to 
include a significant proportion of patients with structural and functional endothelial 
dysfunction and may have contributed to the negative findings in the study.  
1.4.2 Prognosis 
Registry data over the last thirty years generally convey an excellent prognosis for 
patients with normal or minimally diseased coronary arteries compared to the general 




afterwards270-273. Kemp et al examined 21,487 patients’ data from the Coronary Artery 
Surgery Study (CASS) between 1976 and 1979270. They identified 4,051 (19%) normal 
or near normal coronary angiograms (defined as “having no segment with a stenosis of 
50% or greater and no left ventricular abnormality.”) Of these, 3,136 (77%, 15% overall) 
were considered entirely normal whilst 915 had a stenosis >0% but <50%. Survival at 
seven years was 96% for those with completely normal arteries and 92% for those with 
<50% luminal stenosis. An ischaemic response to exercise (implying cardiac syndrome 
X) was not associated with increased mortality.  
In contrast, recent evidence suggests that patients with suspected angina and normal 
coronaries may be at higher risk of adverse events than previously thought274. In a 
retrospective cohort taken from a Danish registry of 11,223 patients who had undergone 
coronary angiography for suspected CAD between 1998 and 2009, Jespersen et al 
identified 3,479 (31%) individuals with normal coronary arteries274. Normal was defined 
as 0% stenosis in all coronary arteries. If patients with diffuse, non-obstructive CAD 
(defined as 1-49% luminal narrowing) were included as normal (as they have been in 
some studies269) then a further 1704 patients would be analysed as normal increasing the 
proportion to 46% of the cohort. An asymptomatic control group was taken from the 
Copenhagen City Heart Study (n=5705). The overall 5-year MACCE (major adverse 
cardiovascular or cerebral event – defined in this case as cardiovascular mortality, 
hospitalization for MI, heart failure, or stroke) – free survival probabilities were 0.96 in 
the asymptomatic control group, 0.92 in patients with normal coronary arteries and 0.89 
in people with mild diffuse disease. In the pooled analysis, multivariate-adjusted hazard 
ratios (HRs) for the risk of MACCE were 1.52 (95% confidence interval [CI] 1.27-1.83, 




for patients with mild non-obstructive CAD. The increase in MACCE for both groups 
was driven by an increase in cardiovascular death and hospitalisation with heart failure 
or myocardial infarction. For all-cause mortality, normal coronary arteries and diffuse 
non-obstructive CAD were associated with HRs of 1.29 (95% CI 1.07-1.56, p=0.007) and 
1.52 (95% CI 1.24-1.88, p<0.001) respectively, similar for men and women.  
1.4.3 Further classification – when is normal normal? 
A normal coronary angiogram does not signify the absence of atherosclerosis since only 
the lumen is visualised on an invasive angiogram (unless there is calcification, which may 
be seen as a silhouette without contrast). Therefore atherosclerotic disease associated with 
eccentric remodelling may not be appreciated109. Intracoronary imaging can be used to 
assess atherosclerotic burden. Experimental studies using IVUS (intravascular 
ultrasound) suggest that coronary plaques are present in approximately 30-50% of 
patients with angiographically normal coronary arteries275, 276. In light of the possibility 
of excess mortality in patients with chest pain and normal coronaries compared with the 
general population a sub-classification of people with normal coronary angiograms has 
been proposed to include measures of endothelial dysfunction and coronary flow reserve 
(Table 1.17)277. However, prospective longitudinal outcome data are lacking. 
1.4.4 Non-invasive coronary angiography 
Computed tomography coronary angiography (CTCA) provides a non-invasive structural 
assessment of coronary anatomy. The recently updated National Institute for Health and 
Care Excellence (NICE) guidelines (CG95) recommend CTCA as the first line 
investigation for symptomatic individuals with CAD278. An important advantage of 




thereby increasing its diagnostic sensitivity, although specificity remains an issue. The 
risk of adverse outcomes following normal CTCA are extremely low279, 280. 
1.4.5 Conclusion 
The use of CT has grown significantly following increased demand brought about by the 
NICE guidelines for assessment of recent onset chest pain. Its higher sensitivity allows 
























Table 1.17 Subclassification of patients with angina and angiographically normal 
coronary arteries proposed by Bugiardini et al277 
Subgroup Description 
1 Non-obstructive CAD, including patients with visible plaque by 
intravascular ultrasound (IVUS) and/or severe coronary endothelial 
dysfunction (vasoconstriction during acetylcholine infusion). 
2 Non-atherosclerotic microvascular angina, referring to patients with 
normal IVUS and/or coronary endothelial function but reduced coronary 
flow reserve (CFR). 
3 Normal coronary arteries, referring to people with normal IVUS, 
coronary endothelial function and CFR. Only then would patients be said 
to have ‘non-cardiac chest pain’. 























1.5 SECTION I SUMMARY 
 
In this opening section, I have introduced the topic of my thesis, namely a study of the 
pathophysiology underlying advanced diffuse CAD. I began with a general overview of 
the fundamental concepts of atherogenesis, focusing on the importance of the vascular 
endothelium in maintaining homeostasis and traditional CAD risk factors in contributing 
to endothelial activation and an inflammatory phenotype, with sequential rise in novel 
risk markers, many of which interact to promote further inflammation. Recent genome 
wide association studies have resulted in the discovery of novel variants, although much 
work is needed to fully elucidate the mechanisms by which many of them exert their 
effects.  
Following the general overview, I described the current literature pertaining to people 
with advanced diffuse forms of CAD (to whom this thesis relates) and people with normal 
coronary arteries. The subjectivity of diffuse CAD means that significant heterogeneity 
regarding prevalence and outcomes among published data exists. Intracoronary imaging 
has enhanced our understanding not only of disease morphology but also plaque 
composition and vascular remodelling. Vascular profiling has allowed us to apply 
computer-generated fluid based dynamics to estimate endothelial wall stress and flow 
patterns and correlate them to CAD progression. Relationships between large artery 
stiffness and progressive CAD have been established. Highly relevant markers of innate 
and adaptive immunity as well as platelet and endothelial activation have been correlated 
to the presence of CAD although studies diverge in the strength of the relationship 
between these markers and CAD severity, particularly since the recent change in 




serves to highlight the importance of recognising this manifestation of CAD as challenge 






















OVERVIEW OF THESIS 
In this section, I present my MD proposal, including a detailed description of the 



















2.1 AIMS AND HYPOTHESES 
 
2.1.1 Objectives 
The overall aim of this thesis was to provide a detailed comparison of the 
pathophysiological differences between patients with severe diffuse CAD and focal CAD, 
both also compared to subjects that maintain normal coronary arteries, despite similar 
traditional risk factors across all three groups. Emphasis was placed on measures of 
cardio-vascular interactions, arterial stiffness, systemic microvascular endothelial 




• That patients with diffuse CAD would have abnormal cardio-vascular 
interactions, impaired systemic microvascular endothelial function and increased 
arterial stiffness compared to patients with focal coronary artery disease and 
subjects with normal coronary arteries and that these measures would deteriorate 
more prominently in subjects with diffuse CAD than in subjects with focal CAD.  
• That patients with diffuse CAD would have increased levels of proatherogenic 
monocytes and endothelial and platelet microparticles compared to patients with 
focal CAD and individuals with normal coronary arteries and that longitudinal 
change in cardio-vascular interaction and microvascular function would be 
inversely proportional to longitudinal change in microparticles and 




2.2 MATERIALS AND METHODS 
 
2.2.1 Study design 
This was a prospective observational case-control study. 
2.2.2 Study 1: Cross-sectional study 
I compared fifty patients with diffuse CAD with forty age and sex matched ‘disease’ 
controls with focal CAD and fifty ‘healthy’ controls with normal coronary arteries (Figure 
2.4).  
2.2.2.1 Definitions  
The term ‘diffuse’ is frequently used in literature to describe widespread involvement of 
an organ or anatomical structure by a pathological process. It is commonly used to 
subjectively describe advanced or extensive CAD however there is no standard definition. 
Throughout the published literature there are numerous examples of different models 
employed to quantify the severity and extent of CAD136, 281-283. Indeed, many semi-
quantitative scoring systems have been validated against IVUS and shown to correlate 
with each other135 (Section 1.3.2 and Table 1.8). ‘Severity’ tends to refer to the degree of 
luminal encroachment of a stenotic lesion whereas extent often refers to the number of 
main epicardial vessels with disease123, 136. The term ‘diffuse’ describes the morphology 
of a lesion, which may be mildly stenotic or limited to a single vessel. 
In this thesis, diffuse CAD was defined if more than half the total length of at least two 
major epicardial coronary arteries contained stenoses ≥70% (assessed visually) (Figure 
2.1). Patients with a single vessel chronic total occlusion were required to have diffuse 






Figure 2.1 Example of diffuse two-vessel disease involving the left and right 




Focal CAD was defined as one significant (≥70%) type A or B1 lesion284 (Section 1.3.1, 
Table 1.7) in one segment (i.e., proximal, mid or distal) of a single coronary artery with 















Normal coronary arteries were present if the invasive angiogram showed no visible 
lesions in any segments of any arteries; or if the computed tomography angiogram (both 
performed within the previous year) showed no evidence of calcified or non-calcified 













2.2.2.2 Subject selection 
I reviewed the angiograms of potentially eligible participants attending the Sandwell and 
West Birmingham Hospitals (SWBH) NHS Trust outpatient clinics, catheter laboratories, 
CT (computed tomography) coronary angiography suite, cardiac rehabilitation centres 
and cardiology diagnostic departments. I approached all patients without exclusion 
criteria who met the angiographic criteria described above either by telephone or in 
person. All participating subjects provided written informed consent which was verbally 
updated at each follow up appointment. The study was approved by the Black Country 
Research Ethics Committee (  and the Research & 
Development department at SWBH in accordance with the Declaration of Helsinki. The 
study was insured and sponsored by the University of Birmingham  
 
2.2.2.3 Study procedures                                                                                                                                                
Subjects were invited to the research unit at City Hospital where I collected a detailed 
clinical history including cardiovascular risk factors, an EQ-5D-5L quality of life 
assessment and physical examination. Subjects were fasted and asked to abstain from 
smoking, caffeine or medication on the morning of their appointment except for insulin-
dependent diabetics whose appointments I scheduled around their insulin regime. 
Sublingual GTN spray was permitted if necessary. Patients were asked to bring their 
medication with them so that they can take them straight after their appointment thereby 
minimising interruption to drug therapy. In all patients I performed laser Doppler 
flowmetry followed by transthoracic echocardiography (TTE), followed by analysis of 




minutes of supine rest (since exercise causes mobilisation of Mon3286), by a 20ml blood 
sample 10mls of which was used for immediate flow cytometric analysis of monocyte 
subsets, monocyte-platelet aggregates, measurement of full blood count, biochemical and 
lipid profiles. The rest of the blood was centrifuged for 15 minutes at 3000g (~4000 
revolutions per minute and the supernatant plasma removed and stored at minus 70oC for 
batch analysis of circulating platelet and endothelial microparticles. 
2.2.3 Study 2: Longitudinal study 
I repeated all measures outlined in the cross-sectional study on participants with diffuse 
and focal CAD at six- and twelve months post baseline (Figure 2.4). Patients were studied 
at the same time of day for each follow up appointment to minimise the effect of diurnal 
variation on the study parameters. 
2.2.4 Inclusion criteria 
Participants were required to be over 18 years of age with angiographically proven 
CAD suitable for either one of the two study groups (definitions, section 2.2.2.1), or 
documented normal coronary arteries on either invasive or non-invasive (CT) 
angiography within the last year invasively or non-invasively. 
2.2.5 Exclusion criteria 
Subjects with the following conditions were excluded: left ventricular ejection fraction 
less than 35%, eGFR <30ml/min/1.732, more than mild valve disease, liver failure, any 
myocardial infarction as per the World Task Force classification287 or coronary stenting 
within 3 months, stroke, non-cardiac or cardiac surgery within 12 months, active 
malignancy, autoimmune disease, haematological disorders, active infection, anaemia 




















Figure 2.4 Research protocol. 
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2.3 STUDY METHODS 
 
2.3.1 Assessment of arterial and ventricular elastance 
2.3.1.1 Echocardiography 
I performed M-mode, two and three-dimensional transthoracic echocardiography (TTE) 
and tissue Doppler imaging (TDI) on all participants using a Phillips iE33 ultrasound 
machine (Bothel, WA, USA). Modern off-line QLAB software (Xcelera, Phillip [iE33] 
Ultrasound Quantification Module, USA) was used for quantification of left ventricular 
(LV) function. I took an average of three measurements for all parameters. I calculated 
the effective arterial elastance index (EaI) by dividing central aortic pressure288 (derived 
during pulse wave analysis – section 2.3.1.2) by 3D stroke volume (SV) followed by 
adjustment for body surface area (BSA). End-systolic elastance (Ees) was calculated as 
central aortic pressure (a.k.a end-systolic pressure [ESP]) divided by end-systolic volume 
(ESV). End-diastolic elastance (Eed) was calculated by first estimating the end-diastolic 
LV pressure using the Nagueh formula289 – the ratio of early mitral inflow velocity (E) to 
early mitral annular diastolic TDI velocity (E prime [E’] – E/E’x1.24)+1.9, divided by 
SV290, 291. Arterial-ventricular interaction (Ea/Ees) is thus derived and indexed to BSA. 
The interassay coefficients of variation (CVs) for Ea, Ees and Eed were 4.4%, 5.1% and 
9.8% respectively (Section III). 
2.3.1.2 Pulse wave analysis (PWA) 
I measured the carotid-radial pulse wave and aortic augmentation index (AIx) using a 
SphygmoCor device (SphygmoCor, AtCor medical, Sydney, Australia). Radial artery 
waveforms were recorded over 10 seconds using a high-fidelity hand-held applanation 




SphygmoCor CVMS software system (Version 8). The reason for using PWA was to 
provide an accurate measure of central aortic blood pressure (ESP) as this is also 
estimated by the software. I measured the average of three brachial artery pressure 
measurements following twenty minutes supine rest. This technique was previously 
validated in our laboratory. My average inter- and intra-assay CV for AIx were 7.8% and 


















2.3.2 Assessment of microvascular function 
2.3.2.1 Cutaneous iontophoresis with Laser Doppler assessment of blood flow 
Iontophoresis is the application of an electrical current across the skin which allows the 
delivery of ionic compounds to the cutaneous microcirculation292. The technique has been 
used in various studies to evaluate microvascular endothelial function43, 51, 293, 294. 
Following twenty minutes supine rest, I positioned two small drug delivery chambers on 
the right forearm of each subject approximately 5cm apart (Figure 2.5) and placed a few 
drops of 1% acetylcholine [ACh] (Sigma-Aldrich, Dorset, UK) into the positively 
charged proximal chamber and 1% sodium nitroprusside [SNP] into the negatively 
charged distal chamber. I used a twelve minute protocol as previously published by our 
department43, 295. This consisted of one minute of baseline recording, followed by one 
minute of iontophoresis at 100mA, followed by ten minutes of post-iontophoretic 
recording since maximal smooth muscle vasodilation typically occurs several minutes 
later than endothelial-dependent vasodilation. ACh – a positively charged compound – is 
repelled through the skin during the application of electrical current (MIC1-e 
iontophoresis controller, Moor Instruments, Axminster, UK) whilst SNP (negatively 
charged) is repelled from the chamber containing the negative electrode. ACh acts on the 
endothelium to induce (endothelial-dependent) cutaneous vasodilation whereas SNP, a 
nitrate donor, acts directly on vascular smooth muscle (endothelial-independent 
vasodilation), thereby acting as a control for the experiment. The cutaneous blood flow 
(or flux) was observed using two optical lasers (one for each chamber) attached to a Laser 
Doppler perfusion monitor (DRT, Moor Instruments, Axminster, UK). Results were 
expressed as maximum relative percentage change in perfusion. The average inter- and 




Patients were studied in quiet, darkened, temperature-controlled room (between 19-23ºC 
according to manufacturer guidelines). 
 











2.3.3 Assessment of monocyte subsets and monocyte-platelet aggregates 
2.3.3.1 Monocyte subsets  
Flow cytometric analysis of monocyte subsets was performed by me using the Becton 
Dickinson (BD) FACSCalibur flow cytometer (Becton Dickinson, Oxford, UK) as 
previously described by our group296 (Figure 2.6). Mouse anti-human monoclonal 
fluorochrome-conjugated antibodies anti-CD16-Alexa Fluor 488 (clone DJ130c, AbD 
Serotec, Oxford, UK), anti-CD14-PE (clone MфP9, BD), anti-CD42a-PerCP (clone 
Beb1, BD) and anti-CCR2-APC (clone 48607, R&D) is mixed with 50 microlitres (μl) of 
fresh EDTA anticoagulated whole blood in TruCount tubes (BD) containing a strictly 
defined number of fluorescent count beads. After incubation for 15 minutes, red blood 
cells are lysed by 450μl of lysing solution® (BD) for 15 minutes, followed by dilution in 
1.5 ml of phosphate buffer solution (PBS) and immediate flow cytometric analysis. 
Monocyte subsets are defined as CD14++CD16-CCR2+ (Mon1, classical), 
CD14++CD16+CCR2+ (Mon2, intermediate) and (Mon3, non-classical) in accordance 
with contemporary nomenclature194.  
2.3.3.2 Monocyte-platelet aggregates 
Monocyte-platelet aggregates (MPAs) were defined as events positive to both the 
monocyte markers described above and CD42a (glycoprotein IX). The total MPA count 
and the MPA count associated with each monocyte subset highlighted above were 
similarly expressed as a proportion of the number of count beads. Therefore, MPAs 
associated with Mon1 (classical) are CD14++CD16-CCR2+CD42a+, MPAs associated 
with Mon2 (intermediate) are CD14++CD16+CCR2+CD42a+ and MPAs belonging to 




the percentage of each monocyte subset aggregated to platelets. I prepared all samples for 
monocyte and MPA analysis within two hours of venesection as previous work from our 
department has shown that significant change in absolute count can occur after two hours 
left standing297. The average inter- and intra-assay CV is 13% and 7% for total monocytes, 



















Figure 2.6 Gating strategies and presentation of monocyte subsets. 
Monocytes are initially defined according to their forward scatter (FSC) and side scatter 
(SSC) properties (a). Granulocytes (neutrophils) are then excluded by their higher degree 
of SSC and lack of CD14 expression (b). CD14- natural killer cells are distinguished from 
CD14+ monocytes on the CD16 versus CD14 panel (c). Mon1 (green box) are 
CD14++CD16- cells (d, e and f). CD16+ cells (Mon2 and Mon3) are then distinguished 
according to their expression of CCR2 (g). Mon2 are CD14++CD16+CCR2+ (red box, g 







2.3.4 Assessment of circulating platelet and endothelial microparticles 
Plasma was separated by centrifugation and frozen at -70°c for batched analysis at the 
end of recruitment and follow up. I quantified plasma microparticles using the Apogee 
A50 flow cytometer (Apogee Flow Systems, Hertfordshire, United Kingdom). The 
Apogee machine has the advantage of being able to measure very small microparticles 
below 500 nanometres. The protocol was previously established in our department using 
polystyrene beads of 110, 200, 500 and 1000 nanometre diameter (Apogee Flow Systems, 
Hertfordshire, United Kingdom) to set up the microparticle-size gate in the two small 
angle light scatter detectors (LS1 and LS2)299. Microparticles were defined as events with 
sized between 110 and 1000 nm and gated to test their binding to anti-CD42b (platelets), 
and anti-CD31 (endothelial) antibodies. Prior to each batch, I calibrated the Apogee 
cytometer using Apogee Mix beads (Apogee Flow Systems, Hertfordshire, UK) to 
confirm that the flow rate and bead location within the gates remained stable. Logarithmic 
scales were used for all channels. Intra-assay CVs for EMPs and PMPs were 5.3% and 
14.1% respectively (Section III). 
Stored platelet-rich plasma was subject to further centrifugation at 13,000g for 5 minutes 
to make platelet-free plasma. Platelet microparticles were stained with 5μl of 10% 
biotinylated anti-human CD42b (glycoprotein [GP] Ib) antibody (Abcam, Cambridge, 
United Kingdom) and incubated for 30 minutes, at which point 2.5μl of 10% streptavidin-
Alexa Fluor 647 nm-R-phycoerythrin (PE) tandem conjugate (Molecular Probes, 
Invitrogen, Carlsbad, CA) was added, followed by a second incubation of 30 minutes. I 
then diluted the sample with 950µl of filtered phosphate buffered saline (PBS) (final 
dilution 1:20). I followed the same procedure with endothelial microparticles instead 





Figure 2.7 Example dot plots showing enumeration of microparticles.  
Strict CD31 (endothelial, A) and CD42b (platelets, B) positive events are recorded 
within the red gates according to previously determined bead sizes 110-1000nm (picture 












2.3.5 Laboratory measurements 
Routine clinical haematological (full blood count [FBC]) and biochemical (urea and 
electrolytes, cholesterol [total, HDL and non-HDL] and triglycerides) measures were 
performed by SWBH Trust clinical pathology laboratories (XN10 analyser, Sysmex, 
Milton Keynes, UK for haematology and Abbott Architect C4000, Abbott laboratories, 


















2.3.6 Health-related quality of life 
Of the available measures, the EQ-5D (EuroQuol 5 dimension) has become one of the 
most commonly used generic preference-based measures in economic evaluation. The 
EQ-5D comprises five dimensions of health (mobility, self-care, usual activities, 
pain/discomfort, and anxiety/depression). The EQ-5D-5L has five levels of severity on 
each dimension of health (superseding the previous version EQ-5D-3L, with three levels). 
There is also a visual analogue score (VAS), for people to rate their overall health from 
0-100. The EQ-5D-5L and VAS are simple, standardised, generic measures that are 
applicable to a wide range of conditions, treatments and populations300-304. Subjects can 
self-classify their overall health status as a single index value. The tool has been assessed 
and validated in a large European stable CAD cohort, including UK patients305. Broadly, 
instruments for measuring HrQOL are generic or disease-specific. I felt a generic tool 
was more appropriate since disease-specific tools tend either to focus on a single recent 
event or diagnosis, or are only applicable to people with symptoms, whereas many of my 
cohort with established CAD have been event free for months or years. Permission for 










2.4 STATISTICAL CONSIDERATIONS 
 
2.4.1 Power Calculation 
From previous work, I propose that arterial elastance index (EaI) will be increased by 
2/3rd of a standard deviation in patients with diffuse CAD compared to focal CAD and a 
similar magnitude of difference between subjects with focal CAD and normal controls 
(i.e. about 1.3±0.5 mm Hg/ml/m2 in focal patients, 1.7±0.5 mm Hg/ml/m2 in patients with 
diffuse disease, and 1.0±0.3 in normal controls). Thus, to achieve this difference in 
variance at 1- = 0.8 and p<0.05 (ANOVA F statistic approximately 10), 45 subjects per 
group are required. For the longitudinal study, I expect an increase in EaI by 0.5 SD over 
a 6-month period with significant change in the disease control group, paired data on 
n=35 patients are required. This calculation is also sufficient for the measures of 
endothelial function and biomarkers43, 306, 307.   
2.4.2 Statistical Analysis 
Continuous data were subject to Shapiro-Wilks test for normality of distribution. 
Normally distributed continuous data are expressed as mean and standard deviation (SD). 
Non-normally distributed continuous data are expressed as median and interquartile range 
(IQR). Comparisons between the three groups were performed with one-way analysis of 
variance (ANOVA) with Tukey’s post hoc test of pairwise comparisons (for normally 
distributed data) or Kruskal-Wallis test with Dunn-Bonferroni’s post hoc method (for 
non-normally distributed data). Categorical data are expressed as number (%) and 
compared using the chi-squared test with appropriate degrees of freedom or Fishers Exact 
test for comparisons between two groups. Correlations between continuous study 




associations were assessed using multivariate linear or logistic regression models as 
appropriate. Longitudinal data were analysed using Friedman test. A two-sided p < 0.05 
is considered significant. Data obtained were summarised in spreadsheets (Microsoft 
Excel) and analysed using SPSS version 23.  
As part of my doctorate training, I attended tutorials in statistical methodology from Dr 




















VALIDATION AND REPRODUCIBILITY 
This section shows a record of all validation experiments I performed prior to 





















3.1 LASER DOPPLER FLOWMETRY 
 
Coefficients of variation (CVs) were assessed on four subjects over three days and 
recorded as percentage increase from mean baseline to maximum flow. The average 
interassay CVs were 32% for ACh and 21% for SNP (Table 3.1). 
 
Table 3.1 Interassay coefficients of variation for acetylcholine and sodium 
nitroprusside 
Subject Agonist 1st day 2nd day 3rd day Mean SD CV (%) 
1 ACh 816 1478 1161 1152 321 29 
SNP 1153 1627 848 1209 393 33 
2  ACh 647 1929 1436 1337 647 48 
SNP 2148 1780 1872 1933 192 10 
3  ACh 1113 1341 665 1040 344 33 
SNP 1262 928 851 1014 218 22 
4 ACh 355 503 502 453 85 19 
SNP 876 670 626 724 133 18 












Intra-assay CVs were assessed three times in the same day, on three subjects and recorded 
as percentage increase to the nearest whole number from mean baseline to maximum flow 
(flux). Average intra-assay CVs were 33% for ACh and 31% for SNP. 
 
Table 3.2 Intra-assay coefficients of variation for iontophoresis of acetylcholine 


















1  ACh 202 123 109 145 50 35 
 SNP 264 437 727 476 234 49 
2  ACh 1432 989 710 1044 364 35 
 SNP 846 655 499 667 174 26 
3  ACh 847 677 460 661 194 29 
 SNP 1337 1150 910 1132 214 19 

























3.2 PULSE WAVE ANALYSIS  
 
Measures recorded using the SphygmoCor device (Section II) are shown below. I 
studied four healthy volunteers measured on three consecutive days to ascertain 
interassay CVs. Data are recorded to a maximum of 3 significant figures. 
 
Table 3.3 Interassay coefficients of variation for pulse wave analysis, aortic 
augmentation index, heart rate and operator index 
Subject Measurement Day 1 Day 2 Day 3 Mean SD CV 





























































































































































































AIx Aortic augmentation index, AoD Aortic diastolic pressure (central), AoS Aortic 
systolic pressure (central), CV Coefficient of variation, HR Heart rate, MAP Mean 
arterial pressure (central), OI Operator index, SD standard deviation.  
 
 
The average interassay CV for each measure is shown in Table 3.4. 
 
Table 3.4 Average interassay coefficient of variation for pulse wave measures 
Measurement Mean interassay CV (%) 
Ao S (mmHg) 












AIx Aortic augmentation index, AoD Aortic diastolic pressure (central), AoS Aortic 
systolic pressure (central), CV Coefficient of variation, HR Heart rate, MAP Mean 





For intra-assay CVs of pulse wave measures three healthy volunteers were studied three 
times in succession on the same day (Table 3.5).  
 
Table 3.5 Intra-assay coefficient of variation for pulse wave measures 
Subject Parameter 1st  2nd 3rd Mean SD CV (%) 


















































































































































AIx Aortic augmentation index, AoD Aortic diastolic pressure (central), AoS Aortic 
systolic pressure (central), CV Coefficient of variation, HR Heart rate, MAP Mean 





Average intra-assay CVs for the measures in Table 3.5 are shown in Table 3.6. 
 
Table 3.6 Average intra-assay coefficients of variation for pulse wave analysis, 
aortic augmentation index, heart rate and operator index 
Parameter Mean intra-assay CV (%) 
Ao S (mmHg) 












AIx Aortic augmentation index, AoD Aortic diastolic pressure (central), AoS Aortic 
systolic pressure (central), CV Coefficient of variation, HR Heart rate, MAP Mean 













Inter- and intra-assay CVs for AIx were high due to low numbers including some minus 
figures recorded in younger healthy volunteers. I repeated them in older healthy 
volunteers (mean age 58±2.6) more representative of the age of my study population. 
The results are shown in Tables 3.7 and 3.8. 
 
Table 3.7 Repeat AIx interassay coefficients of variation 
Subject Day 1 Day 2 Day 3 Day 4 Mean SD CV (%) 
1 23 27 24 22 24 2.16 9 
2 36 35 34 32 34.3 1.71 5 
3 32 26 27 29 28.5 2.65 9.3 
CV Coefficient of variation. 
 
Average interassay AIx CV (%) = 7.8 
 
Table 3.8 Repeat AIx Intra-assay coefficients of variation 
Subject 1 2 3 4 5 Mean SD CV (%) 
1 39 37 36 39 38 37.8 1.30 3.4 
2 27 27 27 25 27 26.6 0.89 3.4 
3 32 36 36 36 37 35.4 1.95 5.5 
CV Coefficient of variation. 
 








Table 3.9 shows interassay CVs for total monocytes and total MPAs performed using 









Table 3.9 Interassay coefficients of variation for total monocytes and monocyte-platelet aggregates 
Subject Day 1 Day 2 Day 3 Mean SD CV (%) 
Mon MPA Mon MPA Mon MPA Mon MPA Mon MPA Mon MPA 
1 312 31.9 241 26.9 277 30.5 277 29.8 35.5 2.6 12.8 8.7 
2 318 31.8 466 54.5 409 50.4 398 58.2 74.4 10.1 18.7 17.4 
3 362 43.5 426 54.7 414 49.7 400 49.3 34.1 5.63 8.5 11.4 




Average interassay CV is 13% for total monocytes and 12.5% for total MPAs. 
To determine intra-assay variability, I took a blood sample from each subject and then, 




















Table 3.10 Intra-assay coefficients of variation for monocyte subsets and 
monocyte-platelet aggregates 
Subject Parameter Sample 1 Sample 2 Sample 3 Mean SD CV 
(%) 
1 Mon 1 270 226 246 248 22.1 8.9 
Mon 2 37.3 26.0 27.1 30.2 6.22 20.6 
Mon 3 15.8 14.9 14.5 15.1 0.66 4.4 
Total Mon 323 267 288 293 28.4 9.7 
MPA 1 28.6 17.0 24.9 23.5 5.93 25.2 
MPA 2 9.6 4.98 7.90 7.50 2.35 31.3 
MPA 3 1.45 2.28 3.18 2.30 0.87 37.6 
Total MPA 39.7 22.2 36.0 33.3 8.09 24.3 
2 Mon 1 508 488 490 495 10.9 2.2 
Mon 2 75.3 66.6 76.0 72.6 5.24 7.2 
Mon 3 33.9 34.3 36.2 34.8 1.24 3.6 
Total Mon 617 589 602 603 14.0 2.3 
MPA 1 38.9 42.8 42.1 41.3 2.06 5.0 
MPA 2 10.7 6.85 10.4 9.33 2.15 23.1 
MPA 3 5.61 4.9 7.07 5.86 1.11 18.9 
Total MPA 55.3 54.6 59.6 56.5 2.71 4.8 
3 Mon 1 140 169 157 156 14.7 9.4 
Mon 2 18.7 23.0 20.4 20.7 2.16 10.4 
Mon 3 14.4 15.3 15.0 14.9 0.43 2.9 
Total Mon 173 207 193 191 17.2 9.0 
MPA 1 10.8 12.5 10.7 11.3 1.03 9.0 
MPA 2 2.84 4.62 3.26 3.57 0.93 26.0 
MPA 3 2.25 2.29 1.91 2.15 0.21 9.7 
Total MPA 15.9 19.4 15.9 17.1 2.05 12.0 




The average intra-assay CVs from the monocyte measures are shown in Table 3.11.  
 
Table 3.11 Average intra-assay coefficients of variation for monocyte measures  




Total Mon 7 
MPA 1 13 
MPA 2 27 
MPA 3 22 
Overall MPA 14 















I prepared ten samples each from the frozen plasma of four healthy volunteers. Five 
samples were for elucidation of endothelial microparticles and five for platelet 
microparticles (Tables 3.12 and 3.13). After experimenting with different dilutions, I 
found that a 1:20 dilution of sample to phosphate buffered saline (PBS) produced the 
most reliable results. 
 
Table 3.12 Intra-assay coefficients of variation for EMPs 
 







Test 1 Test 2 Test 3 Test 4 Test 5 Mean SD CV (%) 
1 4.4 3.8 3.6 4.3 4.4 4.1 0.37 9.0 
2 10 10 11 10 9.9 10 0.26 2.6 
3 12 13 13 13 13 13 0.45 3.5 
4 1.1 11 11 11 12 11 0.35 3.1 









Test 2 Test 3 Test 4 Test 5 Mean SD CV (%) 
1 303 387 394 379 202 333 81.9 24.6 
2 244 252 258 213 191 232 28.5 12.3 
3 1.05 1.13 0.95 0.80 1.03 0.99 0.13 12.8 
4 1.76 1.65 1.60 2.19 1.71 1.78 0.23 13.1 
5 637 697 700 626 579 647 51.1 7.8 
 

















I performed all the measures required to derive the elastance values on three healthy 
volunteers on three consecutive days (Tables 3.14 and 3.15). 
 
Table 3.14 Interassay coefficients of variation for echocardiographic measures 
Subject Measure Day 1 Day 2 Day 3 Mean SD CV (%) 
1 Ea 2.66 2.73 2.71 2.70 0.04 1.3 
Ees 3.32 3.81 3.76 3.63 0.27 7.4 
Ea/Ees 0.83 0.67 0.69 0.73 0.09 11.9 
Eed 0.08 0.09 0.09 0.09 0.01 6.7 
EF 55 60 62 59 3.61 6.1 
2 Ea 1.65 1.69 1.72 1.69 0.04 2.1 
Ees 2.20 2.30 2.3 2.27 0.06 2.5 
Ea/Ees 0.75 0.69 0.72 0.72 0.03 4.2 
Eed 0.04 0.04 0.03 0.04 0.01 15.7 
EF 57 59 60 59 1.53 2.6 
3 Ea 1.4 1.7 1.6 1.57 0.15 9.8 
Ees 3.7 4.1 4 3.93 0.21 5.3 
Ea/Ees 0.37 0.4 0.33 0.38 0.04 9.6 
Eed 0.08 0.09 0.08 0.08 0.01 6.9 
EF 72 69 67 69 2.52 3.6 
CV coefficient of variation, Ea arterial elastance, Eed end-diastolic elastance, EF 







Table 3.15 Average coefficient of variation for each measure of elastance and left 
ventricular ejection fraction 






CV coefficient of variation, Ea arterial elastance, Eed end-diastolic elastance, EF 

















3.6 SECTION SUMMARY 
 
In this section, the CVs for the methods used in this thesis are presented. In general, they 
are low and in keeping with previous literature. Agarwal et al found that iontophoresis of 
ACh measured as relative percentage change had an average CV of 25.5% with ranges 
from 23% to 39%308. The sphygmoCor technique is well established with good 
repeatability and reproducibility demonstrated in a variety of populations309-311. If 
anything, AIx tends to be the most variable as in young highly compliant vessels, the AIx 
can be negative. There is little data on monocyte and microparticle CVs as they will 
depend upon individual laboratory methods. Previous data from our lab has shown 
absolute monocyte count CV to be around 5%, EMPs <13% and PMPs 18.2% 
(unpublished data). Echocardiographic measures of LV ejection fraction and volumes 
(used to estimate elastances) are well known to have intra- and interobserver variabilities 
of 5-10% depending upon the method used. Three-dimensional, non-contrast measures 
(as used in my study) have been shown to have the lowest temporal variability312. I did 











OBSERVATIONAL ANALYSES OF CLINICAL DATA – THE LOCAL 




















4.1 SECTION INTRODUCTION 
 
The United Kingdom (UK) comprises an ethnically diverse society with approximately 
13% (8.7 million) of the population belonging to black and minority ethnic groups 
(BMEGs) amongst which there is considerable heterogeneity. Although resident 
throughout the UK, large clusters of BMEGs appear in metropolitan areas of major 
conurbations313. Birmingham, the second most populous city in the UK, has 
approximately three times the national average of BMEGs314.  
The major burden of cardiovascular (CV) disease within these groups is partially 
explained by the higher prevalence of traditional CV risk factors such as hypertension 
and diabetes. Although extensive, there is considerable inter- and intra-ethnic variability 
of CV disease. For example, African Americans have higher rates of CAD than Afro-
Caribbeans living in Britain or natively, who are more likely to develop cerebrovascular 
or renal disease than CAD. On the other hand, the South Asian diaspora have similar 
epidemic proportions of CAD as do those who remain on the subcontinent313– defined as 
India, Pakistan, Sri Lanka, Nepal, and Bangladesh – and within which, there is also 
significant heterogeneity315, 316. Almost 30% of the Birmingham population are South 
Asian. 
Epidemiological evidence shows that many South Asian groups – male and female – 
living in the western world have a higher burden of cardiovascular disease than other 
ethnicities315, 317. Furthermore, CAD develops at a younger age (often <40 years in men) 
and is more aggressive in South Asians318. While major risk factors like diabetes and 
abdominal obesity are more prevalent in South Asians, other important risk factors such 




Asians have smaller coronary artery lumens thus theorising that even the same burden of 
CAD becomes severe more quickly than it otherwise would320. Others have reported a 
difference in high and low-density lipoprotein (HDL and LDL) particle size as a potential 
contributor. The smaller LDL particles found in Asian Indians are more susceptible to 
oxidative stress and hence more atherogenic, whilst the smaller HDL particles identified 
in the same group are less protective than larger ones321. 
Whilst the precise underlying mechanisms are unclear, many of these observations are 
reflected in the following analyses of our own clinical cardiology databases, which 















4.2 ETHNIC DIFFERENCES IN THE DIURNAL VARIATION OF 
SYMPTOM ONSET TIME FOR ACUTE ST-ELEVATION MYOCARDIAL 
INFARCTION – AN OBSERVATIONAL COHORT STUDY 
 
4.2.1 Introduction 
A morning peak of ST-segment elevation myocardial infarction (STEMI) has 
traditionally been described however variations of this common perception exist322-324. 
Studies regarding South Asian populations are conflicting with some showing complete 
absence of circadian rhythm323 and others reporting an excess between midnight and 
noon324. There is little data examining circadian symptom onset of acute myocardial 
infarction (AMI) in Afro Caribbeans. This study compares the circadian rhythm of 
STEMI onset in White European (WE), South Asian (SA) and Afro Caribbean (AC) 
patients. 
4.2.2 Hypothesis  
There will be differences in peak time of presentation of AMI between the ethnicities. 
4.2.3 Methods 
The methods described below have been published. I did all the data collection, analysis 
and wrote the final paper.  
4.2.3.1 Patients and setting 
In a retrospective survey of our British Cardiovascular Intervention Society (BCIS) 
database, I identified consecutive patients undergoing primary percutaneous coronary 
intervention (PPCI) for acute STEMI at our institution (Sandwell and West Birmingham 




collects data from all hospitals in the UK that perform PCI and records information about 
every procedure performed325.  
PCI is defined as the use of any coronary device to approach, probe, or cross one coronary 
lesion with the intention of performing a coronary intervention. The database is compliant 
with UK data protection legislation. Data are collected prospectively at each hospital, 
electronically encrypted, and transferred online to a central database. Each patient entry 
offers details of the patient journey, including the method and timing of admission, 
inpatient investigations, results, treatment, and outcomes325. Acute STEMI was diagnosed 
in the setting of chest pain accompanied by an ECG demonstrating ST-segment elevation. 
Afro Caribbean, WE and SA patients were categorised into groups. Symptom onset time 
was based on patient recollection during the history and the ambulance record. Hospital 
arrival time was based on the recorded arrival time at the emergency department (ED). 
For patients already in hospital it was taken as the symptom onset time. Both timings 
were categorised into six 4-hour intervals (00:00-03:59, very early morning; 04:00-07:59, 
early morning; 08:00-11:59, morning; 12:00-15:59, afternoon; 16:00-19:59, evening; and 
20:00-23:59, night). Definitions of the clinical and procedural characteristics recorded for 
each group are listed in Appendix 7.  
4.2.3.2 Outcomes 
We recorded and compared the proportion of each ethnic group with symptom onset and 
hospital arrival in a particular time category. We also analysed the association between 
symptom onset time and door-to-balloon time (DTBT). DTBT was defined as the time in 
minutes from the arrival at the PCI capable centre to inflation of the first device restoring 




brought about by incorrect recording of dates associated with the times (leading to several 
minus figures) we excluded patients with a recorded door-to-balloon time of less than 10 
minutes. We also excluded patients with a DTBT of greater than 300 minutes, partly to 
include the patients who had the most to gain from myocardial salvage and partly to 
exclude recording errors. 
4.2.3.3 Statistical analysis 
Continuous, normally distributed variables are presented as mean and standard deviation 
(SD) – non-normal data as median plus interquartile range (IQR). Continuous data were 
analysed using one-way analysis of variance (ANOVA) if normally distributed or 
Kruskal-Wallis H Test if not normally distributed. Categorical variables are presented as 
numbers and percentages and were analysed using Chi Square. Standard and hierarchical 
multiple regression were used to determine the predictive capabilities of variables where 
necessary. A two-sided p value <0.05 was considered statistically significant. SPSS 
version 21 was used for analysis. 
4.2.4 Results 
4.2.4.1 Patients 
A total of 1505 patients underwent PPCI between the specified time points and are 
included in the analysis. The cohort consisted of 68 ACs (4.5%), 1021 (68%) WEs, 407 
(27%) SAs, 7 (0.5%) ‘other’ and 2 (0.1%) unspecified cases. After exclusion of the 7 
‘other’ and 2 non-specified cases 1496 patients remained in the analysis. 
Baseline and procedural data with unadjusted p values are shown in Table 4.1. WEs were 
significantly older at symptom onset (p<0.001), more likely to be current smokers 




were less often female (p=0.007), and had significantly more hypercholesterolaemia 
(p=0.007) whilst both SAs and ACs were more likely to have hypertension (p=0.013). 
White Europeans had fewer radial procedures (p=0.011) whilst SAs were more likely to 
have multivessel disease (p=0.046). South Asians and ACs tended to have left anterior 





































Age (SD) 57 (14) 63 (13) 58 (14) <0.001 
Females n (%) 22 (32) 277 (27) 81 (20) 0.007 
Elderly n (%) 10 (15) 235 (23) 60 (15) 0.001 
Family history of 
CAD n (%)* 
15 (22) 319 (32) 142 (36) 0.051 
Previous MI n (%) 
Previous CABG n (%) 













Diabetes n (%) 24 (35) 153 (15) 156 (38) <0.001 
Hypertension n (%) 39 (57) 475 (47) 219 (54) 0.013 
Hypercholesterolaemia 
n (%)* 
21 (31) 425 (43) 195 (50) 0.007 
Ventilation pre-
admission n (%) 
2 (2.9) 59 (5.8) 24 (5.9) 0.603 
Cardiogenic shock n 
(%) 
9 (13) 124 (12) 61 (15) 0.352 
Current smoking n 
(%)* 
 
26 (38) 450 (46) 108 (28) <0.001 
PVD n (%)* 3 (4.4) 86 (8.5) 23 (5.7) 0.122 
Previous stroke n (%) 3 (4.4) 52 (5.1) 15 (3.7) 0.545 
Renal failure n (%)* 1 (1.5) 24 (2.4) 15 (3.8) 0.313 
Radial n (%) 46 (68) 531 (54) 235 (61) 0.011 
Circulatory support n 
(%) 
5 (7.6) 110 (11) 53 (13) 0.279 
Thrombus aspiration n 
(%) 
27 (40) 445 (44) 181 (44) 0.762 
LAD culprit n (%) 33 (49) 429 (43) 197 (50) 0.058 
Longest stent (mm) 23 (18-38) 23 (16-31) 23 (18-32) 0.339 
Largest balloon 
median (IQR) 






GP 2b/3a inhibitors n 
(%) 
20 (29) 317 (31) 131 (32) 0.844 
No. of vessels 
attempted (mean+SD) 
1.07 (0.26) 1.07 (0.35) 1.12 (0.46) 0.046 
In hospital death n (%) 6 (8.8) 64 (6.3) 30 (7.4) 0.580 
* One-way ANOVA, ** denominator reflects cases reported, § Kruskal-Wallis, all other 
tests Chi square, SD standard deviation, IQR interquartile range, CAD coronary artery 
disease, MI myocardial infarction, PCI percutaneous coronary intervention, CABG 
coronary artery bypass graft, PVD peripheral vascular disease, LAD left anterior 
descending (artery), GP glycoprotein. 
 
4.2.4.2 Outcomes 
4.2.4.2.1 Symptom onset 
The proportions of each group that developed symptoms during each categorised time are 
shown in Table 4.2. Overall the highest incidence of AMI symptom onset was between 
08:00 and noon (n=352) with WE and SA ethnicities mirroring this trend (both p < 0.001). 
A significantly higher proportion of the SA population, compared to the AC and WE 
population in this sample, developed symptoms between 20:00 and 23:59 (p=0.026) 
(Figure 4.1.) This remained significant in a multivariate logistic regression model after 
adjustment for age and gender (odds ratio [OR] 1.54, confidence interval [CI] 1.12-2.11, 
p=0.008) and after further adjustment for other significantly different baseline variables 
(diabetes, hypertension, hypercholesterolaemia and current smoking) (OR 1.60, CI 1.12-
2.28, p=0.009.) Forty four percent of WEs developed symptoms between 08:00 and 
15:59, with a significantly higher proportion experiencing symptoms between 12:00 and 
15:59 when compared with SAs alone (p=0.011 data not shown.) After adjustment for the 
same variables this remained significant at p=0.017 (OR 1.52 CI 1.08-2.14.) Afro 
Caribbean ethnicity was not associated with diurnal variation in AMI symptom onset 















00:00-03:59 9 (13) 127 (12) 59 (14) 0.580 
04:00-07:59 12 (18) 159 (16) 74 (18) 0.465 
08:00-11:59 12 (18) 250 (24) 90 (22) 0.320 
12:00-15:59 12 (18) 202 (20) 57 (14) 0.038 
16:00-19:59 13 (19) 157 (15) 53 (13) 0.322 
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4.2.4.2.2 Hospital presentation 
Despite the differences between ethnicities in the timing of symptom onset throughout 
the day there did not appear to be any differences in the timing of presentation to hospital 
(Table 4.3) other than an increased likelihood for Afro Caribbeans to arrive in the evening 
(16:00-19:59). 
 
Table 4.3 Time of arrival at PCI centre (door time) 







00:00-03:59 8 (12) 123 (12) 50 (12) 0.989 
04:00-07:59 5 (7.4) 112 (11) 57 (14) 0.144 
08:00-11:59 16 (24) 260 (25) 107 (26) 0.876 
12:00-15:59 13 (19) 234 (23) 76 (19) 0.187 
16:00-19:59 17 (25) 169 (17) 54 (13) 0.038 













4.2.4.2.3 Quality measures 
The application of criteria to exclude spurious measures enabled us to analyse DTBT in 
1370 (92%) patients. Symptom onset between 12:00 and 15:59 was found to be predictive 
of reduced DTBT at multivariate analysis after correcting for age, gender, ethnicity, 
diabetes, cardiogenic shock and pre-procedural ventilation (p=0.034). Symptom onset 
between 12:00 and 15:59 conferred a higher likelihood of achieving the internationally 
recognised DTBT target of less than 90 minutes (OR 0.66, 95% CI 0.47-0.92; p=0.016). 
DTBT was marginally longer in those whose symptoms developed at night (20:00-23:59), 
although this did not reach statistical significance (p=0.09). 
 
4.2.5 Discussion 
Notable findings include a morning excess of AMI onset in WE and SA patients but not 
for ACs, a second night time (20:00-23:59) peak for SAs and an association between 
afternoon symptom onset and shorter DTBT.  
To my knowledge this is the first report of a possible bimodal distribution of AMI 
symptom onset in SAs who appeared to have a significantly higher night time (20:00-
23:59) onset than other ethnicities but this would need to be confirmed with larger 
numbers (with specific tests for bimodality incorporated into the study design) as would 
the apparent absence of diurnal variation of AMI symptom onset in ACs. This could be 
related to ethnic differences in cortisol production326. Heart rate and blood pressure also 





Symptom onset time is an important predictor of increased pre-hospital delay, reperfusion 
times and subsequent infarct size328-330. The fact that white patients appear to develop 
symptoms more frequently during the afternoon than other ethnicities may partly explain 
the association found in some studies between increased reperfusion time and non-white 
ethnicity331.  
Limitations include low numbers of Afro Caribbean patients in the cohort, the 
geographical diversity of the South Asian and Afro Caribbean populations leading to 
considerable heterogeneity within those groups, and the fact that symptom onset time can 
be difficult to determine precisely due to inconsistencies in patient recollection. 
 
4.2.6 Conclusion 
South Asian ethnicity was associated with an increased likelihood of night time (20:00-
23:59) symptom onset compared with WE and AC ethnicities, whilst WEs were more 
likely than other ethnicities to develop symptoms in the afternoon (12:00-15:59). In 










4.3 SYMPTOM-TO-DOOR TIMES IN PATIENTS PRESENTING WITH 
ST-ELEVATION MYOCARDIAL INFARCTION – DO ETHNIC OR 
GENDER DIFFERENCES EXIST? 
 
4.3.1 Introduction 
The relative contribution of ethnicity itself as an independent predictor of poorer hospital 
performance markers, such as symptom-to-door time (STDT) or door-to-balloon time 
(DTBT), leading to poorer outcomes in AMI due to CAD has been evaluated in several 
studies with conflicting conclusions325, 332, 333. Recent analyses have shown no difference 
in in-hospital mortality between SAs and patients of other ethnicities after adjustment for 
risk factors325, 334. Some investigators report an increased likelihood that SAs and female 
patients develop atypical chest pain, which may delay the diagnosis of AMI335. We 
recently reported an increased tendency for SA patients to develop symptoms of AMI at 
night336, which may affect the immediacy by which people seek help. Despite the 
perception that these groups have uncharacteristic pain, there is evidence that they seek 
immediate help just as frequently (if not more so) than WEs and males337. This paper 
examines the association between pre-hospital delay, female gender and ethnic minority 
patients (AC and SA). 
4.3.2 Hypothesis 
Women and ethnic minority (AC and SA) patients present to hospital later after the onset 








4.3.3.1 Study population and setting 
At the time of my analysis twenty-four-hour PPCI was delivered to half a million people 
across the two acute hospital sites at SWBH NHS Trust. The same body of cardiologists 
covered both sites when on call and the patients’ location at the onset of symptoms 
determined where they were taken. Now, following re-configuration in September 2015, 
all patients are brought to a single site for coronary intervention (see appendix 7 for 
procedural definitions). 
Using the SWBH version of the BCIS database (described in 4.2.3.1) consecutive patients 
receiving PPCI for STEMI between January 2008 and January 2013 were identified. 
STEMI was defined using standard ECG criteria in the presence of ischaemic chest pain. 
Analyses were performed with the cohort grouped according to gender and then according 
to ethnicity (SA, AC or WE.) 
4.3.3.2 Outcomes 
The main outcome measure was STDT which is defined as the time in minutes between 
a patient arriving at a PCI capable hospital (not first medical contact) and the time of 
symptom onset according to the patient’s recollection. Other outcome measures include 
the symptom-to-call time (STCT) which is defined as the difference between the onset of 
symptoms and the call for medical assistance, and in hospital mortality which is defined 
as death from any cause prior to discharge or at 30 days if the latter was shorter. We 
excluded those patients with a documented STDT of less than 10 minutes and those 





4.3.3.3 Statistical Analysis 
Baseline characteristics were compared across gender types using the Chi squared test for 
categorical variables and Student’s T test or one-way analysis of variance (ANOVA) for 
continuous normally distributed variables. For non-normally distributed variables the 
Mann-Whitney U test or the Kruskal-Wallis test was used. Discrete variables are 
expressed as numbers and percentages, continuous variables as mean and standard 
deviation or median and interquartile range. Differences in STDT were analysed with 
non-parametric tests and subject to multivariate analysis to adjust for age, ethnicity (in 
the female population), gender (between the ethnic groups) and significant baseline 
variables. In hospital mortality was examined using chi square for between group 
differences and logistic regression to account for age, gender and differences in baseline 
characteristics. A p value <0.05 was considered significant. Data were analysed using 
SPSS 21.  
4.3.4 Results 
4.3.4.1 Patients 
Altogether 1157 patients underwent PPCI during the study period. Eighty patients who 
were already in the cardiac centre at symptom onset, seventeen inter-hospital transfers 
and 40 patients with a recorded STDT less than 10 minutes were excluded. One thousand 
and twenty patients remained in the analysis of which 768 (75%) were male (Table 4.4). 
South Asian (n=263) and AC (n=38) patients were more likely to be diabetic and younger 
than WE patients (n=719) and there was significantly less smoking amongst SAs (Table 
4.5). Women were more likely to be diabetic, hypertensive and older than males (p=0.019, 




vascular disease or have a family history of CAD, (p=<0.001, 0.009 and 0.039 
respectively) and women were more likely to require intra-aortic balloon support than 
men. There were no differences in the requirement for any form of circulatory support 
between the ethnic groups. 
 
Table 4.4 Gender related clinical and procedural characteristics  
Variable Gender (n=1020)  





Age (mean±SD) 59 (13) 67 (14) <0.001** 
Family history of CAD n (%) 255 (34) 65 (27) 0.04 
Previous MI, n (%)  
Previous CABG, n (%)  










Diabetes n (%) 136 (18) 62 (25) 0.02 
Hypertension n (%) 353 (45) 152 (61) <0.001 
Hypercholesterolaemia n (%) 321 (42) 118 (47) 0.18 















Ventilation pre-admission n (%) 29 (4) 4 (2) 0.09 
IABP n (%)  60 (8) 30 (12) 0.04 
Current smoking n (%) 327 (44) 77 (31) <0.001 
PVD n (%) 48 (6) 28 (11) 0.009 




Renal failure n (%) 16 (2) 8 (3) 0.27 
Procedural 
Glycoprotein inhibitors n (%) 290 (38) 85 (35) 0.40 
Radial access n (%) 400 (52) 118 (48) 0.32 
Thrombus removal n (%) 348 (45) 105 (43) 0.49 
Mean no. of DES implanted 
(SD) 
1.14 (1.06) 1.01 (1.06) 0.09** 
Median stent diameter mm 
(IQR) 
3.25 (3.0-3.5) 3.0 (2.75-3.5) 0.002* 
Median stent length mm (IQR) 23 (15-30) 20 (15-32) 0.78* 
Outcomes 
Median STDT (IQR) 113 (68-247) 132 (72-312) 0.07* 
Median STCT (IQR) 100 (45-253) 125 (55-316) 0.03* 
Median DTBT (IQR) 68 (55-85) 72 (59-89) 0.09* 
In hospital death n (%) 33 (4) 27 (11) <0.001 
SD standard deviation, CAD coronary artery disease, MI myocardial infarction, CABG 
coronary artery bypass grafting, PCI percutaneous coronary intervention, W-E White 
European, A-C Afro-Caribbean, SA South Asian, IABP intra-aortic balloon pump, PVD 
peripheral vascular disease, DES drug eluting stent, mm millimetres, STDT Symptom-
to-door-time, STCT symptom-to-call-time, DTBT door-to-balloon-time, IQR 
interquartile range, *Mann-Whitney U, **Student’s T test, all other p values derived 














Table 4.5 Clinical and procedural characteristics by ethnic group 














Age (mean±SD) 63 55 58 <0.001* 
Male n (%) 530 (74) 27 (71) 211 (80) 0.09 
Family history of CAD n 
(%) 
217 (31) 12 (32) 91 (36) 0.34 
Previous MI, n (%)  
Previous CABG, n (%) 













Diabetes n (%) 91 (13) 13 (34) 94 (36) <0.001 
Hypertension n (%) 337 (47) 23 (61) 145 (55) 0.05 
Hypercholesterolaemia n (%) 294 (41) 13 (34) 128 (49) 0.02 
Ventilation pre-admission n 
(%) 
22 (3) 1 (3) 10 (4) 0.82 
Current smoking n (%) 314 (45) 16 (43) 74 (29) <0.001 
PVD n (%) 58 (8) 1 (3) 7 (3) 0.64 
Previous stroke n (%) 34 (5) 0 (0) 11 0.69 
Renal failure n (%) 16 (2) 0 (0) 8 (3) 0.81 
IABP n (%) 62 (9) 2 (5) 24 (9) 0.90 
Procedural 
Glycoprotein inhibitors n 
(%) 
259 (36) 14 (37) 100 (38) 0.35 
Radial access n (%) 342 (48) 23 (61) 150 (57) 0.004 
Thrombus removal† n (%) 312 (44) 17 (45) 122 (46) 0.74 




Median stent diameter mm  3.25  3.5 3.25 0.66*** 
Median stent length mm  23 20 23 0.51*** 
Outcomes  










Median DTBT (IQR) 69 (55-84) 85 (69-107) 71 (57-90) 0.012 
In hospital death n (%) 44 (6.1) 3 (7.9) 19 (7.2) 0.96 
SD standard deviation, CAD coronary artery disease, MI myocardial infarction, CABG 
coronary artery bypass grafting, PCI percutaneous coronary intervention, PVD 
peripheral vascular disease, IABP intra-aortic balloon pump, DES drug eluting stent, 
mm millimetres, STDT symptom-to-door-time, STCT symptom-to-call-time, DTBT 
door-to-balloon-time, IQR interquartile range, *Analysis of variance (ANOVA), 
















Females trended towards longer unadjusted STDT (p=0.07) and had significantly longer 
unadjusted STCT (p=0.03). After correction for age and ethnicity there was no association 
between female sex and longer STDT or STCT (p=0.15 and p=0.1 respectively). 
Unadjusted in-hospital mortality was significantly higher in females (p<0.001) but this 
association was not present on logistic regression after adjustment for age (odds ratio 
[OR] 0.69 95% confidence interval [CI] 0.40-1.18, p=0.17)  
The crude STDT was not different between the ethnic groups (p=0.37). On linear 
regression analysis after adjustment for age, gender and diabetes SAs showed a trend 
towards longer STDT than other ethnic groups (p=0.08). Afro Caribbeans did not 
(p=0.58). Overall SAs showed a trend towards increased hospital mortality which was 
present on stepwise multivariate logistic regression after adjustment for age and gender 
(odds ratio [OR] 1.7 95% CI 0.96-3.10, p=0.07), but after adjustment for diabetes there 
was no association with mortality (OR 1.5, 95% CI 0.80-2.86, p=0.21). There was no 




This study was designed to assess the impact of ethnicity and gender on STDT in patients 
who develop STEMI whilst in the community. We showed a trend towards longer STDT 
for both females and SAs that disappeared after adjustment for differences in baseline 
variables between men and women and between SAs and other ethnic groups. Afro 




Symptom-to-door time accounts for the largest proportion of total ischaemic time338 and, 
in many cases, is broadly divided into time of symptom onset to call for medical 
assistance; and call for medical assistance to arrival at the emergency department. The 
latter usually consists of the time taken for emergency medical services to arrive at the 
patient’s location and then transfer them to the nearest PPCI centre. Other variations of 
this process exist – patients may initially call their own doctor or transport themselves to 
a non-PCI capable facility. Previous studies have suggested that SAs are less likely to call 
emergency medical services following the onset of chest pain338, 339 and use of such 
services is associated with shorter STDT. This may contribute to the trend observed in 
this study. The reasons behind this are not clear but could relate to the increased 
prevalence of atypical coronary ischaemic symptoms such as abdominal pain, nausea and 
fatigue without chest pain although as far as I am aware this has only been observed in 
patients presenting with stable symptoms319. In any case the data presented here do not 
support prehospital delay as a contributor to mortality in SAs which seems to be explained 
by the excess of cardiovascular risk factors particularly diabetes. Indeed, a recent large 
registry analysis has shown no difference in mortality between SAs and WEs after 
adjustment for diabetes325. 
Contrary to previous studies340 we found no significant gender differences in STDT, 
suggesting that pre-hospital delay does not contribute to higher inpatient mortality seen 
in females post STEMI. In accordance with several other studies the excess early female 
mortality in this cohort was entirely explained by advancing age and its associated 
comorbidities341-343. In contrast to this and other studies, de Boer et al344 found that the 
higher female mortality rate did not disappear after adjustment for baselines 




times may have been responsible for this observation in their cohort but were not able to 
support this owing to a lack of data. 
Over the last thirty years, community interventions to reduce patient associated delays 
have had mixed success. Some studies reported no change in patient behaviour despite an 
increase in knowledge because of the intervention338, 345, 346. Others observed significant 
reductions in pre-hospital time delay associated with an increased proportion of patients 
diagnosed with AMI or unstable angina347, 348. Some reported significant increases in non-
cardiac chest pain attendances whilst others did not. No studies, including one randomised 
controlled trial, have shown any effect on mortality.  
4.3.6 Limitations 
Similarly to the previous analysis, there were small numbers of AC patients and time of 
symptom onset was determined from patient recall and may be inaccurate especially if 
asked during pain. Significant language barriers might exist between hospital staff and a 
proportion of the patients also leading to inaccurate recording and inputting of data; 
however, English-speaking family members are often present or staff members on duty 
may share the same language as the patient. As an observational study, there is always 
the possibility of inherent biases and confounders brought about by data that is missing 
or incorrectly entered although every effort was made to validate our findings by referring 
to the case notes when necessary. Although, a single centre study, the findings are highly 







4.3.7 Conclusion   
In this retrospective, observational cohort study neither female gender nor ethnicity could 
be shown to be associated with significant pre-hospital delay. Any differences in, or 



















4.4 SIMULTANEOUS COMPUTERISED ACTIVATION OF THE 
PRIMARY PERCUTANEOUS CORONARY INTERVENTION PATHWAY 
IMPROVES DOOR-TO-BALLOON TIME BUT NOT MORTALITY 
 
4.4.1 Introduction 
The major morbidity and mortality caused by the presence of CAD is AMI brought about 
by the sudden occlusion of one or more coronary arteries, the sequelae of which includes 
sudden cardiac death and heart failure. The latter half of the previous century has seen 
vast improvements in the treatment of this potentially devastating complication of CAD 
culminating in the latest generation of stent technology based on our current 
understanding of endothelial vascular biology. This has been combined with innovation 
within hospitals throughout the UK to deliver models of care aimed at providing prompt 
revascularisation in the setting of AMI. Where ST-segment elevation is present on an 
ECG the preferred strategy is PPCI349. Since our PPCI service began in 2005 considerable 
efforts have been made to implement evidence-based strategies to reduce DTBT for acute 
STEMI patients both inside and outside of normal working hours but, mainly due to 
logistical reasons, DTBTs are more difficult to achieve out-of-hours ([OOH] – 17:00-
0900 weekdays, weekends and public holidays)350.  
This paper details the impact of a new protocol introduced in mid-July 2009 to alert the 
out-of-hours PPCI team. Prior to then, team members were telephoned separately 
following discussion with the interventionist. Since then, the team has been activated 
directly by the emergency department or paramedics independently of the cardiologist 
using a computerised paging system which transmits simultaneously to dedicated mobile 




independently associated with reduced DTBT but mortality throughout the study periods 
was unchanged. 
4.4.2 Hypothesis 
The introduction of simultaneous computerised activation of the PPCI pathway would 
result in shorter DTBT and an increase in the overall proportion of patients achieving 
DTBT under 90 minutes as recommended in international guidelines and that this would 
reduce overall mortality. 
4.4.3 Methods 
4.4.3.1 Patient population 
I analysed consecutive patients undergoing OOH PPCI for acute STEMI at our institution 
between 2007 and 2012 using SWBH NHS Trust Myocardial Ischaemia National Audit 
Project (MINAP) data. The study cohort was divided into two groups, patients presenting 
before the introduction of the computerised alert protocol (Group 1) and patients 
presenting afterwards (Group 2). The MINAP is a national registry of patients admitted 
to hospital with acute coronary syndrome. It was established in 1999, in response to the 
national service framework for coronary heart disease, to examine the quality of 
management of myocardial infarction in hospitals in England and Wales351. We excluded 
106 patients who were either transferred from other hospitals or developed AMI whilst 
already in hospital or had a DTBT greater than 300 minutes. 
 
4.4.3.2 Outcome measures 
The main outcome measures were DTBT and all-cause pre-discharge and one-year 




meeting target DTBT we divided patients into two groups: <90 minutes and ≥90 
minutes and analysed them as categorical variables. We also recorded clinical 
characteristics and STDT (defined in section 4.3.3.2) since any mortality difference 
would need to account for this. STDT was categorised as less than 2 hours or greater 
than 2 hours. 
 
4.4.3.3 Statistical analysis 
Based upon strategies already known to improve DTBT350 we expected to see a reduction 
of approximately 15 minutes in group 2 as compared with group 1. Baseline 
characteristics were compared using the Fisher’s Exact test or the Chi squared test for 
categorical variables and analysis of variance for continuous variables. Discrete variables 
are expressed as numbers and percentages, continuous variables as mean and standard 
deviation or median and interquartile range. Differences in DTBT were tested in 
univariate and multivariate logistic analyses and a p value <0.05 was considered 
significant. The data were analysed using SPSS 21.  
 
4.4.4 Results 
Out of a total of 1340 patients, 1234 patients (mean age 61, 75% male) were included in 
the analysis of which 793 (64%) patients received OOH PPCI – 295 patients in Group 1 
and 498 patients in Group 2. The clinical characteristics and outcomes of each group are 







Table 4.6 Clinical characteristics, symptom-to-door time, door-to-balloon time, in-
hospital and one-year mortality of patients receiving out-of-hours primary 
percutaneous coronary intervention before and after implementation of the 




OOH n = 295 
Post computerised 
PPCI activation 
OOH n = 498 
p value 
Mean Age (SD) 61 (13.3) 60 (13.9) 0.60§ 
Male, n (%) 213 (72) 369 (74) 0.56 
WE, n (%) 
AC, n (%) 









Previous MI, n (%) 56 (19) 73 (15) 0.11 
Angina, n (%) 60 (20%) 86 (17) 0.09† 
Hypertension, n (%) 147 (50) 247 (50) 0.43† 
Hypercholesterolaemia, 
n (%) 
110 (37) 206 (41) 0.33 
PVD, n (%) 6 (2) 21 (4) 0.11 
CVA, n (%) 9 (3) 30 (6) 0.08 
CKD, n (%) 9 (3) 15 (3) 1.00 
Diabetes, n (%) 48 (16) 100 (20) 0.18 
Previous PCI, n (%) 36 (12) 58 (12) 0.82 
Previous CABG, n (%) 8 (3) 13 (3) 1.00 
Smoking, n (%) 195 (66) 339 (68) 0.69 
Cardiac arrest at 
presentation, n (%) 
25 (8) 54 (11) 0.33 
Anterior infarction, n 
(%) 
108 (37) 209 (42) 0.49 
Thienopyridine platelet 
inhibitor, n (%) 





inhibitor, n (%) 
183 (62) 199 (40) <0.0001 
OTHT minutes, 
median (IQR) 
123 (63-296) 113 (67-269) 0.96 
DTBT minutes, median 
(IQR) 
92 (75-11) 76 (64-97) <0.0001 
DTBT < 90 minutes, n 
(%) 
141 (48) 349 (70) <0.0001 
In-hospital mortality, n 
(%) 
12 (4) 25 (5) 0.60 
1-year mortality, n (%) 18 (6) 49 (10) 0.09 
† Chi square test, § student’s T test, all others Fisher’s exact test, WE White-European, 
AC Afro-Caribbean, SA South Asian, MI myocardial infarction, PVD peripheral 
vascular disease, CVA cerebrovascular accident, CKD chronic kidney disease, PCI 
percutaneous coronary intervention, CABG coronary artery bypass grafting, IV 
intravenous, OOH out-of-hours, OTHT (symptom) onset to hospital time, IQR 


















4.4.4.1 Door-to-balloon time 
The unadjusted median DTBT were 92 minutes (interquartile range [IQR] 75-111) for 
Group 1 and 76 minutes (IQR 64-97) for Group 2 (odds ratio [OR] 2.6, 95% confidence 
interval [CI] 1.9-3.4, p<0.0001). This also remained significant on multivariate logistic 
regression analysis after adjustment for age, gender, ethnicity, admitting hospital, direct 
999 admission (defined as an emergency ambulance from the community, as opposed to 
self-presentation), cardiac failure at presentation, cardiac arrest on admission, and 
previous coronary artery bypass grafting (OR 2.8, 95% CI 1.6-5.0, p<0.0001). Figure 4.2 
shows the median DTBT for Groups 1 and 2 compared with patients presenting during 
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PPCI primary percutaneous coronary intervention 
Figure 4.2 Door-to-balloon times of patients admitted to hospital out-of-hours and 




The proportion of patients admitted to hospital OOH achieving a DTBT <90 minutes 
increased from 48% (n=141) in Group 1 to 70% (n=349) in Group 2 (p<0.0001). The 
difference in the proportion of OOH patients achieving a DTBT <90 minutes as compared 
with patients admitted during routine hours are shown in Figure 4.3.  
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PPCI primary percutaneous coronary intervention 
Figure 4.3 The proportion of patients out-of-hours achieving a door-to-balloon 
time of less than 90 minutes as compared with patients presenting in routine hours 
before and after the introduction of the simultaneous primary percutaneous 








4.4.4.2 All-cause mortality 
In hospital mortality was 4.1% (n= 12) in Group 1 and 5% (n=25) in Group 2 (p=0.60). 
All-cause mortality at 1 year was 6.1% (n=18) in Group 1 and 9.9% (n=49) in Group 2 
(p=0.09). To exclude possible biases due to modifications in the standard of care of 
patients (such as pharmacological therapy, interventional procedure and physician 
expertise), we analysed the mortality rates for PPCI performed in the same two periods 
but during working hours (Figures 4.4 and 4.5). On regression analysis introduction of 
the new system was not related to any change in in-hospital or one-year mortality (OR 
0.8, 95% CI 0.4-1.6, p=0.54 and OR 0.59, 95% CI 0.34-1.04, p=0.07 respectively).  
Analysis of between group mortality rates after exclusion the of 120 patients with cardiac 
arrest lead to no difference in in-hospital [1.9% (Group1) vs 1.2% (Goup2), p= 0.44] or 
1-year [4.4% (Group1) vs 5.6% (Group2), p=0.41] mortality, either overall or out-of-
hours [in hospital 1.5% (Group 1) vs 1.4% (Group 2) p=1.0, and 1 year 3.4% (Group 1) 
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PPCI primary percutaneous coronary intervention 
Figure 4.4 In-hospital mortaliy in patients admitted out-of-hours and during 
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Figure 4.5 One-year mortality in patients admitted out-of-hours and during 















4.4.4.3 Symptom-to-door time 
The proportion of patients presenting OOH with a STDT longer than 2 hours prior to the 
protocol introduction was 51% (134/262) and after the protocol was 46% (227/489), 
p=0.22. When we analysed overall mortality over the five-year study period according to 
STDT (less than 2 hours versus longer than 2 hours) we found no difference in in-hospital 
or 1-year death rates (3.8% [15/390] vs 5.0% [18/361] p=0.48 and 7.7% [30/390] vs 8.9% 
[32/360] p=0.60 respectively). 
 
4.4.5 Discussion 
This study shows a significant improvement in DTBT following the introduction of the 
new alert protocol for patients admitted to hospital OOH – with a significantly higher 
proportion of patients achieving the internationally recognised target of less than 90 
minutes. Despite the reduced DTBT, mortality remained unaltered – whereby (although 
not the primary purpose of this paper) the mortality rates of patients treated OOH 
compared with routine hours are similar in group 1 despite a difference in DTBT of 22 
minutes.  
 
Strategies known to reduce DTBT include: having emergency department physicians 
activate the catheterisation laboratory, having a single call to a central page operator 
activate the laboratory, activating the laboratory whilst the patient is en route to the 
hospital, expecting staff to arrive in the catheterisation laboratory within 20 minutes after 
being paged, having a cardiologist on site and having staff in the emergency department 




introduced incorporated three of these strategies so it is not surprising that DTBTs 
improved significantly.  
 
Studies to date evaluating the association of both short and long-term mortality with 
DTBT have been conflicting353-356. Previous work from our department has suggested that 
only the highest risk patients benefit from the shortest DTBT possible357. As this 
population accounts for the minority of PPCI cases the benefit in this group may be lost 
in the overall mortality rates. There is also the possibility that once a lower threshold has 
been reached (for example 2 hours) then no further overall mortality benefit is seen until 
the next lowest threshold (for example 30 minutes) is reached, with smaller reductions 
not producing the effect required to see mortality reduction.  
 
Our data are in keeping with recent evidence which suggests that despite an improvement 
of DTBT in many hospitals, short and longer-term mortality remain unaltered358. In one 
study the median DTBT decreased from 83 minutes in 2005/6 to 67 minutes in 2008/9, 
with 83% of patients achieving a DTBT of less than 90 minutes in 2008/9 compared with 
59% in 2005/6 and no corresponding improvement in mortality358. Parikh et al359 also 
found that implementing similar strategies as part of a ‘Code STEMI’ brought about 
significant reductions in DTBT but had little impact on in-hospital mortality. The main 
limitation of that study was the sample size. The present study supports those findings in 
a larger cohort and adds longer term mortality data. Brodie et al354 found that total time 
to reperfusion had little effect on one and six-month mortality in those undergoing PPCI. 
Interestingly we also found no difference in overall early or late mortality rates between 




correcting for baseline variables and DTBT (data not shown). Strategies focusing on 
reducing this component of total ischaemic time, specifically symptom-to-call time, have 
had limited success in the past346, 360 which might account for why 50% of patients still 
take longer than 2 hours to arrive at hospital after the onset of myocardial ischaemia with 
some taking considerably longer. In contrast, Rathore et al believe that DTBT should be 
as short as possible, advocating the implementation of targets below the current 90-
minute threshold to achieve an in-hospital mortality reduction of 0.8% below 60 minutes 
and 1.3% below 30minutes. This is important for myocardial salvage and infarct size but 
many observational studies, including the present study, do not support this strategy, 




These data are from a single, medium volume centre so results may not be generalisable 
to other centres however they raise important questions regarding the appropriateness of 
further strategies to reduce door to balloon time with its associated cost. Presently, there 
is no robust method in place to record data for patients that activate the primary PCI 
pathway but do not require intervention so we were unable to ascertain the proportion of 
‘false alarm’ patients in each of the two groups. We excluded 106 patients from the 
analysis. Whilst these patients may have had different clinical characteristics to those 
studied which could affect the outcome, the level of confounding that would be brought 
about by their inclusion justifies their exclusion. The MINAP data focuses on the clinical 
aspects of myocardial infarction management rather than the technical aspects of the 




access site. However, audit data from our department suggests that our use of techniques 
known to improve mortality such as drug eluting stents and radial access has increased 
since the beginning of the study period. This would be expected, if anything, to have a 
positive effect on mortality. Also, we did not have data on infarct size. Finally, as 
symptom time is self-reported by the patient and therefore subject to recall bias, 
ambulance records rather than notes from the emergency department were used to record 
the symptom onset time. 
 
4.4.7 Conclusion 
The change in protocol was independently associated with a reduction in OOH DTBT 
and a significant increase in the number of OOH patients achieving a DTBT of less than 














4.5 SECTION SUMMARY 
 
The proportion of WE and SA patients with symptomatic CAD approximately represents 
that of the wider regional populace. Afro-Caribbean patients are underrepresented 
compared to their proportion of the wider community which is consistent with other 
reports of low CAD rates in this group313. Other demographical features of CAD patients, 
such as the proportion of females and older patients, the younger age of onset of 
symptomatic and more aggressive CAD in SAs and the distribution of traditional risk 
factors across ethnicities, are in keeping with the literature. As far as possible I applied 
this information to my recruitment to ensure evenly matched groups for the 
pathophysiological studies and thus minimise confounding. At our institution, it is 
relatively unusual to find no visible CAD in patients referred for invasive coronary 
angiography. This could reflect a high referral threshold. However, the fact that 
emergency admission rates for CAD and stroke in Birmingham are above the national 
average361 despite having a younger population (almost 50% of Birmingham’s population 

















SECTION V  






















5.1 SECTION OUTLINE 
 
This section contains the results of my experiments. Firstly, I present the cross-sectional 
and longitudinal pathophysiological data consisting of the vascular studies (arterial and 
ventricular elastance indices, aortic augmentation pressure and index and cutaneous 
iontophoresis) followed by biomarkers (monocyte subsets, monocyte-platelet aggregates 
and circulating microparticles), and secondly, the health-related quality of life data.  
5.1.1 Hypotheses to be tested 
The aims and hypotheses are discussed in detail in Section II. Briefly, the hypotheses 
are that; 
• Patients with diffuse CAD will have increased arterial and ventricular elastance 
indices with abnormal ventricular-arterial interaction, increased aortic 
augmentation index and worse endothelial-dependent microvascular function 
than patients with focal CAD or no CAD. 
• Diffuse CAD patients will have higher levels of Mon2 and Mon3, MPAs 
associated with Mon2 and Mon3, and larger numbers of circulating endothelial 
and platelet microparticles compared to patients with focal CAD or no CAD. 
• Subjects with diffuse CAD have poorer quality of life than subjects with focal 
CAD or normal coronary arteries. 
• At one-year follow up patients with diffuse CAD will exhibit a worsening trend 









5.2.1 Clinical Characteristics 
A total of 140 patients (age 57 ± 8.5, 61% male, 64% white-European) were included in 
the cross-sectional study (Table 5.1).  
The groups were matched for age (p=0.28), gender (p=0.56) and conventional risk factors. 
South Asians (24% of the study population) tended to have more diffuse CAD (p=0.07). 
There was no significant difference in smoking rates, although current smoking was 
observed less in focal CAD patients (many of whom were ex-smokers) than in diffuse or 
no CAD patients (p = 0.09). 
Diffuse CAD patients had significantly more previous coronary bypass surgery (p<0.001) 
whereas patients with focal CAD had more previous PCI (p=0.07). Subjects without CAD 
had significantly less secondary preventive medication (aspirin, beta blocker, 
angiotensin-converting enzyme/angiotensin receptor blocker or statin) than either of the 
two study groups (p<0.001 for all). Subjects without CAD had significantly higher blood 
pressure (p<0.01) and pulse rates (p=0.04). There were no significant differences in either 
the use of secondary prevention medication or blood pressure and pulse recordings 








Table 5.1 Demographic and baseline clinical characteristics  
Characteristic Diffuse CAD 
(n = 50) 
Focal CAD 
(n = 40) 
Normal 
(n = 50) 
p value 
Age, mean (SD) 59 (7) 57 (10) 56 (8) 0.28* 

























Hypertension 28 (56) 15 (38) 27 (54) 0.17 
Hypercholesterolaemia 34 (68) 23 (58) 31 (62) 0.59 
Previous MI 29 (58) 17 (43) - 0.14 
Previous PCI 35 (70) 35 (88) - 0.05 
Previous CABG 18 (36) 0 - <0.001 
Previous stroke 2 2 1 0.73 















Premature CAD in family 18 (36) 12 (30) 16 (32) 0.65 
Aspirin 46 (92) 38 (95) 12 (24) <0.001 
Beta blocker 39 (78) 31 (78) 8 (16) <0.001 
ACE/ARB 43 (86) 28 (70) 17 (34) <0.001 
Statin 47 (94) 37 (93) 27 (52) <0.001 
Height cm, mean (SD) 168 (9.7) 169 (10) 169 (10) 0.79* 
Weight kg, mean (SD) 80 (16) 83 (15) 88 (21) 0.08* 




WHR, mean (SD) 0.94 (0.05) 0.92 (0.09) 0.95 (0.09) 0.17* 
BSA m2, mean (SD) 1.89 (0.20) 1.94 (0.21) 1.97 (0.25) 0.17* 
Systolic BP mmHg, mean 
(SD) 
126 (18) 126 (17) 137 (16) 0.001* 
Diastolic BP mmHg, mean 
(SD) 
71 (9.7) 75 (10) 84 (10) <0.001* 
Pulse rate bpm, mean (SD)  64 (11) 67 (12) 70 (13) 0.04* 
Data are expressed as number and percentage unless otherwise stated, *One-way 
analysis of variance, all others Chi-square test, ACE angiotensin converting enzyme, 
ARB angiotensin receptor blocker, BMI body mass index, BSA body surface area, BP 
blood pressure, bpm beats per minute, CABG coronary artery bypass graft, MI 

















5.2.2 Baseline laboratory data 
Total and non-HDL cholesterol were higher in patients with no CAD compared to both 
CAD groups (both p<0.0001), but similar between the two CAD groups (Table 5.2). 
Other measures were similar across the groups. 
 




(n = 50) 
Focal CAD 
(n = 40) 
Normal 




140 (131-149) 140 (127-137) 146 (129-153) 0.26 
WBC, 
109cells/L 
6.7 (5.9-8.1) 7.3 (6.2-8.3) 6.9 (5.5-8.7) 0.66 
Neutrophils, 
109cells/L 
3.9 (3.4-4.9) 4.4 (3.6-5.1) 4.0 (2.9-5.2) 0.75 
Lymphocytes, 
109cells/L 
2.0 (1.5-2.4) 2.1 (1.4-2.6) 1.9 (1.5-2.5) 0.97 
Monocytes, 
109cells/L 
0.5 (0.4-0.6) 0.6 (0.5-0.7) 0.6 (0.4-0.7) 0.37 
Eosinophils, 
109cells/L 
0.16 (0.1-0.29) 0.21 (0.13-0.36) 0.18 (0.1-0.27) 0.17 
Basophils, 
109cells/L 
0.04 (0.03-0.06) 0.05 (0.04-0.07) 0.05 (0.03-0.07) 0.65 
Platelets, 
109cells/L 
233 (183-272) 244 (199-287) 251 (200-301) 0.35 
eGFR, 
ml/min/1.73m2 *  
83 (71-90) 82 (71-90) 81 (71-90) 0.96 
Cholesterol, 
mmol/L  
3.8 (3.4-4.5) 4.0 (3.0-4.7) 4.9 (3.9-5.5) <0.0001 
HDL, mmol/L 1.2 (1.0-1.3) 1.2 (1.0-1.5) 1.3 (1.1-1.5) 0.18 
Non-HDL, 
mmol/L 






1.3 (0.8-1.7) 1.3 (0.9-1.8) 1.4 (1.1-2.1) 0.25 
Data are expressed as median and interquartile range and analysed using Kruskal-Wallis 
Test with Dunn’s post-hoc multiple comparisons test unless otherwise stated, WBC 
white blood cells, eGFR estimated glomerular filtration rate, g/l grams per litre, * values 
above 90 are not individually measured so the true medians are likely to be 
underestimated, HDL high density lipoprotein, mmol/L millimoles per litre. 
 
5.2.3 Arterial and ventricular elastance indices, ventricular-arterial coupling and 
radial applanation tonometry 
5.2.3.1 Cross-sectional analysis 
EaI was lower in diffuse CAD patients compared to the control group (p=0.03), but no 
different to the focal CAD group (p=0.45) (Table 5.3). Central ASP (ESP) was 
significantly lower in both the diffuse and focal CAD groups compared to the normal 
group (p=0.004 and p=0.009 respectively), as was central mean arterial pressure 
(p<0.001) (Table 5.4). Compared with controls and patients with focal CAD, subjects 
with diffuse CAD had higher early mitral inflow and tissue Doppler velocities (p=0.008 
and p=0.01) and higher EDPs and EDVs (p=0.01 and p=0.04). LV-Ees and LV-Eed were 
not significantly different between the groups (p=0.19 and p=0.70 respectively). AIx and 
AP were similar between the groups (p=0.87 and p=0.79 respectively). The median OI 
was >95% for each group with no significant differences.  
5.2.3.2 Longitudinal analysis 
During follow up patients with diffuse CAD showed an increase in LV Eed (p=0.02) 
with no change in Ees (p=0.79), EaI (p=0.11) or VAC (p=0.67) (Table 5.5). Patients 
with focal CAD showed no longitudinal change in elastance (p=1.00 for Ees, p=0.31 for 




throughout follow up in both groups (p=0.59 and p=0.49 for diffuse and focal CAD 
respectively). 
 
Table 5.3 Baseline echocardiographic parameters and measures of elastance 
 Diffuse  
(N = 50) 
Focal  
(N = 40) 
Normal  
(N = 50) 
p value 
LVOTd, cm 1.9 (1.80-2.00) 2.0 (1.83-2.10) 2.0 (1.90-2.10) 0.07 







Mitral E, cm/s 94 (20) 83 (18) 85 (15) 0.008* 
IVRT, ms 90 (70-110) 80 (70-100) 90 (80-100) 0.33 
IVCT, ms 60 (50-70) 55 (40-70) 50 (40-70) 0.66 







EDP, mmHg 15 (13-18) 13 (12-15) 13 (12-16) 0.01 
ESP (ASP), mmHg 115 (104-130) 119 (104-129) 131 (116-140) <0.001 
EDV index, ml/m2 44 (38-50) 39 (33-45) 42 (36-48) 0.04 
ESV index, ml/m2 14 (12-17) 12 (10-17) 14 (12-16) 0.27 
SV index, ml/m2 28 (25-33) 26 (22-31) 28 (23-31) 0.20 
LVEF, (%) 65 (7) 67 (7) 65 (7) 0.38* 
Diastolic TDI, cm/s 11 (9-13) 9 (8-11) 9 (8-11) 0.01 
Ees, mmHg/ml/m2 7.2 (6.5-10.3) 9.2 (6.8-11.5) 9.2 (7.5-10.7) 0.12 
EaI, mmHg/ml/m2 4.2 (3.4-5.0) 4.3 (3.6-5.3) 4.7 (4.1-6.0) 0.05 
VAC 1.9 (1.4-2.5) 2.0 (1.7-2.5) 1.8 (1.5-2.5) 0.64 







Data are expressed as median and interquartile range and analysed using Kruskal-Wallis 
Test unless otherwise stated, *one way analysis of variance, ASP aortic systolic 
pressure, CSA cross-sectional area, EaI arterial elastance index, EDP end-diastolic 
pressure, EDV end-diastolic volume, Eed end-diastolic elastance, Ees left ventricular 




isovolumetric contraction, IVRT isovolumetric relaxation, LVEF left ventricular 
ejection fraction, LVOTd left ventricular outflow tract diameter, LVOT VTI left 
ventricular outflow tract velocity time integral, SV stroke volume, TDI tissue Doppler 
imaging, VAC ventricular-arterial coupling. 
 
 
Table 5.4 Estimation of central blood pressures and aortic augmentation index 
Derived variable Diffuse  
(n = 50) 
Focal  
(n = 40) 
Normal  
(n = 50) 
p value 
Central MAP, mmHg 87 (77-95) 89 (79-100) 100 (92-106) <0.001 
Central PP, mmHg 46 (11) 42 (11) 44 (11) 0.43* 
AIx@75bpm, (%) 23 (8) 24 (10) 25 (10) 0.59 
AP, mmHg 13 (9.3-19) 14 (8-19) 13 (8.3-19) 0.79 
OI 97 (92-98) 96 (87-99) 96 (90-98) 0.79 
Data are expressed as median and interquartile range and analysed using Kruskal-Wallis 
Test unless otherwise stated, *one-way analysis of variance, AIx@75bpm aortic 
augmentation index adjusted for heart rate, AP augmentation pressure, ASP aortic 
systolic pressure, MAP mean arterial pressure, mmHg millimetres of mercury, OI 












Table 5.5 Longitudinal analysis of arterial and ventricular elastance and aortic 
augmentation index 

























































AIx@75bpm aortic augmentation index adjusted for heart rate, CAD coronary artery 
disease, EaI arterial elastance index, Eed end diastolic elastance, Ees End systolic 
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5.2.4 Cutaneous microvascular function 
5.2.4.1 Cross-sectional analysis 
There was a strong trend towards worse microvascular response to ACh (endothelial 
dependent function) in patients with diffuse CAD than in subjects with focal CAD or 
normal coronaries (p=0.06). There was no difference between the groups in endothelial-
independent function (p=0.74) (Table 5.6 and Figure 5.2). 
5.2.4.2 Longitudinal analysis 
Endothelial-dependent microvascular function improved throughout follow up in 
patients with diffuse CAD (p=0.036). Endothelial independent function was unchanged 
throughout the follow up period in both groups (Table 5.7). 
 
Table 5.6 Cross-sectional analysis of microvascular endothelial function 
Flow Diffuse CAD Focal CAD No CAD p value 


































Data expressed as median and interquartile range and analysed with Kruskal-Wallis test, 
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Table 5.7 Longitudinal analysis of microvascular endothelial function 
CAD 
morphology 
Baseline 6 months 12 months p value 
























Data expressed as median and interquartile range and analysed with Kruskal-Wallis test, 















5.2.5 Monocyte subsets and monocyte-platelet aggregates 
5.2.5.1 Cross-sectional analysis 
There were no between group differences in monocyte subsets (p=0.65 for Mon1, p=0.14 
for Mon2, p=0.83 for Mon3, p=0.62 for total monocytes) (Table 5.8).  
MPAs associated with Mon2 were significantly higher in the diffuse CAD group 
compared to the focal CAD or control groups (p=0.003 and p=0.004, respectively) (Table 
5.8 and Figure 5.3).  
The proportion of Mon2 aggregated to platelets was significantly higher in the diffuse 
group compared to the focal group (p=0.007). MPAs associated with Mon1, Mon3 and 
total MPAs were similar between the groups (p=0.48, p=0.71, p=0.21, respectively).  
5.2.5.2 Longitudinal analysis 
There was a significant reduction in total MPA counts in patients with diffuse (p<0.001) 
and focal CAD (p=0.006) over 12 months follow up (Table 3). MPAs with Mon1 declined 
significantly in both groups (p<0.048 for diffuse CAD and p=0.02 for focal CAD); MPAs 
with Mon2 declined only in patients with diffuse CAD (p<0.001). Total monocytes and 










Table 5.8 Cross-sectional analysis of monocyte subsets and monocyte-platelet 
aggregates 
Counts, per µl Diffuse CAD 
(n = 50) 
Focal CAD 
(n = 40) 
No CAD 
(n = 50) 
p 
value 
Total monocytes* 480 (138) 511 (157) 487 (161) 0.62 
Mon1* 397 (124) 427 (143) 413 (143) 0.59 
Mon2 34 (24-55) 32 (14-54) 24 (17-40) 0.09 
Mon3 39 (25-49) 44 (26-59) 37 (25-58) 0.93 
Total MPA 53 (41-65) 52 (35-68) 42 (28-74) 0.21 
MPA with Mon1 34 (29-48) 36 (26-54) 32 (18-55) 0.48 
MPA with Mon2 10 (4-14) 5 (2-8) 5 (2-7) <0.001 
MPA with Mon3 5 (4-9) 6 (4-9) 5 (3-8) 0.71 
Data are expressed as median and interquartile range unless otherwise stated, * mean and  
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Figure 5.3 Monocyte-platelet aggregates associated with Mon2 











































































































Data are expressed as median and interquartile range unless otherwise stated, * mean and 










5.2.6 Platelet and endothelial microparticles 
5.2.6.1 Cross-sectional analysis 
Baseline counts of EMPs were significantly higher in patients with diffuse CAD than in 
patients with focal CAD (p=0.004) or normal coronaries (p=0.016) (Figure 5.4). There 
were no differences in PMP counts (p=0.62) (Table 5.10). 
5.2.6.2 Longitudinal analysis  
EMPs showed a significant decline over 12 months in subjects with diffuse CAD 
(p<0.001) and in subjects with focal CAD (p=0.007). PMP levels increased at 6 months 
and declined below baseline at 12 months in diffuse CAD patients (p=0.007) and were 
unchanged in subjects with focal CAD (p=0.18) (Table 5.11). 
 
Table 5.10 Cross sectional analysis of endothelial and platelet microparticles 
Microparticle type Diffuse CAD Focal CAD No CAD p value 
EMP (1,000,000/µl) 10 (7.9-11) 7.4 (4.8-9.4) 8.4 (5.4-9.8) 0.002 
PMP (10,000/µl) 9.1 (1.9-250) 14 (2.0-210) 4.9 (1.4-137) 0.62 
Data are expressed as median and interquartile range, CAD coronary artery disease; 
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Figure 5.4 Endothelial microparticles by study group. 
 
Table 5.11 Longitudinal analysis of endothelial and platelet microparticles 
Counts CAD 
morphology 


























Data are expressed as median and interquartile range, CAD, coronary artery disease; 





5.2.7 Correlation and regression analyses of pathophysiological data 
There was a significant negative correlation between counts of MPAs with Mon2 and 
endothelium-dependent microvascular function in patients with diffuse CAD (r= -0.37, 
p=0.008) – a correlation not present in patients with focal CAD or normal coronary 
arteries. Longitudinal analysis showed a persistent inverse relationship between the two 
variables in patients with diffuse CAD (r= -0.32, p=0.03) (Figure 5.5). There was no 
correlation between EMPs and microvascular endothelial function in diffuse CAD 
patients.  
Whilst MPAs associated with Mon1 also declined significantly during follow up in 
diffuse CAD patients, they did not correlate with microvascular function (r= -0.08, 
p=0.61).  
In focal CAD patients, there were also significant declines in total MPA and Mon1 related 
MPAs during follow up, but these did not correlate with microvascular function (both 
r=0.13, p=0.44). 
On multivariable logistic regression levels of MPAs with Mon2 and EMPs were 
independent predictors of diffuse CAD after adjustment for age, gender, ethnicity, body 
mass index, previous myocardial infarction and use of beta blocker, ACE/ARB, statin, 
aspirin or clopidogrel (odds ratio [OR] 1.11, 95% confidence interval [CI] 1.02-1.19, 
p=0.012 for MPAs with Mon2 and OR 1.46, 95% CI 1.09-1.96, p=0.01 for EMPs) (Tables 
5.12 and 5.13). The predictive capability persisted after further adjustment for previous 
revascularisation (PCI and/or CABG) (OR 1.11, CI 1.02-1.20, p=0.014 for MPAs with 




The difference in EaI between the study groups was not present after correction for blood 
pressure (OR 1.28, 95% CI 0.86-1.91, p=0.22). 
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Figure 5.5 Longitudinal decline in monocyte-platelet aggregates associated with 
Mon2 parallels improvement in microvascular endothelial function in patients 
with diffuse coronary artery disease. r= -0.32, correlation coefficient of the change 













Table 5.12 Multivariable logistic regression of predictors of diffuse coronary 
artery disease – Mon2 related monocyte-platelet aggregates 
Variable Odds ratio 
(95% confidence interval) 
p value 
Age 1.05 (0.99-1.11) 0.12 
Gender 0.66 (0.24-1.80) 0.41 
White ethnicity 0.40 (0.15-1.11) 0.08 
Mon2 monocyte-platelet aggregates 1.10 (1.02-1.19) 0.01 
Body mass index 0.96 (0.86-1.07) 0.45 
Previous myocardial infarction 3.17 (1.14-8.83) 0.03 
Beta blocker 1.90 (0.63-5.78) 0.26 
ACE inhibitor ARB 2.34 (0.78-7.05) 0.13 
Statin  2.67 (0.55-13.1) 0.23 
Aspirin 4.87 (1.11-21.4) 0.04 
Clopidogrel 1.51 (0.56-4.09) 0.42 















Table 5.13. Multivariable logistic regression of predictors of diffuse coronary 
artery disease – endothelial microparticles 
Variable Odds ratio 
(95% confidence interval) 
p value 
Age 1.04 (0.99-1.11) 0.15 
Gender 0.68 (0.25-1.80) 0.43 
White ethnicity 0.60 (0.21-1.66) 0.32 
Endothelial microparticles 1.46 (1.09-1.96) 0.01 
Platelet microparticles 1.22 (0.81-1.83) 0.35 
Body mass index 0.98 (0.89-1.09) 0.72 
Previous myocardial infarction 4.19 (1.47-12.0) 0.007 
Beta blocker 1.63 (0.55-4.86) 0.38 
ACE inhibitor ARB 2.19 (0.72-6.71) 0.17 
Statin  3.54 (0.65-19.2) 0.14 
Aspirin 5.31 (1.22-23.1) 0.03 
Clopidogrel 2.25 (0.83-6.07) 0.11 













5.2.8 Health related quality of life 
All patients completed the both parts of the EQ-5D-5L questionnaire at each visit (Figures 
5.6-5.10). Mobility, self-care, usual activities and anxiety/depression were similar 
between the study groups (p=0.32, p=85, p=0.81 and p=0.32, respectively) and there was 
no difference in visual analogue score at baseline (Figure 5.11) (p=0.97). Differences 
were present in the level of pain and discomfort reported between patients with focal 
CAD and subjects with normal coronaries. Participants with normal coronaries more 
often reported severe pain, while focal CAD patients reported more moderate and extreme 
pain (p=0.02) (Figure 5.9). There were no significant changes in quality of life measures 
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Figure 5.6 EQ-5D-5L: mobility. Shows the proportion of patients in each group 
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Figure 5.7 EQ-5D-5L: self-care. Shows the proportion of patients in each group 
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Figure 5.8 EQ-5D-5L: usual activities. Shows the proportion of patients in each 
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Figure 5.9 EQ-5D-5L: pain/discomfort. Shows the proportion of patients in each 
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Figure 5.10 EQ-5D-5L: anxiety/depression. Shows the proportion of patients in 
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Figure 5.11 EQ-5D-5L: visual analogue score – subjects were asked to rate their 
overall health on a scale marked 0-100. The graph above shows median response 
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Figure 5.12 Changes in quality of life measures in the diffuse and focal CAD 




The bar graphs show the changes in the proportion of patients reporting each level of the 
5 quality of life measures (mobility, self-care, usual activities, pain and /or discomfort 
and anxiety and /or depression). Diffuse CAD patients are on the left and focal CAD 
patients are on the right. The visual analogue scale is shown as a line graph of each group 





















5.3.1 Ventricular and arterial elastance, ventricular-arterial coupling and aortic 
augmentation index 
The cross-sectional analysis showed no difference between the study groups in measures 
of EaI, LV Ees or VAC. Over twelve months there was a significant increase in LV Eed 
from baseline in patients with diffuse CAD compared to patients with focal CAD despite 
increased ACE inhibitor use in the former.  
Although we found no difference in any of the stated measures of arterial or ventricular 
stiffness between the groups at baseline, we did note that patients with diffuse CAD had 
higher EDP, EDV, early mitral inflow and tissue Doppler velocities than patients with 
focal CAD, or normal coronary arteries. These measures indicate that diastolic stiffness 
is increased in patients with diffuse CAD despite similar LV Eed, (due to concomitant 
increases in EDP and EDV). Furthermore, longitudinal analysis showed an increase in 
LV Eed from baseline in patients with diffuse CAD, despite increased ACE inhibitor use 
in that group. Thus, these data support a temporal relationship between CAD severity and 
diastolic ventricular stiffness.  
Only a few studies have examined measures of elastance and VAC in CAD362, 363 for 
example Kadoi et al362 evaluated Ees and VAC in 16 patients with, and four patients 
without CAD in anaesthetised patients undergoing CABG using transoesophageal 
echocardiography. The 16 CAD patients were stratified by LVEF. The study found that 
Ees, EaI and VAC in patients with CAD and normal ventricular function was similar to 
patients without CAD (undergoing elective abdominal surgery). Only patients with 




found LV Ees, VAC and EaI to be similar in patients with CAD compared to subjects 
without CAD362-364. 
Elastance measures have been more widely studied in the setting of heart failure and 
hypertension since its component variables (pressure and volume) are more readily 
affected by these conditions then they are by CAD. Indeed, long term use of secondary 
prevention drugs in the CAD groups may account for why, if anything, EaI was lower in 
those groups.  
I observed a longitudinal increase in Eed in diffuse CAD patients. While this could be 
due to chance, diastole is more sensitive to ischaemia than systole and studies have shown 
that diastolic function is impaired more readily than systolic function in the context of 
ischaemia, meaning that the local changes in coronary blood flow that occur with more 
extensive CAD preferentially affect diastolic mechanisms365, 366. Indeed, several 
biomarkers associated with coronary endothelial dysfunction correlate with diastolic 
dysfunction in patients with CAD367 and a recent study has shown that coronary pulse-
wave velocity is high relative to aortic pulse-wave velocity in people with stable CAD, 
implying that differential anatomical increases in stiffness parameters are important, and 
supporting the fact that changes in ventricular stiffness measures may occur in the absence 
of aortic stiffness measures368. Oberoi et al171 examined the relationship between CAD 
burden and aortic distensibility in a retrospective, longitudinal study using CTCA and 
found that CAD progression at 12 months follow up CTCA correlated with decline in 
aortic distensibility. Although limited by its retrospective design, it is one of the only 
studies (aside from the present one) to assess the relationship between CAD and arterial-
ventricular stiffness longitudinally. The present study is also strengthened by the fact that 




factors. I saw a trend towards increased EaI and a significant increase in Eed during 
follow up in diffuse CAD patients that was not present in focal CAD patients. AIx 
remained static in both groups. Increased EaI (decreased compliance) promotes early 
wave reflection leading to increased systolic and pulse pressure and reduced diastolic 
pressure and coronary perfusion. While I did not see evidence of this within the year, 
these findings raise the possibility that a longer follow up period might reveal a temporal 
relationship between CAD severity and EaI, as well as with diastolic stiffening, especially 
since no change in Eed was seen in patients with focal CAD. Whether LV Eed can predict 
those patients with severe CAD at risk of developing ischaemia-associated 
cardiomyopathy would need to be evaluated in larger prospective studies. 
I found no difference in AIx between the groups at baseline or longitudinally, suggesting 
it is not associated with the severity or progression of CAD. There have been 
inconsistencies in the literature regarding the usefulness of AIx as a marker of CAD369-
371. These results are in keeping with several previous studies. Hope et al found no 
association between central AIx and the extent or severity of CAD assessed using the 
modified Gensini's and Sullivan's extent scores372. Patvardhan et al found no association 
with AIx and the presence of CAD373. Differences in the populations studied could be a 
factor in the variance, as could differences in the degree of CAD assessed for example 
Mcleod et al excluded cases with flow limiting lesions371. The impact of arterial wave 
reflection may just be related to age and other comorbidities, explaining why those with 
normal coronaries (but similar risk factor prevalence) have similar reflected wave 






5.3.2. Cutaneous microvascular function 
Patients with diffuse CAD had a strong trend towards worse microvascular endothelial 
function than patients with focal CAD or normal coronaries. Impaired cutaneous 
microvascular endothelial function has been shown to correlate with CAD risk factors 
such as diabetes374, obesity375, hypertension376 and dyslipidaemia377 as well as CAD itself, 
and has been used as a surrogate for coronary microvascular function in previous 
studies378-381.  
The attenuated overall group difference could be due to the presence of traditional CAD 
risk factors in my normal coronary artery control group. Indeed, my normal group was 
relatively hypertensive compared to the study groups. While studies using completely 
healthy individuals as controls have the capability to demonstrate larger differences382 the 
impact of other risk factors combined with CAD can confound interpretation. My study 
has the advantage that coronary anatomy was known for each group and demonstrates a 
clear trend that supports the presence of worse microvascular endothelial dysfunction in 
patients with diffuse CAD compared to patients with focal CAD or patent coronary 
vessels382-386.  
Impaired coronary vasoregulation may involve several pathways. In the present study 
sodium nitroprusside was used to assess endothelium-independent vasodilation in the 
microvasculature and showed that maximal perfusion achieved was similar across all 
three study groups. Firstly, this proves that the drug delivery method was efficacious and 
secondly, suggests that CAD severity/diffuseness is linked predominantly to 




The longitudinal analysis showed a significant improvement in endothelium-dependent 
microvascular function in patients with diffuse CAD that was not present in subjects with 
focal CAD which was associated with a decline in MPAs associated with Mon2. 
5.3.3 Monocyte subsets and monocyte-platelet aggregates 
Perhaps the most notable finding of my study is that levels of MPA associated with Mon2 
were twice as high in patients with diffuse CAD as compared to the other groups. They 
were also found to be independently predictive of the presence of diffuse CAD. This is 
the first study that assesses the impact of MPAs related to specific monocyte subsets in 
patients with diffuse CAD. 
In previous studies MPA levels were increased in humans with stable CAD214, 223 as well 
as those with acute MI389 and those undergoing PCI390. In a small study, Mickelson et al 
noted that in patients undergoing elective single vessel PCI, higher MPA levels were 
associated with subsequent target vessel restenosis and progression of CAD requiring 
surgical revascularisation225. My study supports a role for Mon2 related MPAs in the 
development of accelerated CAD. Indeed, chemokine-chemokine receptor (CCR) 5 
(RANTES - regulated on activation normal T-cell expressed and secreted), a potent 
chemoattractant factor for monocytes and T cells, is highly expressed on CD16+ 
monocytes, especially Mon2391. CCR5 has a prominent role in human atherosclerotic 
lesion progression. 
This study also showed that MPAs with Mon2 were inversely related to microvascular 
endothelial function (Figure 5.5). Di Serafino et al222 prospectively assessed the 
contribution of coronary endothelial dysfunction and functionally significant obstructive 




authors reported higher MPA levels in subjects with coronary endothelium dysfunction 
as well as an inverse correlation between the two. 
Platelet activation has a key role in monocyte activation and recruitment to activated 
endothelium. MPAs are not only recruited to Von Willebrand Factor expressed on 
activated endothelial cells, but also induce the expression of additional platelet-borne 
receptors on the monocyte surface which can support the adhesion of unaggregated 
monocytes392. Thus, interaction between monocytes and platelets is an important link 
between vascular inflammation and thrombosis and may be more relevant than 
monocytes alone for the development of more aggressive CAD, with the present study 
providing further delineation and implicating MPAs associated with Mon2. These 
observations may reflect the fact that CCR5 (RANTES) and CCR2, potent 
chemoattractant factors for monocytes and T cells, are highly expressed on Mon2 – 
approximately 8-fold higher than on Mon3391. Both chemokine receptors have prominent 
roles in human atherosclerotic progression. In fact, several surface markers relevant to 
atherosclerosis are preferentially expressed on Mon2 monocytes in healthy donors and, 
therefore, may be upregulated in CAD. For example, CD11b regulates leucocyte adhesion 
to activated endothelium, VEGFR (vascular endothelial growth factor receptor) 1 and Tie, 
which have major roles in angiogenesis – important for the progression of inflammation 
and the development of collateral circulation in advanced CAD,194 or TLR (toll-like 
receptor) 4. TLR4 signalling promotes CAD progression in a variety of ways, not least 
by mediating monocyte infiltration and subsequent macrophage FOAM cell formation 
within activated endothelium. It also mediates the release of several inflammatory 
cytokines (such as IL6, MCP1, and TNFɑ) from activated monocytes via receptors that 




(CD14dim) monocytes did not express CCR2 at all, and, in comparison to Mon2, produced 
no reactive oxygen species and expressed little mRNA for myeloperoxidase and 
lysozyme in response to TLR4, indicating that Mon2 produce most of the 
proinflammatory cytokines in that setting. Mon3 monocytes were found to possess an 
anti-inflammatory profile in the context of TLR4394. Thus, the findings from the present 
study likely reflect the imbalance of the immune system in favour of proinflammation – 
and increased monocyte-platelet cross talk in the Mon2 monocyte subpopulation – in 
people with advanced CAD, that is not present in people with focal CAD.  
The excess of Mon2 related MPAs could also be a marker of plaque vulnerability, as well 
as the extent of stable plaque disease, as alluded to in some studies limited by the lack of 
individual subset analysis389, 395. Many previous studies have reported Mon2 and Mon3 
together (as CD16+ monocytes). Nonetheless CD16+ monocytes have been associated 
with severity of CAD203, late lumen loss due to in-stent restenosis of bare metal stents206 
and cardiac events396. Contemporary data suggest that Mon2 is likely to have been driving 
these associations and the present study emphasises the importance of platelet interaction 
with the Mon2 subset in the context of diffuse CAD.  
There is a paucity of longitudinal data evaluating monocyte or MPAs in patients with 
diffuse coronary artery disease. In my study, patients with diffuse CAD showed a 
significant decline in Mon2 related MPAs during follow up. Importantly, this decline was 
paralleled by a significant improvement in endothelial-dependent microvascular function 
in that group. This was not observed in subjects with focal CAD. These findings imply 
that microvascular dysfunction could be an important part of the mechanism linking a 





As this was a non-interventional study however, the longitudinal changes observed in 
both measures could be due to many reasons e.g. variations in platelet and/or monocyte 
regulation223, 397 or increased ACE inhibitor use in diffuse CAD patients398. Down 
regulation of MPA formation following monocyte recruitment into atherosclerotic lesions 
could theoretically allow for concomitant lesion progression and Mon2 related MPA 
decline. In addition to its chemoattractant effect,399 animal studies have shown RANTES 
to be particularly prominent during the chronic phase of inflammation, resulting in 
increased CCR 1 and CCR5 expression, as well as increased numbers of monocytes and 
macrophages within areas of inflammation400. Furthermore, CCR5 receptor blockade 
results in experimental atherosclerotic lesion reduction, reduction in the recruitment of 
monocytes, mast cells, and neutrophils and, in some cases, near-complete resolution of 
inflammation400-403. Activated platelets promote CCL5-mediated monocyte arrest on 
injured endothelium, thus enhancing monocyte recruitment into developing 
atherosclerotic lesions. Increased CCR5+ cell recruitment into atherosclerotic lesions 
may explain the reduced levels of Mon2 related MPAs over time in patients with diffuse 
CAD, a phenomenon noted in previous cross-sectional studies214 but expanded upon here 
with longitudinal data.  
 
Nevertheless, whilst it is beyond the scope of this study to pinpoint the precise reason 
behind the longitudinal changes, the presence of a negative correlation between 
microvascular endothelial function and Mon2 related MPAs could be an important 
finding in patients with diffuse CAD and requires further study. A recent investigation by 
Taqueti et al247 found that reduced coronary flow reserve (CFR) – an index of 




independently of luminal stenosis and extent of CAD. There was also an association 
between CAD extent and microvascular function. One might hypothesise therefore, that 
Mon2 related MPAs could underlie the association between reduced CFR and poor 
clinical outcomes – a notion implied by De Serafino’s work222 – and supported by a 
population study in patients undergoing elective coronary angiography208. 
 
5.3.4 Platelet and endothelial microparticles  
My study also shows for the first time that CD31+/CD42b- EMPs are significantly higher 
in patients with severe, diffuse CAD compared to subjects with focal CAD or normal 
coronary arteries.  
 
CD31 (platelet endothelial cell adhesion molecule [PECAM]-1) is a constitutive antigen 
expressed in high levels on mature endothelial cells. Its expression on EMPs is thought 
to reflect those EMPs derived mainly through endothelial cell apoptosis404. Persistent 
inflammatory stimulation of vascular endothelium leads to apoptosis and promotes 
progression of atherosclerosis so it is likely that endothelial cell apoptosis is a key 
pathophysiological mechanism differentiating focal CAD from more aggressive forms of 
the disease where reparative capability is reduced405. Indeed, we found no difference in 
EMP levels between subjects with focal CAD versus subjects with normal coronary 
arteries implying that distinct pathways – favouring endothelial cell death – may be 
involved in the development of diffuse coronary disease in middle age.  
 
Reports regarding the impact of severity of stable CAD on MPs are mainly limited to 




coronary syndrome235, 236, many of which include either control subjects with 
undocumented coronary anatomy, or no control group235-237. This study demonstrates an 
association between apoptotic EMPs and severity of stable CAD in subjects with 
multiple, equivalent risk factors231, 406. It shows a pattern of changes consistent with some 
related studies in the field. Koga et al showed that CD144 EMPs independently predict 
the presence of CAD in patients with diabetes mellitus without symptomatic episodes of 
angina231. CD144 – an inducible antigen – is specific for EMPs derived from endothelial 
activation407. In a prospective study of 200 patients with stable CAD, Sinning et al found 
that circulating CD31+/annexin V+ MP levels above the median were associated with a 
higher risk of death from cardiovascular causes and need for revascularisation during 6-
year follow up242. This would support CD31 EMPs as a marker of more aggressive CAD 
phenotypes. Interestingly, Sinning’s group reported only a non-significant trend (p=0.08) 
in the association between EMPs and CAD extent. This most likely reflects the 
contribution of coronary endothelial dysfunction to subsequent plaque rupture events in 
people with single vessel CAD, since multivessel CAD is known to carry a worse 
prognosis than single vessel CAD237, 408.  
                                                                                                                          
In vitro experiments demonstrate that CD31 antigen is also expressed on ∼5% of 
activated and 10% of non-activated platelets409, however, we saw no difference in PMP 
(CD42b+) levels between the groups, implying that the MPs were predominantly 
endothelial in origin.  
 
Incorporating data from numerous in vitro experiments, MPs are now considered 




processes though their role in healthy individuals is less well understood. Thus, more than 
simply being a marker of severe endothelial dysfunction and possibly advanced CAD, 
EMPs also act as intercellular messengers, promoting the synthesis and release of 
proinflammatory cytokines, stimulating the expression of adhesion molecules 
(particularly ICAM-1) and augmenting the expression of adhesion molecule counter-
receptors – such as CD11b – on Mon2 monocytes, potentially enhancing monocyte-
platelet aggregation194, 228. Rautou et al confirmed some of these in vitro findings when 
they observed that exposure to (mainly leucocyte) MPs isolated from advanced 
atherosclerotic plaques in humans rapidly increased intercellular adhesion molecule-1 at 
the endothelial cell surface, suggesting that the proinflammatory effects of MPs occur 
throughout the atherosclerotic process410. Indeed, in some cases, MPs may be even more 
potent than their parent cells which could explain the relative abundance of EMPs in 
patients with accelerated CAD found in the present study 234. 
 
Potential benefits of EMP formation on endothelial integrity include increased endothelial 
progenitor cell release411, control of cell death mechanisms and induction of adaptive 
immunity412. Hence, EMPs may reflect the severity of the endothelial injury, but also the 
need for reparative angiogenesis due to atherosclerotic lesions of coronary arteries413. 
These favourable regulatory functions have mostly been studied in vitro so their relevance 
in vivo remains undetermined.  
 
Throughout follow up, I observed a decline in EMPs in both CAD groups (although the 
effect was stronger in patients with diffuse CAD). As mentioned in section 5.3.4, this 




cutaneous microvascular function in the diffuse CAD group is unclear. Previous studies 
have correlated apoptotic EMPs with coronary endothelial function although in their 
analysis, Werner et al exclude subjects with severe CAD (those with surgical disease) and 
normal coronaries237. One reason for the lack of correlation in the present study could be 
the range of MP data acquired, such that despite clear differences in median values there 
was considerable overlap of interquartile ranges. This remains an important limitation in 
the enumeration of MPs and restricts their use in clinical practice. 
 
5.3.5 Health related quality of life  
There was no difference in HrQOL between the groups. There are several possible 
reasons for this. HrQOL is closely related to symptoms and many studies have shown an 
improvement in HrQOL following coronary revascularisation (during which symptoms 
are often resolved) particularly where pre-operative/procedural health status was poor414-
418. Patients with normal coronaries on the other hand may have persistent unexplained 
symptoms which can adversely affect QOL by a number of mechanisms such reduced 
physical activity419 or higher levels of anxiety. Even in the absence of symptoms, the 
groups were age, gender and risk factor matched which meant that subjects with normal 
coronaries had other conditions that could contribute to worse QOL such as diabetes420 
or hypertension421. Several patients in my diffuse CAD group had had previous CABG. 
Randomised data comparing HrQOL after CABG versus PCI has been inconsistent with 
some showing more improvement after CABG422 and others no difference423, 424.  
Longitudinal analysis revealed no significant change in either CAD group. VAS scores 
also remained similar in both groups which could represent small group numbers or be 




consistent with comparable studies some of which have shown change as early as three 
months425, 426 albeit in response to the treatment of CAD, whereas the objective here was 
simply to provide an evaluation of general HrQOL between the groups.  
Male sex and white ethnicity showed a trend towards higher VAS scores whereas Afro 
Caribbean ethnicity, diabetes and physical inactivity showed a trend toward lower VAS 
scores. Despite not meeting statistical significance, these are valid signals as similar 
observations have been made consistently throughout the literature427-430. Many studies 
have also described increasing age as a negative predictor of VAS scores which was not 


















Despite the careful design of this study, there are several limitations to consider. 
5.4.1 Limitations of study design 
This is single centre, observational data and is therefore susceptible to inherent bias. There 
is a selection bias since all patients were, at some point, symptomatic. However, the 
experimental data are prospective. Also, to strengthen the results by reducing unconscious 
bias, data analysis would have ideally been performed by an investigator who was 
unaware of the study participants’ group allocation.  
The degree of luminal stenosis in CAD patients was assessed visually which could have 
resulted in misclassification of some cases. I made every effort to minimise this potential 
by selecting patients in whom the severity and morphology of disease was obvious. 
It is routine practice at our centre to provide PCI at the time of coronary angiography to 
stable patients who require it. Therefore, due to ethical considerations, patients were most 
often studied post angioplasty. Although no patients were studied within two months of 
stenting, I cannot rule out the possibility of long-term modification of peripheral MPA 
levels by intracoronary stents.  
AIx was not obtained at the time of cardiac catheterisation. Rather, they were determined 
weeks, months or sometimes years later. However, to make sure that the measures taken 
represented the intended disease morphology, patients with normal coronaries or focal 
CAD were studied a maximum of one year post coronary angiography on the basis that 




diffuse CAD are already at an advanced stage of the continuum of CAD and cannot go 
‘backwards’. 
One-year follow up may be considered short for detecting changes in vascular function 
(especially those measured using ultrasound) although previous similar studies have 
shown differences in measures of aortic distension over one year171. Most studies 
assessing longitudinal monocyte and microparticle dynamics have been following an 
intervention (pharmacological or otherwise)390, 431, 432, exercise433 or acute illness216, 434, 
435. However, this study was designed to investigate the natural history of these 
biomarkers and their behaviour in patients with stable CAD and was the most pragmatic 
timeframe in which to complete the study. Furthermore, CAD is a continuous process. As 
such, both the cross sectional and longitudinal measures in this study represent a snapshot 
in the natural cardiovascular history of the subjects involved and it is impossible to 
accurately determine the pattern of measures outside of the study timeframe. However, 
due to legitimate time constraints, only one-year follow up data could realistically be 
achieved. 
5.4.2 Methodological limitations 
The non-invasive measurement of Ees index from ESP/ESV index ratio assumes that the 
theoretical volume when no pressure is generated (Vo – which has not been well defined 
in humans) is negligible compared with end-systolic volume. Several single beat methods 
have been proposed to estimate the end systolic pressure volume relationship (ESPRV)290, 
436, 437, with the method employed by Bombardini et al364 being perhaps the most easily 
applicable. The linearity of ESPVR simplifies its prediction using this approach however 




relationship (EDPVR), where the curve is less linear. However, the same approach was 
used for all patients and previous studies have shown that the LV EDPVR can be 
reasonably estimated from a single pressure-volume point, and the predicted relationships 
are generally well correlated with directly measured data438. Also, the use of radial 
applanation tonometry in my study allowed more accurate central systolic blood pressure 
estimation than previous studies applying a correction factor to the brachial systolic 
pressure290, 364.  
The methodology used to detect and exclude CAD should be considered. Invasive 
coronary angiography provides information about luminal pathology only. Subjects with 
eccentric vascular remodelling may have CAD but demonstrate apparently normal 
coronaries. CTCA is a sensitive tool for the detection of vascular wall calcification and 
abnormal remodelling in CAD439. To identify subjects with no CAD at all (i.e. no extra-
luminal CAD), I tried to use CTCA as much as possible. Unfortunately, due problems 
with missed or cancelled appointments and the high proportion of females referred for 
CTCA, I still had to recruit subjects from the invasive lists but since focus of my study 
was flow limiting CAD, I would not consider this a major limitation. 
I quantified microvascular function in the peripheral circulation which is an indirect 
assessment of central processes, although studies have validated this approach440 and 
moreover, invasive measurement such as coronary flow reserve has its own limitations441. 
Iontophoresis of acetylcholine (laser Doppler) has been shown to have good 
reproducibility when performed in a controlled environment308.  
Laser Doppler flowmetry (used to assess microvascular function) is sensitive to various 




achieve highly standardised conditions, for example each person was studied in the same, 
temperature-controlled room (specified according to manufacturer guidelines). Follow up 
measures were performed at the same time of day (where possible) by the same operator 
(myself), using the same technique each time. Despite this approach, heterogeneity in the 
microvascular responses can be brought about by uncontrollable factors such as variation 
in capillary density or the number of hair follicles between patients442. 
Nonspecific, current induced vasodilatation (the so called galvanic response caused by 
the process of iontophoresis itself rather than the vasoactive drugs) is an important 
confounding factor443. Current induced release of neuropeptides is a popular theory but 
the mechanisms are incompletely understood293. Various strategies have been applied to 
avoid this effect such as the limitation of current strength or total iontophoretic charge444, 
or special vehicle solutions445 but the lack of a standardised protocol makes between-
study comparisons difficult293.  
There is also the possibility of under estimation of MPA counts due to EDTA causing the 
platelets to clump together. EDTA-dependent chelation of calcium, at the appropriate 
temperature, can change the expression of the platelet glycoprotein 2b receptor, allowing 
autoantibodies to bind and induce platelet aggregation. However, this effect should be 
negligible, and the same methodology was used for all subjects. 
5.4.3 External confounders 
Interpretation of the longitudinal analyses are hampered by uncontrollable confounders 
such as changes in diet or exercise or unspecified changes to a patient’s circumstances 
leading to other subtle lifestyle changes. Operator variation was kept to a minimum by 




the impact of factors such as antibody denaturation or shifts in calibration parameters over 
time. 
EQ-5D does not contain any disease-specific measures however it has been validated in 
patients with ischaemic heart disease303, 304. I did not correct for psychosocial factors such 
as income, education or marital state but these have mainly been shown to be of 


















5.5 SUMMARY OF KEY RESULTS 
 
• MPAs associated with Mon2 and EMPs were associated with diffuse CAD. Levels 
of both markers were significantly higher than in patients with focal CAD or 
subjects with normal coronary arteries. 
• There was a significant inverse correlation between Mon2 related MPAs and 
endothelial-dependent microvascular function in patients with diffuse CAD. The 
correlation was evident at baseline and on longitudinal analysis. 
• There was a strong trend towards worse endothelial-dependent microvascular 
function in patients with diffuse CAD compared with focal CAD or subjects 
without CAD. 
• MPAs associated with Mon1, MPAs associated with Mon3 and total MPAs were 
similar between the groups at baseline. 
• Total monocytes and monocyte subsets were similar between the groups at 
baseline (although patients with diffuse CAD showed a non-significant trend 
towards higher Mon2 levels).  
• Arterial and ventricular elastance indices (EaI, Ees and Eed), VAC and AIx were 
similar between the groups at baseline. 
• During follow up there was a significant increase in Eed index in diffuse CAD 
patients. 
• Quality of life measures were similar between the groups and essentially 






































6.1 SUMMARY OF FINDINGS 
 
Section IV contains retrospective analyses of data collected routinely in patients with 
acute CAD and served to highlight the clinical burden of CAD locally in terms of acute 
myocardial infarction. I found that South Asian ethnicity is associated with late evening 
presentation to hospital with STEMI, that there was no difference in symptom-to-door 
time between men and women or different ethnic groups and that despite the successful 
reduction of door-to-balloon time in our centre, mortality from STEMI had remained 
constant throughout the 5-year study period. 
Section V contains the results of my experiments. The main finding is a significant excess 
of MPAs associated with Mon2 and circulating EMPs in patients with established, diffuse 
flow limiting CAD compared to patients who developed flow limiting CAD more focally 
(affecting a single segment of one coronary artery) or patients who, despite similar age 
and traditional risk factors, had normal coronary arteries (Section V, Tables 5.8 and 5.10). 
During 12 months follow up, I observed a decline in Mon2 related MPAs that was 
inversely correlated with improvement in endothelial-dependent microvascular function 
in patients with diffuse CAD (Section V, Figure 5.5). EMPs also declined significantly 
during follow up. 
After adjusting for the effect of blood pressure medications I found no baseline 
differences in elastance measures (LV Ees, LV Eed, EaI, VAC or AIx) between the 
groups (Section V Tables 5.3 and 5.4). However, EDP, EDV, early mitral inflow and 
tissue Doppler velocities were all higher in patients with diffuse CAD compared to 
participants with focal, or without CAD. Furthermore, Eed increased during follow up in 




I did not detect a significant difference in monocyte levels between the groups at baseline 
or during follow up.  
There was no difference in self-reported HrQOL between the groups at baseline or on 





















The present thesis represents a detailed assessment of cardio-vascular interactions, 
arterial stiffness, systemic microvascular endothelial function, monocyte subsets, 
monocyte-platelet aggregates and circulating microparticles in patients with severe, 
diffuse CAD, patients with focal CAD and subjects with no CAD.  
Patients with diffuse CAD had similar cardio-vascular interactions and aortic 
augmentation indices to patients with focal CAD and people with normal coronary 
arteries but they also had higher LV filling pressures and volumes and my findings 
indicate that patients with diffuse CAD may be more susceptible to changes in diastolic 
elastance.  
Levels of Mon2 related MPAs and apoptotic EMPs were higher in patients with diffuse 
CAD than in subjects with focal CAD or normal coronaries. Mon2 related MPAs 
correlated inversely with endothelial-dependent microvascular function in subjects with 
diffuse CAD and suggest that microvascular endothelial apoptosis could be an important 
determinant of this unfavourable type of CAD. Levels of PMPs between the groups were 
similar which would be consistent with overall low-level platelet activation in stable CAD 
compared to acute thrombo-occlusive states. 
Reported HrQOL was similar across all three groups which likely reflects the impact of 
undiagnosed chest pain in subjects with normal coronary arteries versus those who are 






6.3 FUTURE DIRECTIONS 
 
Improvements in the treatment of acute CAD mean more people reach a point where CAD 
is advanced and diffuse, thus making it less amenable to conventional therapies thus 
increasing the mortality and morbidity associated with the condition. Future directions 
should perhaps be focused on a) identifying people at risk of developing the condition, 
and b) cell-specific targeting of the immune system. 
In this thesis, I show that improvement of microvascular endothelial-dependent function 
in patients with diffuse CAD over one year parallels a decline in Mon2 associated MPAs. 
Future prospective longitudinal studies could examine whether these changes relate 
temporally to CAD burden, with intravascular imaging or CTCA. 
Mon2 monocytes have been associated with poorer cardiovascular outcomes. Follow up 
time was a limitation of my study, but further research could focus on whether MPAs 
with Mon2 are better predictors of adverse outcome than Mon2 alone. Prospective long-
term follow-up of people with focal CAD, with serial measurements of MPAs associated 
with Mon2, to see who develops diffuse CAD and whether Mon2 related MPAs are truly 
predictive of this type of CAD would be beneficial and would strengthen the case for their 
use as pharmaceutical targets. 
Monocytes as delivery vehicles for therapeutic agents is an area that has seen recent 
attention, predominantly in mice446. Feasibility in humans for CAD treatment is not 
known. 
The underlying mechanism by which platelets regulate the activation, polarisation and 




light-chain-enhancer’ of activated B cells (NF-κB) pathway and signal transduction via 
phosphorylation of Lyn kinase447. This requires clarification since the precise role of 
Mon2 is still being defined. It is possible that MPAs associated with Mon2 facilitate a 
functional transition from Mon1 and Mon2. On the other hand, Mon2 related MPAs may 
enhance the production of anti-inflammatory cytokines or angiogenic factors. IL10, 
produced preferentially by Mon2, is known to inhibit the NF-κB pathway so evidently a 
complex interplay exists. The recent CANTOS (Canakinumab Anti-inflammatory 
Thrombosis Outcome Study) trial randomised over 10,000 patients to 50mg, 150mg or 
300mg of Canakinumab respectively against placebo and found a statistically significant 
reduction in the primary endpoint (non-fatal myocardial infarction, any non-fatal stroke, 
or cardiovascular death) with the 150mg dose compared to placebo448. Canakinumab, an 
IL1ß inhibitor, effectively reduced high sensitivity C reactive protein and whilst it may 
benefit stable CAD who have ongoing inflammatory risk after appropriate lipid-lowering 
therapy, it did so at the expense of increased risk of fatal infection. Herein lies the real 
challenge of the future – targeting the immune system with enough specificity to slow, or 
even halt the progression of CAD whilst maintaining adequate defence against infection. 
Molecular imaging techniques such as the tracer principle (labelling a biomolecule with 
a radioisotope and following its distribution throughout the body) have gained substantial 
interest over the past decade. Their diverse range of applications includes imaging of 
inflammatory cells such as macrophages as well as platelets and angiogenesis449. More 
recently multi-modal hybrid imaging (PET/MRI) has been reported to quantify both 
monocyte-associated myocardial inflammation and remodelling450. Ultimately these 




be used in conjunction with measures of systemic microvascular function to identify 
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Appendix 3: Standard Operating Procedure; pulse wave analysis 
SOP 106  
Pulse wave analysis (PWA) 
Sern Lim: November 2008  
updated by Richard Brown: January 2014 
 
Background 
Left ventricular (LV) contraction generates a forward travelling pressure wave. Some of 
this pressure wave will be reflected at sites of impedance mismatch (e.g. bifurcations and 
lesion sites). Increased arterial stiffness results in earlier return of the reflected pressure 
wave in systole rather than diastole. The reflected pressure wave will increase systolic 
blood pressure, termed pressure augmentation and may be expressed as the augmentation 
index. Increased arterial tone, such as that associated with endothelial dysfunction also 
increases the reflected wave and the augmentation index. The analysis of the arterial 
pressure wave, termed pulse wave analysis (PWA) may therefore provide information on 






You will need: 
• Patient. 
• SphygmoCor with pressure transducer. 
• Laptop computer with SphygmoCor software. 
• Power cables and USB connection cables. 
• ECG monitoring dots. 
• BP recorder. 
• Salbutamol inhalers and GTN spray. 
 
2. Preparation 
a. Allow the subject to rest in the room for about 10 minutes before scanning. 
The test should be done in a supine position. 
b. While the patient is resting, you should connect the power cables to the 
SphygmoCor machine (at the back) and the laptop computer. The 
computer should then be connected to the SphygmoCor machine (use the 
USB connection at the back). The ECG cables should be connected to the 
SphygmoCor machine (in front where it says ‘ECG’).  
c. Switch on the SphygmoCor machine first. The lights in front will blink. 
When the lights stop blinking and green light stays on ‘ready’, turn on the 
computer. This sequence will allow the software in the computer to 




d. The SphygmoCor icon should be on the computer desktop. Double-click 
to activate the software. A warning will come on the screen, just click 
‘allow’. 
e. You will see PWA and PWV on the top left of the screen. Click on PWA 
for pulse wave analysis. 
f. Click ‘create new’ on the top right of the screen. You will need to enter 
the patient details in the relevant boxes (e.g.: date of birth) and click 
‘update’. 
g. Click on PWA on the top left for pulse wave analysis and then ‘study’ on 
the top left of the screen. Choose radial or carotid by ticking the box. 
Measure the patient’s brachial blood pressure (Omron). Take 3 
measurements and use the average of the last two readings.  
h. Enter BP measurements. Height and weight if you have the data.  
i. Place the ECG leads on the patient and click ‘Capture data’ on the top right 
of the screen. You are now ready to go! 
3. In the drawer of the tonometer machine, you will find the Millar tonometer with 
a plastic cap to protect the high-fidelity tip (this cap is important, DO NOT lose 
it!). The tonometry should be connected already. DO NOT disconnect the 
tonometer. Remove the plastic cap and it is ready for use. 
4. Feel for the radial or carotid pulse (depending on which you want to measure) and 
place the tonometer over the pulsation. You will see a pressure trace on screen. 
The screen will automatically adjust the scale to accommodate the pressure trace. 




the measurement, press the spacebar on the laptop. The machine will not take the 
last 2 seconds of recording to give you time to let go and press the spacebar.  
5. The computer screen will then change to the data screen with the ensemble-
averaged pressure trace (radial or carotid depending on the one you have chosen) 
shown and the derived central arterial pressure trace. First thing to do: check the 
quality control box on the top left of the screen. If this number is red, then the data 
is of insufficient quality and the measurement will need to be repeated.  
6. The data will be available at the bottom of the screen. At the top right of the screen, 
click ‘Export’ to save the data in your folder. You can store the data as a text file 
or jpeg (the screen shot). I would suggest you store both, then your study is done! 
 
Potential problems 
1. The high-fidelity tonometer is very sensitive to pressure (that is what it is meant to 
do!). You will need practise to achieve a consistent level of pressure to obtain 
reproducible readings. It is generally more difficult for carotid artery compared to the 
radial artery. 
2. To avoid any problems with the computer, it should NOT be used for any other 
reasons (e.g.: surfing the internet). The computer and the tonometer (plus ALL the 
cables and ECG leads) should ALWAYS be kept together. 
3. Every operator should create a folder for him/herself and store ALL the data in that 






Appendix 4: Standard Operating Procedure; assessment of peripheral 
microvascular endothelial function by laser Doppler iontophoresis 
 
Standard Operating Procedure 107 
Measurement of cutaneous microvascular endothelial function 
 
Written by Richard Brown January 2014 
 
 
Health and Safety / COSHH 
Some subjects may be allergic to Ach & SNP453. Some may respond adversely to the 
electrical current. Obtain consent. 
 
The function of large arteries such as the aorta, brachial and femoral can be assessed by 
their dilation response to changes in blood flow (i.e. flow mediated dilatation, FMD). This 
assessment is not possible in the study of small arteries and arterioles, often within 
vascular beds such as the skin. However, the recent development of perfusion imaging 




Laser Doppler perfusion imaging is based on four separate technologies  
• (a) the Doppler shift phenomenon (change of the wavelength of the moving object 
proportionally the speed of the object, i.e., blood cells),  




• (c) perfusion of skin with pharmacologically active drugs (acetylcholine [Ach] 
and sodium nitroprusside [SNP]) that will alter small blood vessels close to the 
surface of the skin, and  
• (d) the electrical delivery of these agents into the skin (iontophoresis).  
 
Thus, the method allows an evaluation of the perfusion of surface tissues (e.g. skin) in 
real time scale. Changes in skin blood flow can be determined in response to various 
stimuli. Vasoactive substances can be used to alter the flow of blood in the skin vessels 
if delivered by an appropriate means.  
Iontophoresis is a delivery method that uses the charge of a vasoactive substance to allow 
it to be driven through the skin using an electric current. Sodium nitroprusside is a 
vasoactive substance with a negative charge that can be delivered through the skin to the 
microcirculation; once it has passed through the skin it acts as a nitrate donor and 
therefore acts directly on the vessel’s smooth muscle to cause vasodilatation. Thus, it is 
independent of the endothelium in its vasodilatory action. Acetylcholine on the other 
hand, is a positively charged molecule that can similarly be delivered to the subcutaneous 
tissues by iontophoresis, but it acts on the endothelium rather than on the smooth muscle 
wall, causing endothelial release of nitric oxide. Thus, acetylcholine acts in an 
endothelium-dependent way on the vessel wall to produce vasodilatation. The vasoactive 
substances are provided close to the skin in a small perfusion chamber that also acts as an 
electrode. A second electrode is required to complete the circuit, and this is attached to a 
nearby section of skin. 
 
1. Test solutions 
Quantities of 1% acetylcholine chloride (Ach) and 1% sodium nitroprusside (SNP) (both 
from Sigma-Aldrich) must be prepared in sterile filtered distilled water (Fistreem 
International) and appropriate volumes (approximately 1ml aliquots) stored in plastic 
tubes in a fridge at 4°C for up to 1 month. These solutions are transferred from the plastic 
tubes to the largest of the three holes in the centre of the iontophoresis chamber with a 
plastic disposable transfer pipette (stored in the preparation room and the laboratory). 
Ensure the reagents reach room temperature. SNP solution should be protected from the 
light, so you will need something to wrap the test tube in, such as some tinfoil or inside a 
glasses case. 
 
2. Preparing the Laser Doppler Flow meter (MoorSoft DRT4 Axminster Devon, 
UK)455.  
The laser requires at least 10 minutes to warm up so do this well before the subject is 
assessed. 
1. To switch on the LD, press the black switch at the back of the Laser Doppler block. 
(grey box) 




3. Start MoorSoft DRT4 icon (Laser Doppler software) on the desktop. If this is not 
already on the desktop it will require installing which will in turn require administrator 
privileges. The software for V2.0 can be downloaded from this link; 
https://dl.dropboxusercontent.com/u/107876031/DRT4/Setup.exe  
The registration code for the DRT4 was given to me by the engineers as WB4JG PSLDW 
ZH PSLDW which will need to be entered into the software once installed and run. If you 
have any problems with this you can email Dave Bridges on dbridges@moor.co.uk or 
Brian Lock on lock@moor.co.uk. 
It is important to run the DRT4 machine via the software on the computer and not through 
the LD machine itself (by simply pressing ‘run’ – the top blue button). This is because 
trying to download data from the DRT 4 to the PC/laptop can be unreliable. Once the 
software has been installed, you will need to make sure your PC/laptop is communicating 
with the DRT4 (LD machine). This is done via the grey 9 pin cable provided which plugs 
into the back of the hospital PC in research room 4. If, however, you wish to use a personal 
laptop you may require a USB converter as this 9-pin connection is not available on some 
laptops. The DRT4 uses a non-standard RS232 pinout so the USB converter will have to 
be bought from moor instruments if required. The software should already be configured 
to the manufacturer’s specifications. Once connected, you should be able to instruct the 
DRT4 using your computer. 
4. If the machine has not been used for a while between research fellows or in any case 
1/month it will require calibrating. First take the white optical probe labelled ‘channel 1’ 
and plug it into the top space on the left-hand side of the LD/DRT4 machine. Then take 
the other white optical probe labelled ‘channel 2’ and plug that into the bottom of the two 
holes on the left-hand side of the machine (picture 1). You then need to press the yellow 
triangular shaped button (which looks more like a hazard warning then a button) located 
in between the two ports for the lasers to come on (black arrow, picture 1).  
Picture 1 
Next take the calibration stand which should fit together as shown in picture 2. This 








milky fluid is the probe flux standard (PFS) used for calibration. Place this in the 
base of the calibration stand as shown. 
 
 
Picture 2 Calibration stand with PFS 
 
On the DRT 4 opening screen there should be an option saying, ‘probe calibration’. Press 
the blue button corresponding to this then select ‘recalibrate probe’, press ‘menu’ (which 
is synonymous with ‘enter’). For channel 1 select probe 1 followed by ‘enter/menu’ and 
immerse channel 1 (probe 1) into the PFS. Make sure the detector part of the probe is in 
the centre of the fluid (i.e. not up against the wall of the bottle). Do the same for channel 
2. Once calibration is complete (picture 3) press the button to exit. The machine is now 










3. Patient preparation 
3.1. Use right forearm, it should be clean (picture 4). Technically one could use either 
forearm but there are high degrees of variability between them (see below) so consistency 
is essential. 
3.2. Ask the patient to lie down on a couch and place their arm on a comfortable cloth 
pad next to them on the couch. The room temperature should be constant (ideally 19-
23°C). Make sure the participant is comfortable and the hand is stable. 
3.3. Remove any hair from the forearm gently with a single-use razor. 
3.4. Use a Skin Prep (e.g., Skintact) gently to prepare the area of the scans, leave the 




4. Iontophoresis and Data acquisition 
4.1. During assessment, the patient is laying on the couch comfortably in a constant room 
temperature room for 20 minutes before the start of measurements (picture 5). All 
measurements should be performed in dim light. The forearm is placed on a supportive 
cloth/pillow.  
4.2. A hairless area of forearm skin in the chosen arm is cleaned with a 40% ethanol swab 
and the iontophoresis chambers (glass chambers with a larger hole in the middle and two 
smaller ones towards the edge (MoorSoft UK) placed over the skin about 5-10cm apart. 
They are attached using the double-sided adhesive discs supplied. 
4.3. The iontophoresis chamber attached to the red wire (positive charge) should be 
proximal to the one attached to the black wire.  
4.4. The proximal chamber is then filled with about 0.5 ml Ach (using transfer pipette) 
whilst ensuring that no air bubbles are visible below the glass cover. SNP (0.5ml) goes 




the central hole in the glass chambers (on top of where the fluid has been placed). Channel 
1 goes into the proximal chamber with Ach in (red wire) and channel 2 to the distal 
chamber with the SNP in. Turn on the analogue input/output module for the DRT4 using 
the black switch at the back. The green screen will then illuminate with mA which should 
read 0.01 or 0.02. No electrical current will be delivered until the appropriate phase of the 
protocol (which is controlled from the computer), so it is best to switch the machine on 






4.5. The protocol should now be ready to run. Go to ‘File, new’ on the software. Provided 
the optical lasers are turned on and the DRT4 is connected to the computer you should 
see flux readings on the computer screen (as well as on the LD screen – which should be 
the same). The standard protocol is 60 seconds baseline recording (analogue module 
turned on but no current) followed by 60 seconds iontophoresis of both drugs (analogue 
module delivers a current to facilitate iontophoresis – patient may feel a tingling 
sensation) followed by 600 seconds (10 minutes) of drug response monitoring making a 
total of 12 minutes. The software controls all the timings, so you do not have to press 
anything except the ‘ion’ icon under the green play sign in the middle of the toolbar when 
you and the patient are ready (picture 6 arrow). You will hear a beep denoting the start of 
baseline and then another beep after a minute has passed denoting the start of 
iontophoresis (at which point the current on the analogue machine should read 101mA 
providing there is good skin contact) and a third and final beep denoting the end of 
iontophoresis and start of drug response monitoring; the machine will automatically stop 
at the end of 12 minutes. You will see flux readings on your screen for each of the two 
channels simultaneously (F1 and F2 where F stands for flux). The flux is an arbitrary 
figure derived from the velocity of the red blood cells multiplied by their concentration 







4.6 At the end of 12 minutes the two glass chambers can be removed from the patient’s 
forearm and cleaned.  
4.7 Complete the procedure by wiping excess fluids from the subject, disposing of waste 
material etc. Power down the LD and switch it off. 
 
5 Analysis of results 
After the readings have been taken, the images are analysed using the dedicated software 
package provided by the manufacturer. Before selecting a region of interest (ROI) it is 
worth saving the recording as a DRT file in case you wish to re-analyse it later. To do this 
go to ‘File and ‘Save as’ and click ‘OK’ on the DRT window that opens subsequently. 
1. To select an ROI (the period of data collection you wish to analyse). Left-click the 
mouse pointer just under the first triangular marker in the white bar at the top of the screen 
underneath the toolbar and drag it across to the second marker. You have now selected 
the baseline 60 seconds.  
2. Let go with the mouse and click ‘Analysis’ ‘New statistics’. You will then have a 
choice. Choose ‘Show statistics of all selected parameters’ click OK. 
3. The software will now display some basic descriptive statistics of the area that you 
have selected. These are your baseline flux readings (picture 7). 
4. Click ‘File’ (in the top of the new window with the stats in, not the one on the main 
screen) and ‘Save’ to save the information in a folder for the patient. If you want to add 
a study to an existing patient click ‘File’ ‘Append’.  
5. Repeat the process this time with the ROI between the second and third triangular 
markers denoting the maximal flux during drug iontophoresis and again for the final 10 






6. Save changes in the same way for each ROI as in step 4. Files can be saved to ‘My 
Documents’ or to the Moor Soft Machine however when opening up the data in excel 
files are more easily found from My Documents. 
7. Select Export and Images and calculations to Excel to export results to Microsoft 
Excel; alternatively, you can open excel and import the text files which will be converted 
by excel into a compatible format (Microsoft 2010) but then when you save the file it 
needs to be as an xls file. The values for each time point are used to determine the peak 
response (in terms of absolute perfusion units, and also % change from baseline), and area 
under the curve for the perfusion over the 10-minute experiments. 
8. Save results obtained and print them if necessary. 
9. Close software. 
10.Turn off the computer and switch off DRT4. 
11. Write up the result in a legible form.  
 
Troubleshooting 
These are one or two difficulties that I had; 
If you see either of these two messages below (which you shouldn’t now the software has 
been properly installed and set up and all relevant installation files received from the 
manufacturer), it will require a combination of trust IT and MoorSoft engineers to resolve. 
The MoorSoft engineers were very helpful and able to deal queries via telephone and 
email. 
This error message means that one of the files required for installation is either missing 


















Appendix 5: Standard Operating Procedure; enumeration of monocyte subsets 
and monocyte-platelet aggregates  
STANDARD OPERATING PROCEDURE  
 
Absolute count of monocyte subsets and assessment of surface marker expression 
on them by Flow Cytometry 
(extraction of the absolute count protocol) 
 
N.B. Use of the flow cytometry is forbidden  
Without having been officially trained 
 




1. SOPs on venepuncture, good clinical practice 
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Monocytes are circulating blood cells participating in innate immunity, inflammatory 
response as well as other processes such as angiogenesis, formation of tissue 
macrophages and dendritic cells etc. Monocyte include several subsets that can be 
discriminated based on surface expression of CD14 (lipopolysaccharide receptor) and 
CD16 (Fc gamma receptor III). 
 
This method describes enumeration and characterisation of: 
- CD14+CD16- monocytes (about 85%),  
- CD14+CD16+ monocytes (also CCR2+, about 5%) and  
- CD14lowCD16+ monocytes (also CCR2-, about 10%), 
 
2. Materials and Supplier contact details: 
 
1) BD “FACS Flow” Running solution [Becton Dickinson, Catalogue No. 342003] 




BD “FACS Clean” Cleaning Solution [Becton Dickinson, Catalogue No. 
340345].  
2) 3 ml BD Falcon tubes [Becton Dickinson, Catalogue No. 352054]. 
3) BD Lysing solution [Becton Dickinson Catalogue No. 349202]. 
4) Sterile Phosphate Buffered Saline solution, 0.5L bottles [Invitrogen Ltd, 
Catalogue No 20012-068]. 
5) BD TruCount tubes [Becton Dickinson Catalogue No. 340334]. 
6) CD16-Alexa Fluor 488-conjugated monoclonal antibody [AbD Serotec, Oxford, 
UK, Cat No. MCA2537A488]. 
7) CD14 -PE conjugated monoclonal antibody [R&D Systems Europe Ltd, Cat No. 
FAB3832P]. 
8) CCR2-APC conjugated monoclonal antibody [R&D Systems Europe Ltd, Cat 
No. FAB151A]. 
9) CD42a- conjugated monoclonal antibody [Becton Dickinson, Catalogue No. 
340537]. 
10) Clear pipette tips [Alpha Laboratories Limited Catalogue No FR1250 1250µl 
Fastrak Refill NS].  
11) Yellow pipette tips [[Alpha Laboratories Limited Catalogue No FR1200 200µl 
Fastrak Refill NS].  
12) Pipettes required – 2-20µl (grey) 
   5-40µl (red) 
   40-200 µl (yellow) 
   200-1000µl (purple) 
   10-10µl and 100-1000µl digital  
 
3. Detailed method 
 
3.1 General Preparation 
 
3.1.1 Lysing solution.  
 
Make from 50ml concentrate 10x FACS Lysing Solution (kept at room temperature). 
Dilute with 450ml distilled water in ½ litre bottle. This solution should not be used if it 
is older than a month (kept at room temperature). 
 
3.1.2. Master mixes 
Master mixes are made by responsible person in clearly labelled tubes from dark glass. 
Estimated number of samples to be done from one master mix should not exceed 
monthly number of samples done 
 
3.1.3. Time from blood sample collection to beginning of sample preparation should be 
less 30 min, and must not be more than 60 min. 
 
3.2 Blood sample preparation 
 
3.2.1. Place EDTA blood sample on rotator. 




3.2.3. Place Antibodies from the ‘master mix’: 12.5µl (grey) - place on opposite side to 
count beads. Do not touch the pellet! If this happened – change the tube. 
3.2.4. Add blood to the tube. 
- Take 10-100µl digital pipette. 
- Set to 2 x 50µl. 
- Withdraw blood then expel by pressing ‘RESET’, take up blood once again. 
- Wipe pipette tip to remove excess blood. 
- Eject 50µl into AC tube – keep the tip well above the metal greed. Do not touch count 
beads. 
- Replace tube top. 
- Replace rest of blood into EDTA blood tube (keep it in case you need to repeat the 
procedure). 
3.2.5. Vortex all samples (level 3). 
3.2.6. Place samples in dark for 15 minutes (taken from when last sample prepared). 
 
3.3 Start-up procedure [See SOP 195 on General Operation] 
 
- Turn on FC and after few seconds computer. 
- Empty waste (right container) and refill with 360ml distilled water and 40ml bleach 
(ensure no bleach on gloves). 
- Fill machine with left container by FacsFlow to appropriate level (level of 
indentation). 
- Pressurize. 
- Press LOW/PRIME with the arm closed (distilled water in place)- once PRIME light 
goes off press once more. 
- Remove distilled water and place ‘top right’ on rack. 
- Insert FacsClean tube (2ml of FacsClean) – opened arm 1 minute, closed 5 minutes - 
then remove and place ‘top left’ on rack- set FC on ‘high/run’. 
- Insert a tube with sterile PBS – 1 minute open arm, 5 minutes closed arm. 
 
3.4. Further sample preparation 
 
3.4.1. Red blood cell lysing.  
- Use purple pipette(200-1000µl). 
- Put 450µl in AC tube. 
- Place tops on tubes and vortex. 
- Place AC tube in dark for 15 minutes- after which add 1.5mls of PBS, vortex - sample 
ready to run. 
 
3.5. Sample acquisition 
3.5.1. Absolute count 
- Run FacsComp if you are first user of the flow cytometer during the day 
- Press CellQuest icon 
- ‘FILE’ – ‘Open document’ – ‘Data 1’ – ‘Mon protocols’ – ‘Mon no wash’ 
- ACQUIRE – ‘Connect to cytometer’ 
- CYTOMETER – ‘Choose instrument settings’ – ‘Mon no wash’ – ‘Set’ – ‘Done’ 
- Change appropriate directory to save flow data 




- Place AC into cytometer and press ‘Acquire’ (press ‘Acquire’ on top bar, press 
‘Counters’) - once finished, print 
3.5.2. Expression of surface markers 
- ‘FILE’ – ‘Open document’ - choose – ‘Mon wash Luke/Ben’ 
- CYTOMETER – ‘Instrument settings’ – ‘Open’ - choose ‘Mon wash Luke/Ben’ – 
‘Set’ – ‘Done’ 
- ‘WINDOWS’ – ‘Show browser’ 
- Change directory and file name as before 
- Vortex and run tubes 1-5, changing file on each sample (1, 2, 3 etc)- print after each 
 
3.4 Shut down procedure [See SOP 195 on General Operation] 
 
1. In this section, we re-use tubes 1 and 2 with distilled water and FACS clean 
respectively. 
 
2. Install FACS Clean tube 2 over the SIP needle. Press button ‘High’ and ‘Run’ on 
the panel. Leave the support arm out at 90 degrees for approximately 1 minute. 
This cleans the outer portion of the aspiration sheath. The fluid will be rapidly 
aspirated, so ensure that the tube doesn’t empty completely. 
 
3. Now replace the side arm under the Falcon tube and allow to run for 
approximately 5 minutes. This cleans the inner portion of the aspiration sheath 
and the FACS machine itself. 
 
4. Repeat steps 2 and 3 with the distilled water tube 1. Once step 3 is complete, 
Leave the sheath in falcon tube 1 containing distilled water and press 
‘STANDBY’. 
 
5. Open the reservoir draw and depressurize the machine by moving the “Vent 
Valve” toggle switch to the up/rear position. The machine will hiss as it 
depressurizes. 
 
6. Leave the machine on for a further 5 minutes to allow the laser lamp to cool. 
Turning the machine off prematurely will result in the lamp cracking. 
 
7. Finally power down the FACSCalibur (green button) and Apple Mac. 
 
8. Clean up! 
 
9. Note: * IF THE SYSTEM IS TO BE USED AGAIN ON THE SAME DAY… 
 
LEAVE THE SYSTEM ON STANDBY and then 
 






Appendix 6: Standard Operating Procedure; enumeration of platelet and 
endothelial microparticles 
STANDARD OPERATING PROCEDURE 209 
 
Enumeration of Platelet Microparticles using Apogee A50 Flow Cytometry 
 
Silvia Montoro Garcia and Eduard Shantsila 
September 2011 
 
Updated by Dr Jackson Lau and Dr Xiong Qinmei: April 2015 
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Cellular microparticles (MP) are submicron biological structures released from different 
types of cells (e.g., from platelets, leucocytes, endothelial cells, red blood cells) via 
remodelling of plasma membrane in response to numerous conditions, including 
activation and apoptosis456. MPs are generally defined as small (0.1 to 1μm) membrane 
fragments that often expose the anionic phospholipids phosphatidylserine and membrane 
antigens representative of their cellular origin. These characteristics discriminate MP 
from exosomes, which are smaller (<0.1 nm), originate from intracellular multivesicular 
bodies, and differ in antigenic composition. 
 
Some MPs have prothrombotic properties irrespectively from their origin. However, 
presence of certain markers (e.g., tissue factor) on MP surface substantially enhances 
thrombogenic properties. Flow cytometry allows the identification and enumeration of 





The A50-Micro flow cytometer was shown to be superior to most conventional flow 
cytometer for MP analysis due to its design specifically focused for analysis of small 
events. Conventional flow cytometers are limited to measuring particles larger than about 
500nm (y small angle light scatter [forward scatter, FS]). For example, the lower limit of 
resolution of BD FACSCalibur is 5.0μm. Apogee A50 discriminates 20nm particles (latex 
beads), and it also benefits from a volumetric sampling system that accurately counts MP 
per microliter without using count beads. An additional advantage of Apogee A50 is a 
fluidics system that can be refilled with distilled water, saving money on expensive  
reagents.  
 
This SOP describes enumeration of CD42b (GPIb)+ platelet-derived microparticles 
(PMP). N.B. the SOP may be amended for more detailed analysis of MP subpopulations, 




2. Materials and Supplier contact details: 
 
1) Distilled water from the still in the tissue culture room 
 
2) Eppendorfs tubes of 1.5mL, Copolymer PP ‘ultra-clear, snap-shut’ [Appleton 
Woods, #KC 135] 
 
3) Filtered and sterile 1% Phosphate Buffered Saline solution, 0.5L bottles [Life 
Technology, #10010-023] 
(0.22μM filters and syringes are available on the shelves in the tissue culture 
room) 
 
4) CD42b-Biotin conjugated monoclonal antibody, 50μg vial. [Abcam, #AB 30400]  
Antibody can be separated into multiple aliquots and stored in -70°C freezer. 
 Once thawed, to be kept in fridge and use within 7 days. 
 AVOID repeat freeze-thaw action, heat sensitive. 
 
5) Streptavidin- Alexa Fluor -647-R-PE conjugate, 100μL vial. [Life Technology, 
S20992]  
DO NOT FREEZE, heat sensitive. 
 Light sensitive keep wrapped in foil. 
 
6) Red pipette tips, Fastrak Refill Pack NS, 10μL extended microtips, 14 x 96 per 
pack [Alpha Laboratories, #FR 1010]. 
 
7) Yellow pipette tips, Fastrak Refill NS, 200μL extended microtips, 14 x 96 per 
pack [Alpha Laboratories, #FR1200].  
 
8) Sodium Azide, 99.9%, 25gram bottle. [Sigma Aldridge, # 438456-25G] or 





9) ApogeeMix beads for Flow Cytometer performance assessment, 25mL bottle 
[Apogee Flow Systems, Hertfordshire, United Kingdom # 1493]. 
 




3. Detailed method 
 
3.1 General Preparation 
 
1. Peripheral vein blood sample is to be collected with a 21-gauge needle without 
applying haemostasis into sodium citrate Vacutainer tubes (BD Diagnostics). 
Discard the first vacutainer as this may have cell that are activated by the trauma 
(especially platelets). Use only the second vacutainer to generate clinical data 
 
2. Platelet-poor plasma (PPP) must be prepared by centrifugation for 15 min at 
2860g (circa 4000 rpm). 
 
3. Aliquots to be frozen should be centrifuged additionally 2 min at 13000g 
(rendering platelet free plasma, PFP) and frozen in 1.5mL tubes (0.5mL per tube) 
at -70C until use. 
 
3.2 Sample Preparation (to be performed in dark) 
 
1. PPP must be slowly thawed before sample staining at room temperature (RT) and 
not under hot water because it could damage MPs. 
 
2. Avoid repeat freeze-thaw action of plasma as it will degrade MP numbers. 
 
3. Prepare dilutions 1/10 of the CD42b-biotin conjugate and the streptavidin on the 
morning of analysis, do not store the rest for other days. This recipe is for the 
analysis of ten samples of plasma. Increase or reduce the volumes of reagents in 
accordance. 
 
a. Mix 12.5L of CD42b-biotin antibody and 112.5L of sterile and filtered 
PBS in a 1.5mL Eppendorf.  
 
b. Mix 12L of Streptavidin-PR conjugate and 108L of sterile and filtered 
PBS in a 1.5mL Eppendorf.  
 
4. Put 5μL of the 1/10 diluted CD42b-biotin in a 1.5mL Eppendorf.  
 
5. Take 50μL of thoroughly vortexed plasma sample with ‘wet tip’ reverse pipetting 
technique and add to the tube above without touching antibodies. 
 





7. Put 2.5μL of the 1/10 diluted Streptavidin-PE conjugate into the 1.5mL 
Eppendorf.  
 
8. Gently vortex the sample again. Incubate in the dark at room temperature for 30 
minutes (polystyrene cube ‘cool box’). 
 
9. Add 950μL of filtered PBS, to achieve 1:20 dilution. Rate of dilution of samples 
may change depending on concentration of MP in different antibody used.  
 
10. The sample is now ready to be analysed. 
 
3.3 Start-up procedure for Apogee A50 Flow Cytometry 
 
Part 1 – Restoring reagents and general preparation 
 
1. Switch on Flow Cytometer by pressing the only big, black bottom on the machine. 
The attached computer will thus be automatically switched on.  
 
2. The sheath (distilled water) fluid reservoir is located at the top of the flow 
cytometer and the waste reservoir is located on the floor under the flow cytometer. 
 
3. Carefully lift the top of the sheath fluid reservoir (half way along the top of the 
machine) and fill it with distilled water to the level indicated by a red float (little 
plastic float in the clear vertical plastic tube).  
 
The cytometer requires up to 2-3 refills over a continuous 8 hours running period.  
Ensure that distilled water still is kept running.  
 
4. Add small amount (1 plastic spatula full) of sodium azide or ProCLin™ 300 into 
the sheath reservoir upon every refill of distilled water, this will retard bacterial 
or fungal growth in sheath and flow cell.  
Never allow the distilled water in the sheath reservoir to run out. 
Ensure gloves are worn and good ventilation, as pungent odour may be released 
upon dissolving sodium azide.  
 Avoid direct contact with sodium azide. 
 
5. Carefully disconnect/unscrew the waste container and empty contents down sink 
with plenty of water.  
Ensure adequate ventilation as pungent fumes may be released. 
Never run flow cytometer with full waste container, as built up of back pressure 
will “aspirate” waste back into flow cell.  
 
Part 2 – Apogee Histogram and software preparation 
 
6. The computer will automatically open the Apogee Histogram Software. Go to 
SERVICE at the right hand top corner of the screen, open it, and press ‘Flow Cell 
Clean’, this will automatically clean the system and needle before starting. When 




7. Then press ‘Remove air in syringe’. Status will then move to ‘Idle clean’.  
 






(i) PMT: Noise level 
 
PMT Gates Voltage Noise 
SALS 245 0.21 
LALS 400 0.14 
Grn 430 0.08 
Orng 494 0.04 
Red 500 0.03 
 
 Ensure that noise levels are <1.0 in all gates prior to running any actual samples.  
  
Noise is due to background dust in flow cell and decreases accuracy of reading, 
usually increase after leaving Apogee A50 standing idle for > 48 hours. 
  
Reduction in noise can be achieved by multiple times of “FLUSH”, running 
multiple times of filtered distilled water [see part (iii)below] and ‘Flow Cell 
Clean’. 
 
Persistent, elevation of noise level may require servicing to replace parts. 
 
(i) Settings for PMT Voltage: 
 
PMT Gates Voltage Noise 
SALS 245 0.71 
LALS 400 0.14 
Grn 430 0.07 
Orng 494 0.02 
Red 500 0.01 
 
- Ensure that Voltage settings are optimised to 
ensure most optimal detection of MP.  
 
- Alteration in voltage will lead to increase 
excitation and emission, and lead to 
significant alteration of results (upwards shift 





(ii) Settings for Control: 
 
 μL/min (running rate) μL (aspirate volume) 
SAMPLE 10.5 150 
 
 This setting allows for 150μL sample to be aspirated and analysed at 10.5µL/min. 
 
Reduction in running rate will increase precision, but lengthen running time of 
each sample. 
 
In specific circumstances of flushing flow cell to remove dirt and to reduce noise 
level, one may run sample at a faster rate (101μL/min) and after aspirating a 
maximum volume (400μL).   
 
3.3 Running Samples. 
 
Note: This must be learned from an experienced operator and please seek scientific staff 
support to clarify any queries.  
 
1. Click on File (top left) → “Open settings and data” to open instrument settings. 
 
2. Click on the appropriate settings located in ‘Documents’. This will open the 
instruments settings for PMPs quantification settings.  
 
3. The settings are predefined to enumerate CD42b-positive events with size less 
1μm but more ~100 nm. This has been done during optimization of the protocol 
with different size beads (100, 200, 400, 500nm, 1μm and 2μm). 
 
4. Open swing arm at bottom right of the flow cytometer, place the sample and put 
the arm in the ‘running’ position (from “clean position”) to acquire the sample (in 
a 1.5 mL Eppendorf). The system will automatically aspirate from the sample 
without pressing any button, once the arm is switched to the “running” position.  
ENSURE that there is adequate volume to prevent aspiration of air. 
 
5. The machine will say ‘Aspirate sample’, and then ‘Running sample’. 
 
6. The sample will now run until the event collection is complete; the time of the 
acquisition will depend on the volume aspirated and running speed. If the software 
buffer is full (1,000,000 events) a message will appear asking whether the sample 
should be acquired further (with erasing the last data) or the acquisition should be 
stopped.  
 
7. Press “NO” and the sample will be stopped. If you want to stop the sample before 
reaching the limit of buffer size, press “STOP” during acquisition (at the right-





8. After the acquisition stops, move arm to the ‘clean’ position and discard the 
Eppendorf with the sample. The system will automatically clean the needle and 
tubes with pre-determined 2 flush cycles. 
 
9. Save data by clicking in “Save data file as” under “File”, the system will also 
autosave the data file in “My documents”.  
 
10. Absolute number of MP of interest will be expressed as events/μL at the bottom 
of the CD42b+ window gate. This number must be multiplied by the plasma 
dilution (such as x20). 
 
11. Obtain all the data and apply in into the appropriate spreadsheet of your project.  
 
 
3.4 Shut-down procedure  
 
10. After moving the arm to the clean position and discarding the Eppendorf, the 
system can be cleaned and shutdown. Press button “Shutdown” at the right corner 
of the software panel and leave the system for cleaning (takes 2 - 4 minutes). This 
will be done automatically. 
 
11. After the system has been automatically cleaned, a window will appear 
“Shutdown completed”, close the software and the control panel. 
 
12. Finally, shut down the computer, this will automatically shut down the cytometer 
too. 
 
13. Clean up the work station. 
 
14. Note: Leave the cytometer on if to be used again later that day.  
 
 
4. Interpretation of the results 
 























The vertical (Y) axis (RED) is the 
staining with CD42b-Streptavidin 
red fluorochrome for platelets. The 
horizontal (x) axis (SALS) is shows 
small angle scatter.  
 
 
Note the gate which defines the 
number of CD42b positive events.  
 
These have been set by the results 
of the previous isotype 
experiments.  
 
Purple Region-of-Interest (ROI), 
signifies potential CD42b events 
due to detection of excited 
fluorochrome. 
 
Red ROI suggests area of strict 
CD42b/PMP events.   
 
At the bottom of the PMPs plot, 
the number of positive events per 
μL in selected ROI is 
demonstrated = 38537.  
 
Once dilution factor (x100) is 
factored into the calculation = 
3,853,700/μL in undiluted plasma.  
 
 










Note identical layout but much 
less emission is detected by the 
flow cytometer. 
 
Thus, event rates in ROI was 













Validation (CD42b Antibody for PMP detection) 
 
Duplicate agreement was obtained for thoroughly vortexed plasma from the same tube.  
 
Intra-assay coefficients of variation were determined on 5 aliquots of plasma from 6 
subjects (i.e. n=5 per assessment). 
 
Results as below: 
 CD 42b 
 
Sample-A Sample-B Sample-C Sample-D Sample-E 
Test-1 128039 58239 79105 80513 76148 
Test-2 118054 53321 78123 79159 74879 
Test-3 102355 60523 81970 76315 68953 
Test-4 94560 43648 60218 57320 92747 
Test-5 87561 39758 42370 67731 53072 
SD 16696.62 9067.309 16865.46 9693.464 14289.51 
Mean 106113.8 51097.8 68357.2 72207.6 73159.8 
CV 15.70% 17.80% 24.70% 13.40% 19.50% 
 
Mean intra-assay CV: 18.2%. 
 
*As the steps described above are identical for other antibody (such as CD31 
antibody), this protocol is transferrable for detection of endothelial antibody. 
 
Validation (CD31 Antibody for EMP detection) 
   
 CD 31 
 
Sample-A Sample-B Sample-C Sample-D Sample-E 
Test-1 220070 235734 222953 212050 142516 
Test-2 221210 209686 208422 200096 189074 
Test-3 216376 291001 259805 204056 162329 
Test-4 183635 201572 261570 193917 162607 
Test-5 179830 247365 209547 183571 136927 




Mean 204224.2 237071.6 232459.4 198738 158690.6 
CV 10.10% 14.90% 11.40% 5.40% 12.90% 
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Appendix 7: Definitions of the clinical and procedural characteristics relating to 
sections 2.2.2.1, 4.2.3.1 and 4.3.3.1 
The following are defined according to BCIS (British Cardiovascular Intervention 
Society) criteria. Current smoking: regularly smoking one or more cigarette per day or 
having stopped within the previous month. Family history: any first degree relative with 
premature coronary heart disease (males under 55; females under 65). Diabetes: patients 
currently using oral hypoglyaemics and/or insulin. Hypercholesterolaemia: total 
cholesterol above 5.2 mmol or use of hypocholesterolaemic drugs. Hypertension: 
current use of antihypertensives. Cerebrovascular event: loss of neurological function 
caused by an ischaemic insult with residual symptoms at least 72 hours after the 
episode. Renal failure: creatinine > 200 mmol/L or a functioning transplant irrespective 
of creatinine or current dialysis. Cardiogenic shock: systolic blood pressure < 
100mmHg with pulse rate > 100 beats per minute or symptoms and signs consistent 
with hypoperfusion (e.g. clamminess or coolness) or requiring inotropes.  
Coronary angiography and percutaneous coronary intervention were undertaken using 
standard techniques from the radial or femoral artery as appropriate. Patients 
undergoing percutaneous coronary intervention received guideline recommended dual 
antiplatelet therapy and anticoagulation with intravenous heparin at 70-100U/Kg or 
intravenous bivalirudin at 0.75 mg/kg followed by 1.75 mg/kg/hr for the duration of the 
procedure. 
CT imaging was performed using a dual source 256 slice, 128 row CT scanner with 
0.5mm Stellar detector elements, 280ms of gantry rotation time and a total z-axis 




Limited, Surrey, UK). For heart rates over 70 beats per minute, 5–20 mg of intravenous 
metoprolol was administered immediately before the scan. GTN spray was given 
sublingually if systolic blood pressure was ≥ 110 mm Hg. Lesions with an attenuation 
greater than 130 Hounsfield Units were identified as calcified. Total coronary artery 
calcium scoring was performed with inbuilt software according to Agatston criteria 
(Agatston Score 0 –  no coronary calcium, 1-100 –  mild coronary calcium, 101-400 – 
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